[go: up one dir, main page]

US20030202987A1 - Particles of HCV envelope proteins: use for vaccination - Google Patents

Particles of HCV envelope proteins: use for vaccination Download PDF

Info

Publication number
US20030202987A1
US20030202987A1 US10/414,219 US41421903A US2003202987A1 US 20030202987 A1 US20030202987 A1 US 20030202987A1 US 41421903 A US41421903 A US 41421903A US 2003202987 A1 US2003202987 A1 US 2003202987A1
Authority
US
United States
Prior art keywords
hcv
oligomeric particle
val
gly
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/414,219
Inventor
Erik Depla
Geert Maertens
Alfons Bosman
Frans Wijnendaele
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujirebio Europe NV SA
Original Assignee
Innogenetics NV SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26152268&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20030202987(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Innogenetics NV SA filed Critical Innogenetics NV SA
Priority to US10/414,219 priority Critical patent/US20030202987A1/en
Publication of US20030202987A1 publication Critical patent/US20030202987A1/en
Priority to US11/381,408 priority patent/US20070048281A1/en
Priority to US11/445,274 priority patent/US20060275323A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses

Definitions

  • the present invention is based on the finding that the envelope proteins of HCV induce a beneficial immune response in chimpanzees which are chronically infected with a heterologous subtype 1a or subtype 1b HCV strain. More specifically, the present invention relates to the finding that envelope proteins are highly immunogenic and result in the stimulation of both the cellular and humoral immune response. Moreover, the present invention relates to the finding that blocking of cysteines by alkylation results in even more immunogenic proteins. In addition, the envelope proteins of the present invention can be incorporated in particles which display a high immunogenecity and immunoreactivty. It was further demonstrated that such particles may incorporate other proteins.
  • HCV infection is a major health problem in both developed and developing countries. It is estimated that about 1 to 5% of the world population is affected by the virus. HCV infection appears to be the most important cause of transfusion-associated hepatitis and frequently progresses to chronic liver damage. Moreover, there is evidence implicating HCV in induction of hepatocellular carcinoma. Consequently, the demand for reliable diagnostic methods and effective therapeutic agents is high. Also sensitive and specific screening methods of HCV-contaminated blood-products and improved methods to culture HCV are needed.
  • HCV is a positive stranded RNA virus of approximately 9,600 bases which encode at least three structural and six non-structural proteins. Based on sequence homology, the structural proteins have been functionally assigned as one single core protein and two envelope proteins: E1 and E2.
  • the E1 protein consists of 192 amino acids and contains 5 to 6 N-glycosylation sites, depending on the HCV genotype.
  • the E2 protein consists of 363 to 370 amino acids and contains 9-11 N-glycosylation sites, depending on the HCV genotype (for reviews see: Major and Feinstone, 1997; Maertens and Stuyver, 1997).
  • the E1 protein contains various variable domains (Maertens and Stuyver, 1997), while the E2 protein contains three hypervariable domains, of which the major domain is located at the N-terminus of the protein (Maertens and Stuyver, 1997).
  • the latter envelope proteins have been produced by recombinant techniques in Escherchia coli, insect cells, yeast cells and mammalian cells. The usage of an expression system in higher eukaryotes and especially in mammalian cell culture leads to envelope proteins that are effectively recognized by antibodies in patient samples (Maertens et al., 1994).
  • E1 envelope protein needs the E2 envelope protein to reach a proper folding status (Deleersnyder et al., 1997).
  • E1 and E2 form heterodimers which may form the basic unit of the viral envelope (Yi et al., 1997).
  • WO 98/21338 to Liang et al. these presumptions have been used to construct HCV particles, which consist of E1 and E2, as well as Core and P7. In other words, the usage of E1 or E2 separately for immunization and other purposes is not suggested in the prior art.
  • the inventors of the present invention further reasoned that, as the antibody levels against E1 in chronic HCV carriers are among the lowest of all HCV antibodies, it may be beneficial to raise those antibody levels, and possibly the cellular response, to induce control or even clearance of the infection by the host. Also higher levels of cellular immunity against E1 seem to correlate with good response towards interferon therapy (Leroux-Roels et al., 1996).
  • the present invention relates to the surprising finding that administration of an HCV envelope antigen can dramatically improve the state of chronic active hepatitis in an individual infected with a heterologous strain or isolate, both in a heterologous subtype 1a or heterologous subtype 1b infection. Indeed, chronically infected chimpanzees who were administered six doses of 50 ⁇ g E1s (i.e.
  • aa 192-326 of E1 surprisingly showed vigourous humoral and cellular immune responses, which had not been mounted over the entire period of chronic infection before the latter vaccination. Moreover, viral antigen became undetectable in the liver over a period of two to five months and remained undetectable for at least 5 months post-vaccination. Although HCV-RNA titers in the serum did not decrease, liver enzyme levels in the serum showed a clear tendency to normalize. Most importantly, liver histology improved dramatically in both vaccinees.
  • the present invention further relates to the surprising finding that the E1 protein used for vaccination, which was expressed as a single HCV protein without its hydrophobic anchor, forms stable particles.
  • the E1 protein used for vaccination was constructed as a consensus sequence of individual clones derived from a single serum sample from one chronic carrier.
  • the present application relates to the finding that the induction of such anti-E1 responses may be increased by using antigens of a different genotype than the ones of the infection present in the host.
  • the present application relates to the finding that when cysteines of HCV envelope proteins are alkylated, for instance by means of N-(iodoethyl)-trifluoroacetamide, ethylenimine or active halogens, such as iodoacetamide, the oligomeric particles as described above display an even higher immunogenicity.
  • the present invention relates also to the finding that mutation of cysteines of HCV envelope proteins to any other naturally occuring amino acid, preferentially to methionine, glutamic acid, glutamine or lysine, in the oligomeric particles as described above also results in higher immunogenicity, compared to the original envelope proteins.
  • the present invention aims at providing an antigen preparation, which is able to induce specific humoral and cellular immunity to HCV envelope proteins, even (but not solely) in chronic HCV carriers.
  • the same antigens can be used for diagnosis of the immune response.
  • the present invention aims at providing an antigen preparation as defined above, which consists of stable particles of single envelope proteins of HCV. It should be clear that, at present, such particles or a method to prepare such particles, are not known in the art. Moreover, there is no indication in the art that any antigen preparation, including such stable particles or such purified single HCV envelope proteins, could successfully be used as (heterologous) prophylactic or therapeutic vaccine against HCV.
  • the present invention thus also aims at providing a method to produce stable particles, which can be successfully used as a prophylactic or therapeutic agent against HCV, in addition to provide DNA vaccines encoding HCV antigens. More specifically, the present invention aims at providing a method to produce the latter particles based on detergent-assisted particle formation (see further). Furthermore, the present invention aims at providing methods to prepare particles consisting of antigens obtained from different HCV genotypes.
  • the present invention aims at providing an antigen which is a consensus sequence from individual clones, which may allow a more correct folding of the proteins. This in order to avoid stimulation of immunity against non-relevant epitopes.
  • the present invention aims at providing an antigen formulation, in particular for therapeutic vaccination, based on the genotype of HCV by which the chronic carrier is infected.
  • the present invention aims at providing an envelope protein of either a different or a homologous genotype or subtype compared to the genotype or subtype of the chronic carrier.
  • a further aim of the invention is to provide a method for treating or therapeutically vaccinating chronically infected patients using the above-indicated antigens or DNA vaccines, possibly in combination with other compounds.
  • the present invention also aims to provide a method to prophylactically vaccinate humans against HCV.
  • Another aim of the invention is to provide oligomeric particles which have a superior immunogenicity, due to the mutation of at least one cysteine residue of HCV envelope protein into a natural occuring amino acid, preferentially methionine, glutamic acid, glutamine or lysine.
  • alkylation of at least one cysteine residue of HCV envelope protein may be performed.
  • the latter protein can be alkylated by means of ethylenimine, N-(iodoethyl)trifluoroacetamide or active halogens.
  • the instant invention aims to provide the additional use of oligomeric particles as vehicles for presenting non-HCV epitopes efficiently.
  • an anti-envelope antibody such as anti-E1 antibody, e.g. anti-E1 V2 region antibody
  • Another aim of the invention is to provide a T cell stimulating antigen such as Core, E1, E2, P7, NS2, NS3, NS4A, NS4B, NS5A, or NS5B along with the envelope proteins of the invention.
  • a T cell stimulating antigen such as Core, E1, E2, P7, NS2, NS3, NS4A, NS4B, NS5A, or NS5B along with the envelope proteins of the invention.
  • Table 1 provides sequences of E1 clones obtained from a single chronic carrier, the E1 construct used for production of a vaccine is the consensus of all these individual clones.
  • Table 2 provides sequences of the E1 vaccine protein and the E1 protein as found in the infected chimpanzees Phil and Ton.
  • the subtype 1b isolate of Phil differed by 5.92% from the vaccine strain.
  • the difference between the vaccine and the subtype 1a isolate of Ton was 20.74%.
  • Table 3 provides a schematic overview of the changes induced by therapeutic vaccination in two chronically infected chimpanzees (Ton and Phil). Analysis was performed as explained for FIGS. 8 and 11. In addition, histology and inflammation were scored from the liver biopsies.
  • Table 4 provides sequences of peptides used to map the B-cell epitopes. Note that HR overlaps with V4V5.
  • Table 5 shows the rearrangement of NS3 in order to make a shorter protein carrying all major epitopes correlating with viral clearance.
  • Table 6 shows the reactivity in LIA of E1s-acetamide versus E1s-maleimide with sera of chronic HCV carriers. Proteins were immobilized on the LIA membranes. E1s-acetamide was sprayed as such on the LIA strips while E1s-maleimide (also containing biotin-maleimide) was complexed with streptavidin before spraying. Antigens were bound to LIA-membranes, and strips were processed essentially as described in Zrein et al. (1998). Human antibodies directed against these antigens were visualized using a human-anti-IgG conjugated with alkaline phosphatase. NBT and BCIP were used for color development of the strip.
  • Staining was scored from 0.5 to 4, as explained in Zrein et al. (1998). Using a cut-off for this assay of 0.5 the number of positive samples (#pos) and percentage (% pos) is mentioned at the bottom of the table.
  • FIG. 1 Superimposed size exclusion chromatography profiles in PBS/3% Empigen-BB of E1s and E2s proteins expressed and purified according to Maertens et al. (PCT/EP95/03031)
  • FIG. 2 Superimposed size exclusion chromatography (SEC) profiles of E1s and E2s proteins expressed and purified according to Maertens et al. (PCT/EP95/03031), and submitted to another run on the same SEC column in PBS/0.2% CHAPS, to obtain specific oligomeric structures of an estimated apparent molecular weight of 250-300 kDa. Similar degrees of association can be obtained by using 3% betaine.
  • SEC size exclusion chromatography
  • FIG. 3 Superimposed size exclusion chromatography profiles of E1s and E2s proteins expressed and purified according to Maertens et al. (PCT/EP95/03031), submitted to a second run in 0.2% CHAPS or 3% betaine to obtain specific oligomeric structures as shown in FIG. 2, and submitted to a third run on the same SEC column in 0.05% CHAPS, to obtain specific homo-oligomeric structures with an estimated apparent molecular weight of 250-300 kDa E2s) and >600 kDa (E1s). Similar degrees of association can be obtained by using 0.1 or 0.5% betaine.
  • FIG. 4 Dynamic light scattering analysis, expressed as percentage of the number of particles in relation to the observed diameter in nm, of E1s in PBS/0.05% CHAPS.
  • FIG. 5 Dynamic light scattering analysis, expressed as percentage of the number of particles in relation to the observed diameter in nm, of E1s in PBS/0.1% betaine (top) or 0.5% betaine (bottom).
  • FIG. 6 EM staining of (A) E1s in PBS/0.05% CHtAPS and (B) E1s in PBS/3% betaine.
  • FIG. 7 Size distribution of particles of E1s in PBS/0.05% CHAPS.
  • FIG. 8 Evolution of anti-E1 antibodies induced by six consecutive and 3 boost immunizations (indicated by small arrows) in a 1b infected chimpanzee (Phil), and the evolution of ALT, HCV RENA, and anti-E1 antibodies.
  • Anti-E1 antibodies binding to solid phase E1 were detected using an anti-human IgG specific secondary antiserum conjugated with peroxidase. TMB was used as substrate for colour development. The results are expressed as end-point titer.
  • ALT levels were determined with a clinical analyser, and are expressed as U/l.
  • HCV RNA in serum was determined using HCV Monitor (Roche, Basel, Switzerland). Viral load in the liver was determined by semi-quantitative determination of the amount of E2 antigen stained in the liver biopsy using a specific monoclonal (ECACC accession number 98031215 as described in EP application No 98870060.5).
  • FIG. 9 Epitope mapping of the antibody responses induced by immunization with E1 in chimpanzee Phil. Antibodies reactivity towards the various peptides was measured by an indirect ELISA in which biotinylated peptides (see also Table 4) are adsorbed on the microtiterplates via streptavidin. Specific antibodies are detected using an anti-human IgG specific secondary antiserum conjugated with peroxidase. TMB was used as substrate for colour development.
  • FIG. 10 Results of the lymphocyte proliferation assay before and after vaccination in chimpanzee Phil. Frozen PBMC were thawed and stimulated in triplicate with different antigens. Negative control was medium alone, while concanavalin A was used as positive control at a concentration of 5 ⁇ g/ml.
  • PBMC at a concentration of 2-4 ⁇ 10 5 cells/well in a total volume of 150 ⁇ l were cultured in RPMI 1640 medium supplemented with 10% heat-inactivated FCS in U-shaped 96-well microtiterplates together with the controls or 1 ⁇ g/ml of E1 for 90 h at 37° C. in a humidified atmosphere containing 5% CO 2 .
  • FIG. 11 Evolution of anti-E1 antibodies induced by six consecutive and 3 boost immunizations (indicated by small arrows) in HCV subtype 1a infected chimpanzee Ton. Evolution of ALT, HCV RNA in serum and determination of HCV antigen in liver are shown. Anti-E1 antibodies were determined by means of an indirect ELISA: specific antibodies binding to solid phase-coated E1 are detected using a anti-human IgG specific secondary antiserum conjugated with peroxidase. TMB was used as substrate for color development. The results are expressed as end-point titres. ALT levels were determined with a clinical analyser, and are expressed as U/l. HCV RNA was determined using HCV Monitor (Roche, Basel, Switzerland).
  • E2 antigen was stained in the liver biopsy using a specific monoclonal (ECACC accession number 98031215 as described in EP application N o 98870060.5). The semi-quantitative scoring is indicated by black squares for clearly positive staining in the majority of the cells, by grey squares for clear staining in the minority of the cells and by white squares for biopsies showing no detectable staining. HCV RNA is indicated by small black boxes. Staining of E2 could be confirmed by Core and E1 staining (data not shown).
  • FIG. 12 Epitope mapping of the antibody response induced by immunization with E1 in Ton. Antibodies reactivity towards the various peptides was measured by an indirect ELISA in which biotinylated peptides (see also Table 4) are adsorbed on the microtiterplates via streptavidin. Specific antibodies are detected using an anti-human IgG specific secondary antiserum conjugated with peroxidase. TMB was used as substrate for color development.
  • FIG. 13 Analysis of E1 antibody responses to subtype 1a and subtype 1b E1 proteins in chimpanzee Ton.
  • E1 genotype 1a derived from the HCV-H sequence, recombinant vaccinia virus was generated expressing the same part of E1 as for genotype 1b (see infra).
  • E1 was derived from crude lysates from vaccinia virus infected RK13 cells (prepared as described in Maertens et al. (PCT/EP95/03031)).
  • Antibody reactivity was measured by an indirect ELISA in which E1 was adsorbed on the microtiterplates via the high-mannose binding Galanthus nivalis agalutinin (GNA).
  • GAA Galanthus nivalis agalutinin
  • FIG. 14 Results of the lymphocyte proliferation assay before and after vaccination of chimpanzee Ton.
  • Frozen PBMC were thawed and stimulated in triplicate with different antigens. Negative control was medium alone, while concanavalin A was used as positive control at a concentration of 5 ⁇ g/ml.
  • PBMC at a concentration of 2-4 10 5 cells/well in a total volume of 150 ⁇ l were cultured in RPMI 1640 medium supplemented with 10% heat-inactivated FCS in U-shaped 96-well microtiterplates together with the controls or 1 ⁇ g/ml of E1 for 90 h at 37° C. in a humidified atmosphere containing 5% CO 2 .
  • the cells are pulsed with 0.5 ⁇ Ci ( 3 H) thymidine per well. Subsequently, the cultures, are harvested on glass fibre filters and label uptake is determined. Results are expressed as Stimulation Indices (SI): mean cpm antigen/mean cpm medium alone of triplicate determinations.
  • SI Stimulation Indices
  • FIG. 15 Maps of the constructs used to obtain expression of an E2 protein with its N-terminal hypervariable region deleted.
  • Constructs pvHCV-92 and pvHCV-99 are intermediate constructs used for the construction of the deletion mutants pvHCV-100 and pvHCV-101.
  • FIG. 16 Sequence (nucleotides: A; translation: B) corresponding with the constructs depicted in FIG. 15 (see above).
  • FIG. 18 Epitope mapping of the antibody response induced by immunization with different E1s preparations in mice. Antibody reactivity towards the various peptides was measured by an indirect ELISA, in which biotinylated peptides (listed in Table 4) are adsorbed on the microtiterplates via streptavidin. Murine sera were diluted 1/20 and specific antibodies are detected using an anti-mouse-IgG specific secondary antiserum conjugated with peroxidase. TMB was used as substrate for colour development.
  • FIG. 19 Immunoglobulin isotyping profile of mice immunized with different E1s preparations. Specific Ig class and subclass antibodies were adsorbed at the microtiterplate. After capturing of the murine Ig out of immune sera diluted 1/500, E1s was incubated at 1 ⁇ g/ml. The formed immunecomplexes were further incubated with a polyclonal rabbit antiserum directed against E1. Finally, the rabbit antibodies were detected using a goat-anti-rabbit Ig secondary antiserum conjugated with peroxidase. TMB was used as substrate for color development. The results were normalized for IgG 1 (ie the IgG 1 signal was for each animal separately considered to be 1 and all the results for the other isotypes were expressed relative to this IgG 1 result).
  • FIG. 20 Antibody titers induced by two immunizations around day 1000 with E1s-acetamide in chimp Phil. Anti-E1 antibodies were determined by means of an indirect ELISA: specific antibodies binding to solid phase E1 are detected using anti-human IgG specific secondary antiserum conjugated with peroxidase. The titer is expressed in units/ml, these units refer to an in house standard which is based on human sera.
  • FIG. 21 Antibody titers induced by two immunizations around day 900 with E1s-acetamide in chimp Ton. Anti-E1 antibodies were determined by means of an indirect ELISA: specific antibodies binding to solid phase E1 are detected using anti-human IgG specific secondary antiserum conjugated with peroxidase. The titer is expressed in units/ml, these units refer to an in house standard which is based on human sera.
  • FIG. 22 SEC profile of the final detergent reduction step (0.2 to 0.05% CHAPS): E1 alone particle (A), E2 alone particle (B) or an equimolar mixture of E1 and E2; mixed particle (C).
  • the figure also shows an overlay of the OD values of an ELISA specifically detecting E1 only (top), E2 only (middle) and an ELISA detecting only mixed particles (bottom).
  • FIG. 23 SEC profile of the final detergent reduction step (0.2 to 0.05% CHAPS): E1 genotype 1b alone particle (top), E1 genotype 4 alone particle (middle) or an equimolar mixture of E1 genotype 1b and 4, mixed particle (bottom).
  • the figure also shows an overlay of the OD values of an ELISA specifically detecting only mixed particles (see also FIG. 22).
  • the present invention relates to HCV vaccination.
  • HCV antigen for the first time successful immunotherapy of chimpanzees with severe chronic active hepatitis C could be achieved by vaccination with an HCV antigen.
  • the vaccine not only induced high immune responses, but also induced clearance of viral antigen from the liver, and considerable improvement of the histological activity and of liver disease.
  • the present invention further relates to purified single HCV envelope proteins and in particular to oligomeric particles.
  • the oligomeric particles consist essentially of HCV envelope proteins and have a diameter of 1 to 100 nm as measured by dynamic light scattering or possibly electron microscopy. In this regard it should be stressed that the particles can be formed by E1 and/or E2 proteins only, or parts thereof (see infra).
  • the oligomeric particles of the present invention differ fundamentally with the HCV-like particles described in WO 98/21338, which necessarily consist of E1 and E2 and Core and P7.
  • the terms “oligomeric particles consisting essentially of HCV envelope proteins” are herein defined as structures of a specific nature and shape containing several basic units of the HCV E1 and/or E2 envelope proteins, which on their own are thought to consist of one or two E1 and/or E2 monomers, respectively. It should be clear that the particles of the present invention are defined to be devoid of infectious HCV RNA genomes.
  • the particles of the present invention can be higher-order particles of spherical nature which can be empty, consisting of a shell of envelope proteins in which lipids, detergents, the HCV core protein, or adjuvant molecules can be incorporated.
  • the latter particles can also be encapsulated by liposomes or apolipoproteins, such as, for example, apolipoprotein B or low density lipoproteins, or by any other means of targeting said particles to a specific organ or tissue.
  • apolipoproteins such as, for example, apolipoprotein B or low density lipoproteins, or by any other means of targeting said particles to a specific organ or tissue.
  • such empty spherical particles are often referred to as “viral-like particles” or VLPs.
  • the higher-order particles can be solid spherical structures, in which the complete sphere consists of HCV E1 or E2 envelope protein oligomers, in which lipids, detergents, the HCV core protein, or adjuvant molecules can be additionally incorporated, or which in turn may be themselves encapsulated by liposomes or apolipoproteins, such as, for example, apolipoprotein B, low density lipoproteins, or by any other means of targeting said particles to a specific organ or tissue, e.g. asialoglycoproteins.
  • apolipoproteins such as, for example, apolipoprotein B, low density lipoproteins, or by any other means of targeting said particles to a specific organ or tissue, e.g. asialoglycoproteins.
  • the particles can also consist of smaller structures (compared to the empty or solid spherical structures indicated above) which are usually round (see further)-shaped and which usually do not contain more than a single layer of HCV envelope proteins.
  • a typical example of such smaller particles are rosette-like structures which consist of a lower number of HCV envelope proteins, usually between 4 and 16.
  • a specific example of the latter includes the smaller particles obtained with E1s in 0.2% CHAPS as exemplified herein which apparently contain 8-10 monomers of E1s.
  • Such rosette-like structures are usually organized in a plane and are round-shaped, e.g. in the form of a wheel.
  • lipids, detergents, the HCV core protein, or adjuvant molecules can be additionally incorporated, or the smaller particles may be encapsulated by liposomes or apolipoproteins, such as, for example, apolipoprotein B or low density lipoproteins, or by any other means of targeting said particles to a specific organ or tissue.
  • apolipoproteins such as, for example, apolipoprotein B or low density lipoproteins
  • Smaller particles may also form small spherical or globular structures consisting of a similar smaller number of HCV E1 or E2 envelope proteins in which lipids, detergents, the HCV core protein, or adjuvant molecules could be additionally incorporated, or which in turn may be encapsulated by liposomes or apolipoproteins, such as, for example, apolipoprotein B or low density lipoproteins, or by any other means of targeting said particles to a specific organ or tissue.
  • the size i.e.
  • the diameter) of the above-defined particles is usually between 1 to 100 nm, more preferentially between 2 to 70 nm, even more preferentially between 2 and 40 nm, between 3 to 20 nm, between 5 to 16 nm, between 7 to 14 nm or between 8 to 12 nm.
  • the invention further relates to an oligomeric particle as defined above, wherein said envelope proteins are selected from the group consisting of HCV E1, HCV E1s, HCV E2 proteins, SEQ ID No 13 or SEQ ID No 14, or parts thereof.
  • the proteins HCV E1 and HCV E2, and a detailed description of how to purify the latter proteins, are well-described and characterized in PCT/EP 95/03031 to Maertens et al.
  • HCV E1s, SEQ ID No 13 or SEQ ID No 14, or parts thereof can be purified similarly as described for HCV E1 or HCV E1s in PCT/EP 95/03031 to Maertens et al.
  • the protein HCV E1s refers to amino acids 192 to 326 of E1, and represents the E1 protein without its C-terminal hydrophobic anchor.
  • the term “or parts thereof” refers to any part of the herein-indicated proteins which are immunogenic, once they are part of a particle of the present invention.
  • the invention further pertains to oligomeric particles as described herein, wherein at least one cysteine residue of the HCV envelope protein as described above is alkylated, preferably alkylated by means of alkylating agents, such as, for example, active halogens, ethylenimine or N-(iodoethyl)trifluoroacetamide.
  • alkylation of cysteines refers to cysteines on which the hydrogen on the sulphur atom is replaced by (CH 2 ) n R, in which n is 0, 1, 2, 3 or 4 and R ⁇ H, COOH, NH 2 , CONH 2 , phenyl, or any derivative thereof.
  • Alkylation can be performed by any method known in the art, such as, for example, active halogens X(CH 2 ) n R in which X is a halogen such as I, Br, Cl or F.
  • active halogens are methyliodide, iodoacetic acid, iodoacetamide, and 2-bromoethylamine.
  • Other methods of alkylation include the use of ethylenimine or N-(iodoethyl)trifluoroacetamide both resulting in substitution of H by —CH 2 —CH 2 —NH 2 (Hermanson, 1996).
  • alkylating agents refers to compounds which are able to perform alkylation as described herein. Such alkylations finally result in a modified cysteine, which can mimic other aminoacids. Alkylation by an ethylenimine results in a structure resembling lysine, in such a way that new cleavage sites for trypsine are introduced (Hermanson 1996). Similarly, the usage of methyliodide results in an amino acid resembling methionine, while the usage of iodoacetate and iodoacetamide results in amino acids resembling glutamic acid and glutamine, respectively. In analogy, these amino acids are preferably used in direct mutation of cysteine.
  • the present invention pertains to oligomeric particles as described herein, wherein at least one cysteine residue of the HCV envelope protein as described herein is mutated to a natural amino acid, preferentially to methionine, glutamic acid, glutamine or lysine.
  • mutated refers to site-directed mutagenesis of nucleic acids encoding these amino acids, ie to the well kown methods in the art, such as, for example, site-directed mutagenesis by means of PCR or via oligonucleotide-mediated mutagenesis as described in Sambrook et al. (1989).
  • the term “purified” as applied herein refers to a composition wherein the desired components, such as, for example, HCV envelope proteins or oligomeric particles, comprises at least 35% of the total components in the composition.
  • the desired components preferably comprises at least about 40%, more preferably at least about 50%, still more preferably at least about 60%, still more preferably at least about 70%, even more preferably at least about 80%, even more preferably at least about 90%, even more preferably at least about 95%, and most preferably at least about 98% of the total component fraction of the composition.
  • the composition may contain other compounds, such as, for example, carbohydrates, salts, lipids, solvents, and the like, without affecting the determination of the percentage purity as used herein.
  • an “isolated” HCV oligomeric particle intends an HCV oligomeric particle composition that is at least 35% pure.
  • a purified single HCV envelope protein refers to isolated HCV envelope proteins in essentially pure form.
  • the terms “essentially purified oligomeric particles” and “single HCV envelope proteins” as used herein refer to HCV oligomeric particles or single HCV envelope proteins such that they can be used for in vitro diagnostic methods and therapeutics. These HCV oligomeric particles are substanially free from cellular proteins, vector-derived proteins or other HCV viral components.
  • these particles or proteins are purified to homogeneity (at least 80% pure, preferably 85%, more preferably 90%, more preferably 95%, more preferably 97%, more preferably 98%, more preferably 99%, even more preferably 99.5%, and most preferably the contaminating proteins should be undetectable by conventional methods such as SDS-PAGE and silver staining).
  • the present invention also relates to an oligomeric particle as defined above wherein said envelope proteins are any possible mixture of HCV E1, HCV E1s, HCV E2, SEQ ID No 13 and/or SEQ ID No 14, or parts thereof, such as, for example, a particle of the present invention can substantially consist of HCV E1- and HCV E2 proteins, HCV E1- and HCV E1s proteins, HCV E1s- and HCV E2 proteins, and HCV E1-, HCV E1s- and HCV E2 proteins.
  • the present invention also relates to an oligomeric particle as defined above wherein said proteins are derived from different HCV strains, subtypes or genotypes, such as, for example, said proteins are derived from genotype 1b and genotype 4, or are a mixture consisting of HCV envelope proteins from one strain or genotype of HCV and at least one other strain or genotype of HCV.
  • the different HCV strains or genotypes are well-defined and characterized in PCT/EP 95/04155 to Maertens et al. It is stressed again that the whole content, including all the definitions, of the latter document is incorporated by reference in the present application.
  • the present invention relates to oligomeric particles comprising envelope proteins derived from any HCV strain or genotype known in the art or to particles comprising a mixture of proteins derived from any HCV strain or genotype known in the art.
  • the present invention also relates to a consensus sequences derived from individual clones as exemplified below and in the examples section (see further).
  • the present invention further relates to an oligomeric particle as described herein obtainable by a method, as well as to said method to produce said oligomeric particle. Said method is characterized by the following steps:
  • step (I) Purifying HCV envelope proteins, possibly including the use of an optionally first detergent.
  • the purification procedure of step (I) has been described extensively in PCT EP 95/03031 to Maertens et al.
  • the blocking step in the purification procedure as described in PCT EP 95/03031, eg with NEM-biotin is carried out with an alkylation step as described in the present application, preferentially by using iodoacetamide.
  • the purification procedure of step (I) can possibly include the use of a disulphide bond cleavage agent, and possibly include the use of an alkylating agent.
  • the procedure of step (I) results in purified HCV envelope proteins in a solution.
  • step (III) Recovering or purifying said oligomeric particles, possibly including further reducing the concentration of the detergent or salt of step (II), which further assists the formation and stabilization of said oligomeric particles, formed after said replacing.
  • the present invention relates to an oligomeric particle as defined herein, as well as the method to produce said particle, wherein said optionally first detergent is Empigen-BB. More preferably, the present invention relates to an oligomeric particle as defined herein, as well as the method to produce said particle, wherein the detergent of step (II) is CHAPS, octylglucaside or Tween, more preferably Tween-20 or Tween-80, or any other detergent. More preferably, the present invention relates to an oligomeric particle as defined herein, as well as the method to produce said particle, wherein said salt is betaine.
  • the present invention relates to an oligomeric particle as defined above, as well as the method to produce said particle, wherein said Empigen-BB is used at a concentration of 1% to 10% and wherein said CHAPS or Tween is used at a concentration of 0.01% to 10%, or said betaine is used at a concentration of 0.01% to 10%.
  • the present invention relates to an oligomeric particle as defined above, as well as the method to produce said particle, wherein said Empigen-BB is used at a concentration of 3% and wherein said CHAPS or betaine are used at concentrations of 0.2% or 0.3%, respectively, after which buffer is switched and said CHAPS or betaine are used at concentrations of 0.05% or 0.1-0.5%, respectively.
  • the present invention since for the first time successful immunotherapy of chimpanzees with severe chronic active hepatitis C was achieved by vaccination with a purified HCV antigen, the present invention also relates to purified since HCV envelope proteins, in particular E1 or E1s. Moreover, the present invention pertains to a composition comprising said single HCV envelope proteins, and the use thereof as an HCV vaccine, or for the manufacture of an HCV vaccine.
  • the HCV envelope protein used for vaccination is preferably constructed as a consensus sequence of individual subtypes, strains, or clones. Therefore, the present invention also pertains to the use of an HCV antigen (either in the form of peptide, protein, or a polynucleotide) for vaccination or diagnosis.
  • the present invention also pertains to an oligomeric particle, as defined herein, and the use thereof, in which the HCV envelope protein is encoded by a consensus sequences based on quasispecies variability within an isolate (isolate consensus sequence) or based on the consensus sequence of different isolates within a subtype (subtype consensus sequence), type or species (type or species consensus sequence), or the complete HCV genus (genus consensus sequence). Consequently, the amino acid sequence of this consensus HCV envelope protein is a consensus sequence derived from an isolate-, subtype-, strain-, or genus consensus sequence. For the connotation of the term “consensus” is particularly referred to Maertens and Stuyver (1997), and references used therein.
  • the oligomeric particle of the present invention displays epitopes extremely efficiently (see infra).
  • the oligomeric particle is a means to present epitopes in such a way that they can elicit a proficient immune response.
  • the HCV envelope proteins as defined herein do not need to contain HCV epitopes exclusively.
  • the HCV envelope proteins, which form the oligomeric particles may contain epitopes that are derived from HCV solely, and possibly contain epitopes that are derived from other exogenous agents, such as, for example, HBV or HIV.
  • the oligomeric particle with an HCV envelope protein backbone can be used as a vehicle to present non-HCV epitopes, possibly in addition to HCV epitopes. Therefore, the present invention also encompasses an oligomeric particle, as defined herein but possibly without HCV epitopes, and its applications and its manufacture, possibly containing non-HCV epitopes.
  • exogenous agent refers to any agent, whether living or not, able to elicit an immune response, and which is not endogenous to the host, and which is not HCV. Specifically, the latter term refers to the group consisting of pathogenic agents, allergens and haptens.
  • Pathogenic agents comprise prions, virus, prokaryotes and eukaryotes. More specifically, virus comprise in particular HBV, HIV, or Herpesvirus, but not HCV. Allergens comprise substances or molecules able to provoke an immune response in an host on their own when a host is exposed to said allergens. Haptens behave similarly to allergens with respect to the ability of provoking an immune response, but in contrast to allergens, haptens need a carrier molecule.
  • the present invention also relates to a composition comprising an oligomeric particle as defined above. More particularly the present invention relates to a vaccine composition.
  • the term “vaccine composition” relates to an immunogenic composition capable of eliciting protection against HCV, whether partial or complete. It therefore includes HCV peptides, proteins, or polynucleotides. Protection against HCV refers in particular to humans, but refers also to non-human primates, trimera mouse (Zauberman et al., 1999), or other mammals.
  • the particles of the present invention can be used as such, in a biotinylated form (as explained in WO 93/18054) and/or complexed to Neutralite Avidin (Molecular Probes Inc., Eugene, Oreg., USA).
  • a vaccine composition comprises, in addition to an active substance, a suitable excipient, diluent, carrier and/or adjuvant which, by themselves, do not induce the production of antibodies harmful to the individual receiving the composition nor do they elicit protection.
  • Suitable carriers are typically large slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric aa's, aa copolymers and inactive virus particles.
  • adjuvants to enhance effectiveness of the composition include, but are not limited to: aluminium hydroxide, aluminium in combination with 3-0-deacylated monophosphoryl lipid A as described in WO 93/19780, aluminium phosphate as described in WO 93/24148, N-acetylmuramyl-L-threonyl-D-isoglutamine as described in U.S. Pat. No.
  • any of the three components MPL, TDM or CWS may also be used alone or combined 2 by 2.
  • adjuvants such as Stimulon (Cambridge Bioscience, Worcester, Mass., USA) or SAF-1 (Syntex) may be used, as well as adjuvants such as combinations between QS21 and 3-de-O-acetylated monophosphoryl lipid A (WO94/00153), or MF-59 (Chiron), or poly[di(carboxylatophenoxy) phosphazene] based adjuvants (Virus Research Institute), or blockcopolymer based adjuvants such as Optivax (Vaxcel, Cythx) or inulin-based adjuvants, such as Algammulin and GammaInulin (Anutech), Incomplete Freund's Adjuvant (IFA) or Gerbu preparations (Gerbu Biotechnik).
  • a vaccine composition will further contain excipients and diluents, which are inherently non-toxic and non-therapeutic, such as water, saline, glycerol, ethanol, wetting or emulsifying agents, pH buffering substances, preservatives, and the like.
  • excipients and diluents which are inherently non-toxic and non-therapeutic, such as water, saline, glycerol, ethanol, wetting or emulsifying agents, pH buffering substances, preservatives, and the like.
  • a vaccine composition is prepared as an injectable, either as a liquid solution or suspension. Solid forms, suitable for solution on, or suspension in, liquid vehicles prior to injection may also be prepared. The preparation may also be emulsified or encapsulated in liposomes for enhancing adjuvant effect.
  • Vaccine compositions comprise an immunologically effective amount of the polypeptides of the present invention, as well as any other of the above-mentioned components.
  • Immunologically effective amount means that the administration of that amount to an individual, either in a single dose or as part of a series, is effective for prevention or treatment. This amount varies depending upon the health and physical condition of the individual to be treated, the taxonomic group of the individual to be treated (e.g.
  • the amount will fall in a relatively broad range that can be determined through routine trials. Usually, the amount will vann from 0.01 to 1000 ⁇ g/dose, more particularly from 0.1 to 100 ⁇ g/dose.
  • the vaccine compositions are conventionally administered parenterally, typically by injection, for example, subcutaneously or intramuscularly. Additional formulations suitable for other methods of administration include oral formulations and suppositories. Dosage treatment may be a single dose schedule or a multiple dose schedule.
  • the vaccine may be administered in conjunction with other immunoregulatory agents. Therefore, the instant invention pertains to the use of an oligomeric particle as defined herein for prophylactically inducing immunity against HCV. It should be noted that a vaccine may also be useful for treatment of an individual as pointed-out above, in which case it is called a “therapeutic vaccine”.
  • the present invention also relates to a composition as defined above which also comprises HCV core, E1, E2, P7, NS2, NS3, NS4A, NS4B, NS5A and/or NS5B protein, or parts thereof.
  • E1, E2, and/or E1E2 particles may, for example, be combined with T cell stimulating antigens, such as, for example, core, P7, NS3, NS4A, NS4B, NS5A and/or NS5B.
  • the present invention relates to a composition as defined above wherein said NS3 protein, or parts thereof, have an amino acid sequence given by SEQ ID 1 or SEQ ID 2 (see further in examples section).
  • NS3 proteins will preferentially include a reversible modification of the cvsteine residues, and even more preferentially sulfonation of cysteines. Methods to obtain such a reversible modification, including sulfonation have been described for NS3 proteins in Maertens et al. (PCT/EP99/02547). It should be stressed that the whole content, including all the definitions, of the latter document is incorporated by reference in the present application.
  • the present invention also relates to the usage of an oligomeric particle as defined above or a composition as defined above for the manufacture of an HCV vaccine composition.
  • the present invention relates to the usage of an oligomeric particle as defined herein for inducing immunity against HCV in chronic HCV carriers.
  • the present invention relates to the usage of an oligomeric particle as defined herein for inducing immunity against HCV in chronic HCV carriers prior to, simultaneously to or after any other therapy, such as, for example, the well-known interferon therapy either or not in combination with the administration of small drugs treating HCV, such as, for example, ribavirin.
  • composition may also be employed before or after liver transplantation, or after presumed infection, such as, for example, needle-stick injury.
  • the present invention relates to a kit containing the oligomeric particles or the single HCV envelope proteins of the present invention to detect HCV antibodies present in a biological sample.
  • biological sample refers to a sample of tissue or fluid isolated from an individual, including but not limited to, for example, serum, plasma, lymph fluid, the external sections of the skin, respiratory intestinal, and genitourinary tracts, oocytes, tears, saliva, milk, blood cells, tumors, organs, gastric secretions, mucus, spinal cord fluid, external secretions such as, for example, excrement, urine, sperm, and the like.
  • the present invention relates also to a kit for detecting HCV related T cell response, comprising the oligomeric particle or the purified single HCV envelope protein of the instant invention.
  • HCV T cell response can for example be measured as described in the examples section, or as described in PCT/EP 94/03555 to Leroux-Roels et al. It should be stressed that the whole content, including all the definitions, of this document is incorporated by reference in the present application.
  • HCV immunoglobulins for treatment and prevention of HCV infection. It is here for the first time demonstrated that sufficient levels of HCV antibodies, especially HCV envelope antibodies, induce amelioration of Hepatitis C disease. It is also demonstrated for the first time that sufficient levels of antibodies can bind circulating virus, and that the presence of Ab-complexed virus coincides with disappearance of HCV antigen from the liver, and with amelioration of liver disease.
  • HCV envelope antibodies may be induced by vaccination or may be passively transferred by injection after the antibodies have been purified from pools of HCV-infected blood or from blood obtained from HCV vaccinees.
  • the present invention pertains further to specific antibodies, generated against an oligomeric particle as described above or against a composition as described above, or a single HCV envelope protein.
  • the present invention relates to a kit comprising said antibodies for detecting HCV antigens.
  • the term “specific antibodies” as used herein refers to antibodies, which are raised against epitopes which are specific to the oligomeric particle as disclosed in the present invention. In other words, specific antibodies are raised against epitopes which result from the formation of, and are only present on oligomeric particles.
  • there are various procedures known to produce HCV peptides These procedures night result in HCV peptides capable of presenting epitopes.
  • the HCV peptides obtained by these various and different procedures, are capable of presenting similar epitopes. Similar epitopes are epitopes resulting from different production or purifying procedures but recognizable by one and the same antibody.
  • the oligomeric particles of the instant invention present epitopes extremely efficient. Consequently, the epitopes on the oligomeric particles are highly immunogenic.
  • the present invention also pertains to epitopes on oligomeric particles, said epitopes are at least 10 times, preferentially at least 20 times, preferentially at least 50, preferentially at least 100 times, preferentially at least 500 times, and most preferentially at least 1000 times more immunogenic than epitopes on HCV-peptides, which are not produced according to the present invention, ie not produced by detergent-assisted particle formation.
  • said immunogenecity can, for example, be detected and therefore compared by immunising mammals by means of administering comparable quantities of peptides, produced by either method.
  • the term “specific antibody” refers also to antibodies which are raised against a purified single HCV envelope protein.
  • the term “antibody” refers to polyclonal or monoclonal antibodies.
  • the term “monoclonal antibody” refers to an antibody composition having a homogeneous antibody population.
  • the term “antibody” is not limiting regarding the species or source of the antibody, nor is it intended to be limited by the manner in which it is made.
  • the term “antibody” also refers to humanized antibodies in which at least a portion of the framework regions of an immunoglobulin are derived from human immunoglobulin sequences and single chain antibodies, such as, for example, as described in U.S. Pat. No. 4,946,778, to fragments of antibodies such as F ab , F (ab)2 , F v , and other fragments which retain the antigen binding function and specificity of the parental antibody.
  • the present invention also features the use of an oligomeric particle as described above, or a composition as described above to detect antibodies against HCV envelope proteins.
  • the term “to detect” refers to any assay known in the art suitable for detection. In particular, the term refers to any immunoassay as described in WO 96/13590.
  • polypeptide refers to a polymer of amino acids (amino acid sequence) and does not refer to a specific length of the molecule. Thus, oligopeptides are included within the definition of polypeptide. It is to be understood that peptidomimics are inherent in the terms “polypeptide”, “peptide” and “protein”
  • the present invention relates to the use of an oligomeric particle as described herein for inducing immunity against HCV, characterized in that said oligomeric particle is used as part of a series of time and compounds.
  • a series of time and compounds refers to administering with time intervals to an individual the compounds used for eliciting an immune response.
  • the latter compounds may comprise any of the following components: oligomeric particles, HCV DNA vaccine composition, HCV polypeptides.
  • a series comprises administering, either:
  • an HCV antigen such as, for example, an oligomeric particle, with time intervals, or
  • an HCV antigen such as, for example, an oligomeric particle in combination with a HCV DNA vaccine composition, in which said oligomeric particles and said HCV DNA vaccine composition, can be administered simultaneously, or at different time intervals, including at alternating time intervals, or
  • a HCV DNA vaccine composition comprises nucleic acids encoding HCV envelope peptide, including E1-, E2-, E1/E2-peptides, E1s peptide, SEQ ID No 13, SEQ ID No 14, NS3 peptide, other HCV peptides, or parts of said peptides.
  • said HCV peptides comprises HCV envelope peptides, including E1-, E2-, E1/E2-peptides, E1s peptide. SEQ ID No 13, SEQ ID No 14, NS3 peptide, other HCV peptides, or parts thereof.
  • HCV DNA vaccine composition comprises preferentially nucleic acids encoding HCV envelope peptides.
  • HCV DNA vaccine composition consists even more preferentially of nucleic acids encoding HCV envelope peptides, possibly in combination with a HCV-NS3 DNA vaccine composition.
  • an HCV DNA vaccine composition comprises a plasmid vector comprising a polynucleotide sequence encoding an HCV peptide as described above, operably linked to transcription regulatory elements.
  • a “plasmid vector” refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked.
  • Preferred vectors are those capable of autonomous replication and/or expression of nucleic acids to which they have been linked.
  • plasmid vectors are circular double stranded DNA loops which, in their vector form, are not bound to the chromosome.
  • a “polynucleotide sequence” refers to polynucleotides such as deoxyribonucleic acid (DNA), and, where appropriate, ribonucleic acid (RNA). The term should also be understood to include, as equivalents, analogs of either RNA or DNA made from nucleotide analogs, and single (sense or antisense) and double-stranded polynucleotides.
  • transcription regulatory elements refers to a nucleotide sequence which contains essential regulatory elements, such that upon introduction into a living vertebrate cell it is able to direct the cellular machinery to produce translation products encoded by the polynucleotide.
  • operably linked refers to a juxtaposition wherein the components are configured so as to perform their usual function.
  • transcription regulatory elements operably linked to a nucleotide sequence are capable of effecting the expression of said nucleotide sequence.
  • the present invention relates to an immunoassay for detecting HCV antibody, which immunoassay comprises: (1) providing the oligomeric particle or the purified single HCV envelope protein as defined herein, or a functional equivalent thereof, (2) incubating a biological sample with said oligomeric particle, or said HCV envelope protein under conditions that allow the formation of antibody-antigen complex, (3) determining whether said antibody-antigen complex comprising said oligomeric particle or said HCV envelope protein is formed.
  • the HCV E1s protein (amino acids 192-326) was expressed and purified from RK13 cells using recombinant vaccinia virus pvHCV-11A according to the protocol described in Maertens et al. (PCT/EP 95/03031).
  • the purified E1 protein in 3% Empigen-BB which displays an apparent molecular weight corresponding to an E1 homo-dimer (approximately about 60 kDa; FIG. 1), was pooled and the pooled fractions were again applied to a size exclusion chromatography column (according to PCT/EP 95/03031) and run in the presence of 0.2% CHAPS or 3% betaine.
  • E1s protein is devoid of its membrane anchor region
  • a homogeneous population of specifically associated E1 homo-oligomers with an apparent molecular weight of 260-280 kDa could be obtained with both detergents (FIG. 2).
  • Such a homo-oligomeric structure could contain an approximate number of 9 E1s monomers. It should be clear that the latter is a rough estimate as the shape of the oligomer may drastically influence its apparent molecular weight as measured by size exclusion chromatography. By switching from 0.2% CHAPS to 0.05% CHAPS and repeating the same procedure, the apparent molecular weight further shifted beyond the resolution of the column (void of the column, >600 kDa, FIG. 3), suggesting the formation of particles.
  • E1s preparations in 0.05% CHAPS and 0.1% betaine, prepared according to example 1, or in 0.1% betaine, prepared by dilution of preparations in 0.5% betaine, were subjected to analysis by means of dynamic light scattering (DLS).
  • DLS dynamic light scattering
  • the dynamic light scattering technique measures Brownian motion and relates this to the size of particles.
  • the velocity of the Brownian motion is defined by a property known as the diffusion coefficient (usually given by the symbol D).
  • the measured diameter is a value which refers to how a particle diffuses within a fluid. So, it is referred to as hydrodynamic diameter.
  • the diffusion coefficient is derived from an autocorrelation function (variation of intensity fluctuation of light with time). The instrument uses a computer-controlled correlator to calculate the intensity of the autocorrelation function automatically.
  • the above autocorrelation function is corrected to obtain linear curves and the instrument is equipped with a computer program for analysis of the size distribution.
  • the technique has restrictive assumptions similar to those of the technique called multi angle laser light scattering (MALLS) and neither method can be considered to yield absolute data.
  • MALLS multi angle laser light scattering
  • the results of size distributions from DLS have to be interpreted as semi-quantitative indicators of polydispersity, rather than as a true representation of the distribution.
  • E1s structures were spherical, monodisperse particles.
  • the E1s particles in PBS/0.1% betaine showed an average size distribution of 21.3 ⁇ 4 nm, in PBS/0.5% betaine: 27.9 ⁇ 5 nm, whereas a diameter of 12.5 was obtained for E1s in PBS/0.05% CHAPS.
  • the E1s particle in CHAPS had a mean diameter of 8.7 ⁇ 0.27 nm (range 4.3-29.0; 95% CI 5.4) and that the E1s particle in betaine was less homogeneous with a mean diameter of 9.7 ⁇ 0.55 nm (range 4.3-40.5; 95% CI 11.0).
  • the 3% betaine preparation which initially showed a MW of 250-300 kDa as analysed by SEC even shows larger particles than the 0.05% CHAPS preparation, which initially showed a MW of >600 kDa.
  • We therefore hypothesized that intermediate homo-oligomeric forms of E1s obtained by 3% betaine may have formed higher order particles over time.
  • FIG. 7 A size distribution of the particles (FIG. 7) shows that the CHAPS preparation is monodisperse, although a tailing to larger size particles is observed (up to 29 nm for 0.05% CHAPS). Since larger structures are overestimated in DLS analyses, the presence of these larger particles, although less in number, may explain the larger diameter obtained by DLS analysis (example 2). The difference in diameter may also be explained by the fact that DLS measures a particle in motion, while electron microscopy measures static particles. It should be clear that the immunogenicity of these preparations as shown in the examples below is due to the entirety of the preparation, and may be due to the average, smaller, or larger particles, or to the mixture thereof.
  • a chimpanzee (Phil) already infected for over 13 years (5015 days before immunization) with an HCV subtype 1b strain was vaccinated with E1 (aa 192-326) which was derived from a different strain of genotype 1b, with a 95.1% identity on the amino acid level (see also Table 2), and which was prepared as described in examples 1-3.
  • the chimpanzee received in total 6 intramuscular immunizations of each 50 ⁇ g E1 in PBS/0.05% CHAPS mixed with RIBI R-730 (MPLA+TDM+CWS) according to the manufacturer's protocol (Ribi Inc. Hamilton, Mont.).
  • the 6 immunizations were given in two series of three shots with a three week interval and with a lag period of 6 weeks between the two series.
  • the chimpanzee was continuously monitored for various parameters indicative for the activity of the HCV induced disease. These parameters included blood chemistry, ALT, AST, gammaGT, blood chemistry, viral load in the serum, viral load in the liver and liver histology.
  • the immune answer to the immunization was monitored both on the humoral and cellular level. During this period the animal was also monitored for any adverse effects of the immunization, such as change in behaviour, clinical symptoms, body weight, temperature and local reactions (redness, swelling, indurations). Such effects were not detected.
  • ALT (and especially gammaGT, data not shown) levels decreased as soon as the antibody level against E1 reached its maximum (FIG. 8). ALT rebounded rather rapidly as soon as the antibody levels started to decline, but gammaGT remained at a lower level as long as anti-E1 remained detectable.
  • E2 antigen in the liver decreased to almost undetectable levels during the period in which anti-E1 was detectable and the E2 antigen rebounded shortly after the disappearance of these antibodies. Together with the Core and E2 antigen becoming undetectable in the liver, the inflammation of the liver markedly decreased (see also Table 3). This is a major proof that the vaccine induces a reduction of the liver damage, probably by clearing, at least partially, the viral antigens from its major target organ, the liver.
  • FIG. 9 shows that the main epitopes, which can be mimicked by peptides, recognized by the B-cells are located at the N-terminal region of E2 (peptides V1V2 and V2V3, for details on the peptides used see Table 4). Since the reactivity against the recombinant E1 is higher and longer lasting, it can also be deduced from this figure, that the antibodies recognizing these peptides represent only part of the total antibody population against E1.
  • the remaining part is directed against epitopes which cannot be mimicked by peptides, i.e discontinuous epitopes.
  • epitopes are only present on the complete E1 molecule or even only on the particle-like structure.
  • Such an immune response against E1 is unique, at least compared to what is normally observed in human chronic HCV carriers (WO 96/13590 to Maertens et al.) and in chimpanzees (van Doorn et al., 1996), who raise anti-E1 antibodies in their natural course of infection.
  • anti-E1 is in part also directed to discontinuous epitopes but a large proportion is directed against the C4 epitope ( ⁇ 50% of the patient sera), a minor proportion against V1V2 (ranging from 2-70% depending on the genotype), and reactivity against V2V3 was only exceptionally recorded (Maertens et al., 1997).
  • T-cell reactivity indicates that also this compartment of the immune system is stimulated by the vaccine in a specific way, as the stimulation index of these T-cells rises from 1 to 2.5, and remains somewhat elevated during the follow up period (FIG. 10). It is this T cell reactivity that is only seen in Long term responders to interferon therapy (see: PCT/EP 94/03555 to Leroux-Roels et al.; Leroux-Roels et al., 1996).
  • a chimpanzee (Ton) already infected for over 10 years (3809 days before immunization) with HCV from genotype 1a was vaccinated with E1 from genotype 1b, with only a 79.3% identity on the amino acid level (see also Table 2), and prepared as described in the previous examples.
  • the chimpanzee received a total of 6 intramuscular immunizations of 50 ⁇ g E1 in PBS/0.05% CHAPS each mixed with RIBI R-730 according to the manufacturer's protocol (Ribi Inc. Hamilton, Mont.). The 6 immunizations were given in two series of three shots with a three week interval and with a lag period of 4 weeks between the two series.
  • the chimpanzee was continuously monitored for various parameters indicative for the activity of the HCV induced disease. These parameters included blood chemistry, ALT, AST, gammaGT, viral load in the serum, viral load in the liver and liver histology.
  • the immune answer to the immunization was monitored both on the humoral and cellular level. During this period the animal was also monitored for any adverse effects of the immunization, such as change in behaviour, clinical symptoms, body weight, temperature and local reactions (redness, swelling, indurations). Such effects were not detected.
  • ALT levels decreased as soon as the antibody level against E1 reached its maximum (FIG. 11).
  • ALT levels were even significantly reduced after vaccination (62 ⁇ 6 U/l) as compared to the period before vaccination (85 ⁇ 11 U/l). Since less markers of tissue damage were recovered in the serum, these findings were a first indication that the vaccination induced an improvement of the liver disease.
  • E2 antigen levels became undetectable in the period in which anti-E1 remained above a titer of 1.0 ⁇ 10 3 , but became detectable again at the time of lower E1 antibody levels.
  • the inflammation of the liver markedly decreased from moderate chronic active hepatitis to minimal forms of chronic persistent hepatitis (Table 3). This is another major proof that the vaccine induces a reduction of the liver damage, probably by clearing, at least partially, the virus from its major target organ, the liver.
  • FIG. 12 shows that the main epitopes, which can be mimicked by peptides and are recognized by the B-cells, are located at the N-terminal region (peptides V1V2 and V2V3, for details on the peptides used see Table 4).
  • anti-E1 is in part also discontinuous, but a large proportion is directed against he C4 epitope (50% of the patient sera), a minor proportion against V1V2 (ranging from 2-70% depending on the genotype) and exceptionally reactivity against V2V3 was recorded (Maertens et al., 1997).
  • V1V2 ranging from 2-70% depending on the genotype
  • V2V3 exceptionally reactivity against V2V3
  • immunization of a chronic carrier with an E1 protein derived from another subtype or genotype may be especially beneficial to reach higher titers, maybe circumventing a preexisting and specific immune suppression existing in the host and induced by the infecting subtype or genotype.
  • the lower titers observed in the homologous setting (1b vaccine+1b infection) may indicate binding of the bulk of the antibodies to virus. Therefore, the induced antibodies may possess neutralizing capacity.
  • epitopes besides the ones in E1 may be linked with clearing of HCV during acute phase or by interferon therapy.
  • NS3 Leroux-Roels et al., 1996; Rehermann et al., 1996 and 1997; Diepolder et al., 1995 and 1997.
  • CTL epitope mapped by Rehermann and coworkers
  • CD4 T-cell epitope mapped by Diecolder and coworkers
  • This construct already includes the epitopes described by Weiner and coworkers, and Diepolder and coworkers.
  • the non-relevant CTL epitope was changed to the epitope Rehermann and coworkers found to be linked with viral clearance.
  • the construct was additionally modified to contain a methionine at position 1166 to allow initiation of translation. This methionine will be cleaved off in E. coli since it is followed by an alanine. In this way, the introduction of new epitopes, which are not present in the natural NS3, is limited to a minimum.
  • the CTL epitope may be linked to the C-terminus at aa 1468 as depicted in detail in Table 5.
  • HCV NS-3 fragment The coding sequence of an HCV NS-3 fragment was isolated and expressed as described in Maertens et al. (PCT/EP99/02547; clone 19b; HCV aa 1188-1468 was used as starting material).
  • NS3 19b coding sequences fused respectively N- and C-terminally with the Rehermann CTL epitope (named NS-319bTn and NS-3 19bTc, respectively), were first subcloned into the pGEM-T (Promega) cloning vector giving rise to vectors pGEM-TNS-319bTn and pGEM-TNS-319bTc. The PCR-amplified sequences were verified by DNA sequence analysis.
  • the NS-3 19bT sequences are inserted into the pIGRI2 E. coli expression vector.
  • the NS-3 19bT coding sequence was isolated as a 379 bp NcoI/SnaBI fragment and ligated with SnaBI/AllwNI and AlwNI/NcoI fragments from vector pIGRI2NS-3, resulting in the vector pIGRI2NS-3Tn.
  • the NS-3 19bT coding sequence was isolated as a 585 bp SnaBI/SpeI fragment and inserted into the SnaBI/SpeI opened vector pIGRI2NS-3, resulting in the vector pIGRI2NS-3Tc.
  • Both pIGRI2NS-3Tn and pIGRI2NS-3Tc vectors were subsequently transformed to the E. coli expession strain MC1061(pAcI) and after temperature induction of the lambda P L promotor, expression levels were analysed on SDS-PAGE and Western blot, using a polyclonal rabbit anti NS-3 serum.
  • NS-3 19bTn protein (SEQ ID NO:1) MATCINGVCWTVYHGRAAVCTRGVAKAVDFVPVESMETTMRSPVFTDNSS PPAVPQTFQVAHLHAPTGSGKSTKVPAAYAAQGYKVLVLNPSVAATLGFG AYMSKAHGVDPNIRTGVRTITTGAPITYSTYGKFLADGGCSGGAYDIIIC DECHSIDSTSILGIGTVLDQAETAGARLVVLATATPPGSVTVPHPNIEEV ALSSTGEIPFYGKAIPIEVIKGGRHLIFCHSKKKCDELAAKLSGFGINAV AYYRGLDVSVIPTSGDVVVVATDALMTGFTGDFDSVIDCNTCVTQTVDFS
  • E. coli cell pasts from erlenmeyer cultures were broken by a cell disrupter (CSL, model B) at 1.4 kbar in 50 mM TRIS, pH 8. This lysate was cleared by centrifugation (15000 g, 30 min, 4° C.). The supernatant was discarded, since both for the N- and the C-terminal construct NS3 was recovered in the pellet.
  • CSL cell disrupter
  • This pellet turned out to be highly stable for the N-terminal construct allowing thorough washing (first wash with 2% sarcosyl, 0.5 M guanidiniumchloride and 10 mM DTT, second and third wash with 1% Triton X-100, 0.5 M guanidiniumchloride and 10 mM EDTA) before solubilisation. This was not the case for the C-terminal construct. Purification was further pursued on the N-terminal construct. The washed pellet was finally dissolved in 6 M guanidiniumchloride/50 mM Na 2 HPO 4 , at pH 7.2 and was sulfonated as described in Maertens et al. (PCT/EP99/02547).
  • the sulfonated pellet was first desalted on a Sephadex G25 column to 6 M Urea/50 mM triethanolamine, pH 7.5, and finally purified by two sequential anion-exchange chromatographies in the same buffer composition.
  • the first anion-exchange was performed on a Hyper DQ (50 ⁇ m) column (BioSpra Inc. Marlborough, Mass. USA) and the NS3 was recovered between 0.11 and 0.19 M NaCl. After dilution, these fractions were applied to a second Hyper DQ (20 ⁇ m) column (BioSpra Inc. Marlborough, Mass. USA) and the NS3 was recovered in the fractions containing 0.125 M NaCl.
  • E2-715 In the expression cassette, the coding sequence of E2-715 should be preceded by an E1 leader signal peptide, starting at Met364. Therefore, in plasmid pvHCV-92 (FIG. 15), which contains the coding sequence for E2-715 HCV type 1b with the long version of the E1 signal peptide (starting at Met347), a deletion was made by a double-digestion with EcoRI and NcoI, followed by a 5′-overhang fill-in reaction with T4 DNA polymerase.
  • pvHCV-99 which codes for the same protein (E2-715) with a shorter E1 leader signal peptide (starting at Met364).
  • pvHCV-99 was deposited in the strain list as ICCG 3635. It should be clear that HCV or heterologous signal sequences of variable length may be used.
  • the plasmids pvHCV-100 and -101 should contain a deletion in the E2 sequence, i.e. a deletion of the hypervariable region I (HVR-I).
  • HVR-I hypervariable region I
  • amino acids 384(His)-408(Ala) were deleted, while in plasmid pvHCV-101 aminoacids 384(His)-411(Ile) were deleted.
  • PCR amplification (denaturation 5 min 95° C., 30 cycles of amplification consisting of annealing at 55° C., polymerization at 72° C., and denaturation at 95° C. for 1 min each, elongation for 10 min at 72° C.) of the pvHCV-99 template with Gpt-pr [3757] and HCV-pr 408 [8750] resulted in a 221 bp fragment, while amplification with HCV-pr 409 [8749] and TKr-pr [3756] resulted in a 1006 bp fragment. Both PCR fragments overlap one another by 19 nucleotides.
  • PCR amplification of the pvHCV-99 template with Gpt-pr [3757] and HCV-pr 410 [8748] resulted in a 221 bp fragment
  • amplification with HCV-pr 411 [8747] and TKr-pr [3756] resulted in a 997 bp fragment.
  • Both PCR fragments overlap one another by 19 nucleotides.
  • Proteins were visualised by a specific anti-E2 monoclonal antibody (IGH 212, which can be obtained from the inventors at Innogenetics N.V., Zwijnaarde, Belgium) of an estimated molecular weight of 69 and 37 kDa for vvHCV-100 and of 68 and 35 kDa for vvHCV-101. These molecular weights indicate the presence of both a glycosylated and non-glycosylated E2-protein, which was confirmed by treatment of the samples prior to Western-blot analysis with PNGaseF. This treatment results in the detection of only one single protein of 37 kDa and 35 kDa for vvHCV-100 and vvHCV-101, respectively.
  • IGH 212 specific anti-E2 monoclonal antibody
  • Amino acid sequence of the mature E2 derived from pvHCV-100 QKIQLVNTNGSWHINRTALNCNDSLQTGFFAALEYKHKFNSSGCPERLASCRSIDKFAQG (SEQ ID NO 13) WGPLTYTEPNSSDQRPYCWHYAPRPCGIVPASQVCGPVYCFTPSPVVVGTTDRFGVPTY NWGANDSDVLILNNTRPPRGNWFGCTWMNGTGFTKTCGGPPCNIGGAGNNTLTCPTDC FRKHPEATYARCGSGPWLTPRCMVHYPYRLWHYPCTVNFTIFKVRMYVGGVEHRFEAA CNWTRGERCDLEDRDRSELSPLLLSTTEWQILPCSFTTLPALSTGLIHLHQNIVDVQYLYG VGSAVVSLVIK
  • the E1s protein was purified according to the protocol described in PCT/EP 95/03031 to Maertens et al.
  • This protocol includes covalent modification of cysteines (free cysteines and cysteines involved in intermolecular bridging, the latter after reduction of these cysteine bridges using DTT) using maleimide derivates (N-ethyl maleimide and biotin-maleimide, both obtained from Sigma).
  • maleimide derivates N-ethyl maleimide and biotin-maleimide, both obtained from Sigma.
  • active halogens were also evaluated. These compounds, ie the active halogens, block free cysteines by means of alkylation.
  • an active halogen iodoacetamde, Merck
  • mice In total three series of 6 mice each were immunized with E1s using three injections with a three week interval, each injection consisting of 5 ⁇ g E1s at 100 ⁇ g/ml PBS and mixed with an equal volume of RIBI adjuvant (R-700).
  • a first series received E1-maleimide formulated in 0.05% CHAPS
  • a second series received E1-acetamide also formulated in 0.05% CHAPS
  • a third series received E1-acetamide formulated with 0.12% betaine.
  • all mice were bled 10 days after the third immunization.
  • End point titers (defined as the dilution of the serum still resulting in a OD 2 times higher then background values) for each animal individuallv were determined against E1-maleimide and E1-acetamide.
  • FIG. 17 shows these end-point titers, presented as mean with standard deviations. Mice that received E1-maleimide mounted only an antibody response which is able to recognize maleimide-containing epitopes (no reactivity at all on E1-acetamide), mice that received E1-acetamide clearly mount an antibody response against true E1 epitopes, since the antibodies are reactive against both E1-acetamide and E1-maleimide.
  • mice immunized with E1-acetamide (CHAPS and betaine formulated) do mount an antibody response which is able to recognize the peptides V1V2, V2V3, V3V4, V5C4, C4V6.
  • V6 was not part of E1s, we can conclude that antibodies were mounted against C4, V3 (V3V4 is positive while V4V5 is not) and V1V2.
  • Mice immunized with E1s-maleimide mount only a very low response against the V1V2 and V2V3 peptides.
  • the acetamide-modified E1 formulated in betaine was also used to reboost the chimpanzees Phil and Ton. Both chimpanzees were immunized again with two consecutive intramuscular immunisations with a three week time interval (50 ⁇ g E1 mixed with RIBI adjuvant as for the examples 4 and 5). As can be judged from FIGS. 20 and 21, the anti-E1 response could indeed be boosted again, and this to higher levels than obtained in the previous immunisations after two injections. This titration was performed against a standard, which is a mixture of three human high titre anti-E1 sera (obtained from chronic HCV carriers).
  • the anti-E1 titer of these sera was defined as some unit/ml.
  • chimpanzee Phil FIG. 20
  • titers twice as high as in human carriers were induced only after two immunizations.
  • chimpanzee Ton FIG. 21
  • titers up to 140-fold higher were induced. This stresses once more the high immunogenecity of these E1-particles.
  • Alkylated E1 has Superior Qualities for Diagnostic Use
  • E1s-acetamide as described in example 9 was further evaluated as antigen for the detection of anti-E1 antibodies in serum samples from human chronic HCV carriers.
  • these antigens were bound to LIA-membranes, and strips were processed essentially as described in Zrein et al. (1998).
  • Serum samples from 72 blood donors were evaluated first, in order to determine the optimal concentration of the E1 antigen which can be used in the assay in order to exclude “false” positives.
  • E1s-maleimide this concentration proved to be 8 ⁇ g/ml, while for E1s-acetamide a concentration up to 50 ⁇ g/ml did not result in false positive results (no samples showing a relative color staining above 0.5).
  • E1s and E2s were produced and purified as described in Maertens et al. PCT/EP95/030301 except for the fact the maleimide-modificiation was replaced by alkylation using iodoacetamide.
  • E1s and E2s in 3% empigen alone or as an equimolar mixture were injected on a Superdex-200 PC 3.2/30 column equilibrated in PBS/0.2% CHAPS. This column is designed to use with the SMARTTM HPLC equipment from Pharmacia LKB (Sweden). The fractions were screened by means of three different sandwich ELISAs.
  • E1-(IGH 207) and E2-(IGH 223) specific monoclonals were coated at 2 ⁇ g/ml. Fractions of the gel filtration were incubated in a ⁇ fraction (1/2500) ⁇ dilution. Two other E1 (IGH 200) and E2 (IGH 212) monoclonals, conjugated with biotin were used for detection of the bound antigen. The streptavidin-HRP/TMB system was used to develop the bound biotin into a yellow color which was measured at 450 nm.
  • This ELISA system was used in a homologous (anti-E1 coating/anti-E1 detection or anti-E2 coating/anti-E2 detection) and a heterologous set-up (anti-E1 coating/anti-E2 detection). The latter theoretically only detects particles in which both E1 and E2 are incorporated.
  • the reactive fractions were pooled, concentrated on a 10 kDa filter, and again chromatographed on Superdex-200 in PBS/0.05% CHAPS. All these fractions were tested for reactivity by using the different ELISA set-ups. As can be judged from FIG.
  • E1s of genotype 1b and of genotype 4 were produced and purified as described in Maertens et al., PCT/EP95/030301 except for the fact the maleimide-modificiation was replaced by alkylation using iodoacetamide for the genotype 1b.
  • E1s-1b and E1s-4 in 3% empigen alone or as an equimolar mixture were injected on a Superdex-200 PC 3.2/30 column equilibrated in PBS/0.2% CHAPS. This column is designed to use with the SMARTTM HPLC equipment from Pharmacia LKB (Sweden).
  • the major protein containing fractions were pooled, concentrated on a 10 kDa filter, and again chromatographed on Superdex-200 in PBS/0.05% CHAPS. All these fractions were tested for reactivity by using an ELISA set-up which should only detect particles containing E1 from both genotypes. For this ELISA streptavidin was coated at 2 ⁇ g/ml. Fractions of the gel filtration were incubated in a ⁇ fraction (1/2500) ⁇ dilution. An E1 monoclonal antibody (IGH 200) which only recognizes E1 from genotype 1 and 10 was used for detection of the bound antigen.
  • IGH 200 E1 monoclonal antibody
  • the goat-anti-mouse-HRP/TMB system was used for development of the assay into a yellow color which was measured at 450 nm.
  • E1-4 to E1-1b does not result in a major shift in the retention time of the proteins, indicating that particles are indeed still present.
  • These particles contain both E1 proteins, ie E1s of genotype 1b and genotype 4, since only in this set-up the ELISA scores positive.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention is based on the finding that the envelope proteins of HCV induce a beneficial immune response in chronically HCV-infected chimpanzees. The immunization can preferentially be carried out using HCV envelope proteins in the form of particles which are produced in a detergent-assisted manner. The envelope proteins when presented as such to chronic HCV carriers are highly immunogenic and stimulate both the cellular and humoral immune response.

Description

    FIELD OF THE INVENTION
  • The present invention is based on the finding that the envelope proteins of HCV induce a beneficial immune response in chimpanzees which are chronically infected with a [0001] heterologous subtype 1a or subtype 1b HCV strain. More specifically, the present invention relates to the finding that envelope proteins are highly immunogenic and result in the stimulation of both the cellular and humoral immune response. Moreover, the present invention relates to the finding that blocking of cysteines by alkylation results in even more immunogenic proteins. In addition, the envelope proteins of the present invention can be incorporated in particles which display a high immunogenecity and immunoreactivty. It was further demonstrated that such particles may incorporate other proteins.
    • BACKGROUND OF THE INVENTION
  • Hepatitis C virus (HCV) infection is a major health problem in both developed and developing countries. It is estimated that about 1 to 5% of the world population is affected by the virus. HCV infection appears to be the most important cause of transfusion-associated hepatitis and frequently progresses to chronic liver damage. Moreover, there is evidence implicating HCV in induction of hepatocellular carcinoma. Consequently, the demand for reliable diagnostic methods and effective therapeutic agents is high. Also sensitive and specific screening methods of HCV-contaminated blood-products and improved methods to culture HCV are needed. [0002]
  • HCV is a positive stranded RNA virus of approximately 9,600 bases which encode at least three structural and six non-structural proteins. Based on sequence homology, the structural proteins have been functionally assigned as one single core protein and two envelope proteins: E1 and E2. The E1 protein consists of 192 amino acids and contains 5 to 6 N-glycosylation sites, depending on the HCV genotype. The E2 protein consists of 363 to 370 amino acids and contains 9-11 N-glycosylation sites, depending on the HCV genotype (for reviews see: Major and Feinstone, 1997; Maertens and Stuyver, 1997). The E1 protein contains various variable domains (Maertens and Stuyver, 1997), while the E2 protein contains three hypervariable domains, of which the major domain is located at the N-terminus of the protein (Maertens and Stuyver, 1997). The latter envelope proteins have been produced by recombinant techniques in [0003] Escherchia coli, insect cells, yeast cells and mammalian cells. The usage of an expression system in higher eukaryotes and especially in mammalian cell culture leads to envelope proteins that are effectively recognized by antibodies in patient samples (Maertens et al., 1994).
  • It has been suggested that the E1 envelope protein needs the E2 envelope protein to reach a proper folding status (Deleersnyder et al., 1997). In addition, it has been suggested that E1 and E2 form heterodimers which may form the basic unit of the viral envelope (Yi et al., 1997). In WO 98/21338 to Liang et al. these presumptions have been used to construct HCV particles, which consist of E1 and E2, as well as Core and P7. In other words, the usage of E1 or E2 separately for immunization and other purposes is not suggested in the prior art. But, Houghton (1997) reported that repeated immunizations with recombinant gpE1E2 (4×25 μg) of 3 chronically HCV-infected chimpanzees did not induce a significant immune response. The inventors of the present application reasoned that the induction of an anti-envelope immune response in patients with chronic hepatitis C would indeed be desirable and beneficial to the patient, since higher levels of such antibodies seem to correlate with good response to interferon therapy, and may therefore help the patient to clear the virus (PCT/EP 95/03031 to Maertens et al.). The inventors of the present invention further reasoned that, as the antibody levels against E1 in chronic HCV carriers are among the lowest of all HCV antibodies, it may be beneficial to raise those antibody levels, and possibly the cellular response, to induce control or even clearance of the infection by the host. Also higher levels of cellular immunity against E1 seem to correlate with good response towards interferon therapy (Leroux-Roels et al., 1996). [0004]
  • Besides the importance of anti-E1 immunity in relation to interferon therapy, other indications point-out that some other parts of the HCV genome may be important to induce a specific immune response which may allow control of the infection. Also T-cell reactivity against the C-terminal region of the core protein has been observed more frequently in patients responding to interferon therapy (Leroux-Roels et al, 1996). Potentially neutralizing antibodies against the NS4B protein were demonstrated in patients clearing HCV after liver transplant (Villa et al., 1998). Also within NS3 several T-cell epitopes have been mapped which seem to correlate with clearing of HCV during the acute phase (see: PCT/EP 94/03555 to Leroux-Roels et al.; Leroux-Roels et al., 1996; Rehermann et al., 1996 and 1997; Diepolder et al., 1995 and 1997). Furthermore, antibodies to NS5A, like E1 antibodies, show higher levels at baseline before interferon-alpha therapy in long term responders (LTR) as compared to non-responders. [0005]
  • At present, therapeutic vaccination for HCV has not been successful. Also prophylactic vaccination has only been shown to be effective against a homologous strain of HCV (Choo et al., 1994). The present invention relates to the surprising finding that administration of an HCV envelope antigen can dramatically improve the state of chronic active hepatitis in an individual infected with a heterologous strain or isolate, both in a [0006] heterologous subtype 1a or heterologous subtype 1b infection. Indeed, chronically infected chimpanzees who were administered six doses of 50 μg E1s (i.e. aa 192-326 of E1) surprisingly showed vigourous humoral and cellular immune responses, which had not been mounted over the entire period of chronic infection before the latter vaccination. Moreover, viral antigen became undetectable in the liver over a period of two to five months and remained undetectable for at least 5 months post-vaccination. Although HCV-RNA titers in the serum did not decrease, liver enzyme levels in the serum showed a clear tendency to normalize. Most importantly, liver histology improved dramatically in both vaccinees. The present invention further relates to the surprising finding that the E1 protein used for vaccination, which was expressed as a single HCV protein without its hydrophobic anchor, forms stable particles. It should also be noted that, to avoid induction of an immune response against non-relevant epitopes, the E1 protein used for vaccination was constructed as a consensus sequence of individual clones derived from a single serum sample from one chronic carrier. In addition, the present application relates to the finding that the induction of such anti-E1 responses may be increased by using antigens of a different genotype than the ones of the infection present in the host. Moreover, the present application relates to the finding that when cysteines of HCV envelope proteins are alkylated, for instance by means of N-(iodoethyl)-trifluoroacetamide, ethylenimine or active halogens, such as iodoacetamide, the oligomeric particles as described above display an even higher immunogenicity. Finally, the present invention relates also to the finding that mutation of cysteines of HCV envelope proteins to any other naturally occuring amino acid, preferentially to methionine, glutamic acid, glutamine or lysine, in the oligomeric particles as described above also results in higher immunogenicity, compared to the original envelope proteins.
    • AIMS OF THE INVENTION
  • It is clear from the literature that there is an urgent need to develop reliable vaccines and effective therapeutic agents for HCV. Therefore, the present invention aims at providing an antigen preparation, which is able to induce specific humoral and cellular immunity to HCV envelope proteins, even (but not solely) in chronic HCV carriers. The same antigens can be used for diagnosis of the immune response. [0007]
  • More specifically, the present invention aims at providing an antigen preparation as defined above, which consists of stable particles of single envelope proteins of HCV. It should be clear that, at present, such particles or a method to prepare such particles, are not known in the art. Moreover, there is no indication in the art that any antigen preparation, including such stable particles or such purified single HCV envelope proteins, could successfully be used as (heterologous) prophylactic or therapeutic vaccine against HCV. The present invention thus also aims at providing a method to produce stable particles, which can be successfully used as a prophylactic or therapeutic agent against HCV, in addition to provide DNA vaccines encoding HCV antigens. More specifically, the present invention aims at providing a method to produce the latter particles based on detergent-assisted particle formation (see further). Furthermore, the present invention aims at providing methods to prepare particles consisting of antigens obtained from different HCV genotypes. [0008]
  • Moreover, the present invention aims at providing an antigen which is a consensus sequence from individual clones, which may allow a more correct folding of the proteins. This in order to avoid stimulation of immunity against non-relevant epitopes. [0009]
  • Furthermore, the present invention aims at providing an antigen formulation, in particular for therapeutic vaccination, based on the genotype of HCV by which the chronic carrier is infected. In this regard, the present invention aims at providing an envelope protein of either a different or a homologous genotype or subtype compared to the genotype or subtype of the chronic carrier. [0010]
  • A further aim of the invention is to provide a method for treating or therapeutically vaccinating chronically infected patients using the above-indicated antigens or DNA vaccines, possibly in combination with other compounds. The present invention also aims to provide a method to prophylactically vaccinate humans against HCV. [0011]
  • Another aim of the invention is to provide oligomeric particles which have a superior immunogenicity, due to the mutation of at least one cysteine residue of HCV envelope protein into a natural occuring amino acid, preferentially methionine, glutamic acid, glutamine or lysine. Alternatively, alkylation of at least one cysteine residue of HCV envelope protein may be performed. In particular, the latter protein can be alkylated by means of ethylenimine, N-(iodoethyl)trifluoroacetamide or active halogens. In this regard, the instant invention aims to provide the additional use of oligomeric particles as vehicles for presenting non-HCV epitopes efficiently. [0012]
  • It is a further aim of the present invention to provide a method to treat patients, acutely or chronically infected, with an anti-envelope antibody, such as anti-E1 antibody, e.g. anti-E1 V2 region antibody, either alone or in combination with other treatments. [0013]
  • Another aim of the invention is to provide a T cell stimulating antigen such as Core, E1, E2, P7, NS2, NS3, NS4A, NS4B, NS5A, or NS5B along with the envelope proteins of the invention. [0014]
  • All the aims of the present invention are considered to have been met by the embodiments as set out below. [0015]
    • BRIEF DESCRIPTION OF TABLES AND DRAWINGS
  • Table 1 provides sequences of E1 clones obtained from a single chronic carrier, the E1 construct used for production of a vaccine is the consensus of all these individual clones. V1-V5, variable regions 1-5; C4, [0016] constant domain 4; HR, hydrophobic region; HCV-B con, consensus sequence at positions that are variable between clones and HCV-J.
  • Table 2 provides sequences of the E1 vaccine protein and the E1 protein as found in the infected chimpanzees Phil and Ton. The subtype 1b isolate of Phil differed by 5.92% from the vaccine strain. The difference between the vaccine and the [0017] subtype 1a isolate of Ton was 20.74%.
  • Table 3 provides a schematic overview of the changes induced by therapeutic vaccination in two chronically infected chimpanzees (Ton and Phil). Analysis was performed as explained for FIGS. 8 and 11. In addition, histology and inflammation were scored from the liver biopsies. [0018]
  • Table 4 provides sequences of peptides used to map the B-cell epitopes. Note that HR overlaps with V4V5. [0019]
  • Table 5 shows the rearrangement of NS3 in order to make a shorter protein carrying all major epitopes correlating with viral clearance. [0020]
  • Table 6 shows the reactivity in LIA of E1s-acetamide versus E1s-maleimide with sera of chronic HCV carriers. Proteins were immobilized on the LIA membranes. E1s-acetamide was sprayed as such on the LIA strips while E1s-maleimide (also containing biotin-maleimide) was complexed with streptavidin before spraying. Antigens were bound to LIA-membranes, and strips were processed essentially as described in Zrein et al. (1998). Human antibodies directed against these antigens were visualized using a human-anti-IgG conjugated with alkaline phosphatase. NBT and BCIP were used for color development of the strip. Staining was scored from 0.5 to 4, as explained in Zrein et al. (1998). Using a cut-off for this assay of 0.5 the number of positive samples (#pos) and percentage (% pos) is mentioned at the bottom of the table. [0021]
  • FIG. 1. Superimposed size exclusion chromatography profiles in PBS/3% Empigen-BB of E1s and E2s proteins expressed and purified according to Maertens et al. (PCT/EP95/03031) [0022]
  • FIG. 2. Superimposed size exclusion chromatography (SEC) profiles of E1s and E2s proteins expressed and purified according to Maertens et al. (PCT/EP95/03031), and submitted to another run on the same SEC column in PBS/0.2% CHAPS, to obtain specific oligomeric structures of an estimated apparent molecular weight of 250-300 kDa. Similar degrees of association can be obtained by using 3% betaine. [0023]
  • FIG. 3. Superimposed size exclusion chromatography profiles of E1s and E2s proteins expressed and purified according to Maertens et al. (PCT/EP95/03031), submitted to a second run in 0.2% CHAPS or 3% betaine to obtain specific oligomeric structures as shown in FIG. 2, and submitted to a third run on the same SEC column in 0.05% CHAPS, to obtain specific homo-oligomeric structures with an estimated apparent molecular weight of 250-300 kDa E2s) and >600 kDa (E1s). Similar degrees of association can be obtained by using 0.1 or 0.5% betaine. [0024]
  • FIG. 4 Dynamic light scattering analysis, expressed as percentage of the number of particles in relation to the observed diameter in nm, of E1s in PBS/0.05% CHAPS. [0025]
  • FIG. 5 Dynamic light scattering analysis, expressed as percentage of the number of particles in relation to the observed diameter in nm, of E1s in PBS/0.1% betaine (top) or 0.5% betaine (bottom). [0026]
  • FIG. 6 EM staining of (A) E1s in PBS/0.05% CHtAPS and (B) E1s in PBS/3% betaine. [0027]
  • FIG. 7 Size distribution of particles of E1s in PBS/0.05% CHAPS. [0028]
  • FIG. 8 Evolution of anti-E1 antibodies induced by six consecutive and 3 boost immunizations (indicated by small arrows) in a 1b infected chimpanzee (Phil), and the evolution of ALT, HCV RENA, and anti-E1 antibodies. Anti-E1 antibodies binding to solid phase E1 were detected using an anti-human IgG specific secondary antiserum conjugated with peroxidase. TMB was used as substrate for colour development. The results are expressed as end-point titer. ALT levels were determined with a clinical analyser, and are expressed as U/l. HCV RNA in serum was determined using HCV Monitor (Roche, Basel, Switzerland). Viral load in the liver was determined by semi-quantitative determination of the amount of E2 antigen stained in the liver biopsy using a specific monoclonal (ECACC accession number 98031215 as described in EP application No 98870060.5). [0029]
  • FIG. 9 Epitope mapping of the antibody responses induced by immunization with E1 in chimpanzee Phil. Antibodies reactivity towards the various peptides was measured by an indirect ELISA in which biotinylated peptides (see also Table 4) are adsorbed on the microtiterplates via streptavidin. Specific antibodies are detected using an anti-human IgG specific secondary antiserum conjugated with peroxidase. TMB was used as substrate for colour development. [0030]
  • FIG. 10 Results of the lymphocyte proliferation assay before and after vaccination in chimpanzee Phil. Frozen PBMC were thawed and stimulated in triplicate with different antigens. Negative control was medium alone, while concanavalin A was used as positive control at a concentration of 5 μg/ml. PBMC at a concentration of 2-4×10[0031] 5 cells/well in a total volume of 150 μl were cultured in RPMI 1640 medium supplemented with 10% heat-inactivated FCS in U-shaped 96-well microtiterplates together with the controls or 1 μg/ml of E1 for 90 h at 37° C. in a humidified atmosphere containing 5% CO2. During the last 18 h the cells were pulsed with 0.5 μCi (3H) thymidine per well. Subsequently, the cultures, were harvested on glass fibre filters and label uptake was determined. Results are expressed as Stimulation Indices (SI): mean cpm antigen/mean cpm medium alone of triplicate determinations.
  • FIG. 11 Evolution of anti-E1 antibodies induced by six consecutive and 3 boost immunizations (indicated by small arrows) in [0032] HCV subtype 1a infected chimpanzee Ton. Evolution of ALT, HCV RNA in serum and determination of HCV antigen in liver are shown. Anti-E1 antibodies were determined by means of an indirect ELISA: specific antibodies binding to solid phase-coated E1 are detected using a anti-human IgG specific secondary antiserum conjugated with peroxidase. TMB was used as substrate for color development. The results are expressed as end-point titres. ALT levels were determined with a clinical analyser, and are expressed as U/l. HCV RNA was determined using HCV Monitor (Roche, Basel, Switzerland). E2 antigen was stained in the liver biopsy using a specific monoclonal (ECACC accession number 98031215 as described in EP application No 98870060.5). The semi-quantitative scoring is indicated by black squares for clearly positive staining in the majority of the cells, by grey squares for clear staining in the minority of the cells and by white squares for biopsies showing no detectable staining. HCV RNA is indicated by small black boxes. Staining of E2 could be confirmed by Core and E1 staining (data not shown).
  • FIG. 12 Epitope mapping of the antibody response induced by immunization with E1 in Ton. Antibodies reactivity towards the various peptides was measured by an indirect ELISA in which biotinylated peptides (see also Table 4) are adsorbed on the microtiterplates via streptavidin. Specific antibodies are detected using an anti-human IgG specific secondary antiserum conjugated with peroxidase. TMB was used as substrate for color development. [0033]
  • FIG. 13 Analysis of E1 antibody responses to [0034] subtype 1a and subtype 1b E1 proteins in chimpanzee Ton. For this purpose an E1 genotype 1a, derived from the HCV-H sequence, recombinant vaccinia virus was generated expressing the same part of E1 as for genotype 1b (see infra). E1 was derived from crude lysates from vaccinia virus infected RK13 cells (prepared as described in Maertens et al. (PCT/EP95/03031)). Antibody reactivity was measured by an indirect ELISA in which E1 was adsorbed on the microtiterplates via the high-mannose binding Galanthus nivalis agalutinin (GNA). Specific antibodies were detected using an anti-human IgG specific secondary antiserum conjugated with peroxidase. TMB was used as substrate for colour development. The results are expressed as differential OD (OD of well with adsorbed E1 minus OD of well without adsorbed E1).
  • FIG. 14 Results of the lymphocyte proliferation assay before and after vaccination of chimpanzee Ton. Frozen PBMC were thawed and stimulated in triplicate with different antigens. Negative control was medium alone, while concanavalin A was used as positive control at a concentration of 5 μg/ml. PBMC at a concentration of 2-4 10[0035] 5 cells/well in a total volume of 150 μl were cultured in RPMI 1640 medium supplemented with 10% heat-inactivated FCS in U-shaped 96-well microtiterplates together with the controls or 1 μg/ml of E1 for 90 h at 37° C. in a humidified atmosphere containing 5% CO2. During the last 18 h the cells are pulsed with 0.5 μCi (3H) thymidine per well. Subsequently, the cultures, are harvested on glass fibre filters and label uptake is determined. Results are expressed as Stimulation Indices (SI): mean cpm antigen/mean cpm medium alone of triplicate determinations.
  • FIG. 15 Maps of the constructs used to obtain expression of an E2 protein with its N-terminal hypervariable region deleted. Constructs pvHCV-92 and pvHCV-99 are intermediate constructs used for the construction of the deletion mutants pvHCV-100 and pvHCV-101. [0036]
  • FIG. 16 Sequence (nucleotides: A; translation: B) corresponding with the constructs depicted in FIG. 15 (see above). [0037]
  • FIG. 17 Antibody titers obtained in mice upon immunization with different E1 preparations as described in example 9. Titers were determined by means of ELISA: murine sera were diluted 1/20 and further on (0.5 log[0038] 10) and incubated on E1s (either acetamide or maleimide modified) coated on microtiterplates. After washing binding antibodies are detected using an anti-mouse IgG specific secondary antiserum conjugated with peroxidase. TMB was used as substrate for colour development. The results are expressed as end-point titer and standard deviations are shown (n=6).
  • FIG. 18 Epitope mapping of the antibody response induced by immunization with different E1s preparations in mice. Antibody reactivity towards the various peptides was measured by an indirect ELISA, in which biotinylated peptides (listed in Table 4) are adsorbed on the microtiterplates via streptavidin. Murine sera were diluted 1/20 and specific antibodies are detected using an anti-mouse-IgG specific secondary antiserum conjugated with peroxidase. TMB was used as substrate for colour development. [0039]
  • FIG. 19 Immunoglobulin isotyping profile of mice immunized with different E1s preparations. Specific Ig class and subclass antibodies were adsorbed at the microtiterplate. After capturing of the murine Ig out of immune sera diluted 1/500, E1s was incubated at 1 μg/ml. The formed immunecomplexes were further incubated with a polyclonal rabbit antiserum directed against E1. Finally, the rabbit antibodies were detected using a goat-anti-rabbit Ig secondary antiserum conjugated with peroxidase. TMB was used as substrate for color development. The results were normalized for IgG[0040] 1 (ie the IgG1 signal was for each animal separately considered to be 1 and all the results for the other isotypes were expressed relative to this IgG1 result).
  • FIG. 20 Antibody titers induced by two immunizations around [0041] day 1000 with E1s-acetamide in chimp Phil. Anti-E1 antibodies were determined by means of an indirect ELISA: specific antibodies binding to solid phase E1 are detected using anti-human IgG specific secondary antiserum conjugated with peroxidase. The titer is expressed in units/ml, these units refer to an in house standard which is based on human sera.
  • FIG. 21 Antibody titers induced by two immunizations around day 900 with E1s-acetamide in chimp Ton. Anti-E1 antibodies were determined by means of an indirect ELISA: specific antibodies binding to solid phase E1 are detected using anti-human IgG specific secondary antiserum conjugated with peroxidase. The titer is expressed in units/ml, these units refer to an in house standard which is based on human sera. [0042]
  • FIG. 22 SEC profile of the final detergent reduction step (0.2 to 0.05% CHAPS): E1 alone particle (A), E2 alone particle (B) or an equimolar mixture of E1 and E2; mixed particle (C). The figure also shows an overlay of the OD values of an ELISA specifically detecting E1 only (top), E2 only (middle) and an ELISA detecting only mixed particles (bottom). [0043]
  • FIG. 23 SEC profile of the final detergent reduction step (0.2 to 0.05% CHAPS): E1 genotype 1b alone particle (top), [0044] E1 genotype 4 alone particle (middle) or an equimolar mixture of E1 genotype 1b and 4, mixed particle (bottom). The figure also shows an overlay of the OD values of an ELISA specifically detecting only mixed particles (see also FIG. 22).
    • DETAILED DESCRIPTION OF THE INVENTION
  • The invention described herein draws on previously published work and pending patent applications. By way of example, such work consists of scientific papers, patents or pending patent applications. All these publications and applications, cited previously or below are hereby incorporated by reference. [0045]
  • The present invention relates to HCV vaccination. For the first time successful immunotherapy of chimpanzees with severe chronic active hepatitis C could be achieved by vaccination with an HCV antigen. The vaccine not only induced high immune responses, but also induced clearance of viral antigen from the liver, and considerable improvement of the histological activity and of liver disease. The present invention further relates to purified single HCV envelope proteins and in particular to oligomeric particles. The oligomeric particles consist essentially of HCV envelope proteins and have a diameter of 1 to 100 nm as measured by dynamic light scattering or possibly electron microscopy. In this regard it should be stressed that the particles can be formed by E1 and/or E2 proteins only, or parts thereof (see infra). Therefore, the oligomeric particles of the present invention differ fundamentally with the HCV-like particles described in WO 98/21338, which necessarily consist of E1 and E2 and Core and P7. The terms “oligomeric particles consisting essentially of HCV envelope proteins” are herein defined as structures of a specific nature and shape containing several basic units of the HCV E1 and/or E2 envelope proteins, which on their own are thought to consist of one or two E1 and/or E2 monomers, respectively. It should be clear that the particles of the present invention are defined to be devoid of infectious HCV RNA genomes. The particles of the present invention can be higher-order particles of spherical nature which can be empty, consisting of a shell of envelope proteins in which lipids, detergents, the HCV core protein, or adjuvant molecules can be incorporated. The latter particles can also be encapsulated by liposomes or apolipoproteins, such as, for example, apolipoprotein B or low density lipoproteins, or by any other means of targeting said particles to a specific organ or tissue. In this case, such empty spherical particles are often referred to as “viral-like particles” or VLPs. Alternatively, the higher-order particles can be solid spherical structures, in which the complete sphere consists of HCV E1 or E2 envelope protein oligomers, in which lipids, detergents, the HCV core protein, or adjuvant molecules can be additionally incorporated, or which in turn may be themselves encapsulated by liposomes or apolipoproteins, such as, for example, apolipoprotein B, low density lipoproteins, or by any other means of targeting said particles to a specific organ or tissue, e.g. asialoglycoproteins. The particles can also consist of smaller structures (compared to the empty or solid spherical structures indicated above) which are usually round (see further)-shaped and which usually do not contain more than a single layer of HCV envelope proteins. A typical example of such smaller particles are rosette-like structures which consist of a lower number of HCV envelope proteins, usually between 4 and 16. A specific example of the latter includes the smaller particles obtained with E1s in 0.2% CHAPS as exemplified herein which apparently contain 8-10 monomers of E1s. Such rosette-like structures are usually organized in a plane and are round-shaped, e.g. in the form of a wheel. Again lipids, detergents, the HCV core protein, or adjuvant molecules can be additionally incorporated, or the smaller particles may be encapsulated by liposomes or apolipoproteins, such as, for example, apolipoprotein B or low density lipoproteins, or by any other means of targeting said particles to a specific organ or tissue. Smaller particles may also form small spherical or globular structures consisting of a similar smaller number of HCV E1 or E2 envelope proteins in which lipids, detergents, the HCV core protein, or adjuvant molecules could be additionally incorporated, or which in turn may be encapsulated by liposomes or apolipoproteins, such as, for example, apolipoprotein B or low density lipoproteins, or by any other means of targeting said particles to a specific organ or tissue. The size (i.e. the diameter) of the above-defined particles, as measured by the well-known-in-the-art dynamic light scattering techniques (see further in examples section), is usually between 1 to 100 nm, more preferentially between 2 to 70 nm, even more preferentially between 2 and 40 nm, between 3 to 20 nm, between 5 to 16 nm, between 7 to 14 nm or between 8 to 12 nm. [0046]
  • The invention further relates to an oligomeric particle as defined above, wherein said envelope proteins are selected from the group consisting of HCV E1, HCV E1s, HCV E2 proteins, [0047] SEQ ID No 13 or SEQ ID No 14, or parts thereof. The proteins HCV E1 and HCV E2, and a detailed description of how to purify the latter proteins, are well-described and characterized in PCT/EP 95/03031 to Maertens et al. HCV E1s, SEQ ID No 13 or SEQ ID No 14, or parts thereof, can be purified similarly as described for HCV E1 or HCV E1s in PCT/EP 95/03031 to Maertens et al. It should be stressed that the whole content, including all the definitions, of the latter document is incorporated by reference in the present application. The protein HCV E1s refers to amino acids 192 to 326 of E1, and represents the E1 protein without its C-terminal hydrophobic anchor. The term “or parts thereof” refers to any part of the herein-indicated proteins which are immunogenic, once they are part of a particle of the present invention.
  • The invention further pertains to oligomeric particles as described herein, wherein at least one cysteine residue of the HCV envelope protein as described above is alkylated, preferably alkylated by means of alkylating agents, such as, for example, active halogens, ethylenimine or N-(iodoethyl)trifluoroacetamide. In this respect, it is to be understood that alkylation of cysteines refers to cysteines on which the hydrogen on the sulphur atom is replaced by (CH[0048] 2)nR, in which n is 0, 1, 2, 3 or 4 and R═H, COOH, NH2, CONH2, phenyl, or any derivative thereof. Alkylation can be performed by any method known in the art, such as, for example, active halogens X(CH2)nR in which X is a halogen such as I, Br, Cl or F. Examples of active halogens are methyliodide, iodoacetic acid, iodoacetamide, and 2-bromoethylamine. Other methods of alkylation include the use of ethylenimine or N-(iodoethyl)trifluoroacetamide both resulting in substitution of H by —CH2—CH2—NH2 (Hermanson, 1996). The term “alkylating agents” as used herein refers to compounds which are able to perform alkylation as described herein. Such alkylations finally result in a modified cysteine, which can mimic other aminoacids. Alkylation by an ethylenimine results in a structure resembling lysine, in such a way that new cleavage sites for trypsine are introduced (Hermanson 1996). Similarly, the usage of methyliodide results in an amino acid resembling methionine, while the usage of iodoacetate and iodoacetamide results in amino acids resembling glutamic acid and glutamine, respectively. In analogy, these amino acids are preferably used in direct mutation of cysteine. Therefore, the present invention pertains to oligomeric particles as described herein, wherein at least one cysteine residue of the HCV envelope protein as described herein is mutated to a natural amino acid, preferentially to methionine, glutamic acid, glutamine or lysine. The term “mutated” refers to site-directed mutagenesis of nucleic acids encoding these amino acids, ie to the well kown methods in the art, such as, for example, site-directed mutagenesis by means of PCR or via oligonucleotide-mediated mutagenesis as described in Sambrook et al. (1989).
  • The term “purified” as applied herein refers to a composition wherein the desired components, such as, for example, HCV envelope proteins or oligomeric particles, comprises at least 35% of the total components in the composition. The desired components preferably comprises at least about 40%, more preferably at least about 50%, still more preferably at least about 60%, still more preferably at least about 70%, even more preferably at least about 80%, even more preferably at least about 90%, even more preferably at least about 95%, and most preferably at least about 98% of the total component fraction of the composition. The composition may contain other compounds, such as, for example, carbohydrates, salts, lipids, solvents, and the like, without affecting the determination of the percentage purity as used herein. An “isolated” HCV oligomeric particle intends an HCV oligomeric particle composition that is at least 35% pure. In this regard it should be clear that the term “a purified single HCV envelope protein” as used herein, refers to isolated HCV envelope proteins in essentially pure form. The terms “essentially purified oligomeric particles” and “single HCV envelope proteins” as used herein refer to HCV oligomeric particles or single HCV envelope proteins such that they can be used for in vitro diagnostic methods and therapeutics. These HCV oligomeric particles are substanially free from cellular proteins, vector-derived proteins or other HCV viral components. Usually, these particles or proteins are purified to homogeneity (at least 80% pure, preferably 85%, more preferably 90%, more preferably 95%, more preferably 97%, more preferably 98%, more preferably 99%, even more preferably 99.5%, and most preferably the contaminating proteins should be undetectable by conventional methods such as SDS-PAGE and silver staining). [0049]
  • The present invention also relates to an oligomeric particle as defined above wherein said envelope proteins are any possible mixture of HCV E1, HCV E1s, HCV E2, [0050] SEQ ID No 13 and/or SEQ ID No 14, or parts thereof, such as, for example, a particle of the present invention can substantially consist of HCV E1- and HCV E2 proteins, HCV E1- and HCV E1s proteins, HCV E1s- and HCV E2 proteins, and HCV E1-, HCV E1s- and HCV E2 proteins. Furthermore, the present invention also relates to an oligomeric particle as defined above wherein said proteins are derived from different HCV strains, subtypes or genotypes, such as, for example, said proteins are derived from genotype 1b and genotype 4, or are a mixture consisting of HCV envelope proteins from one strain or genotype of HCV and at least one other strain or genotype of HCV. The different HCV strains or genotypes are well-defined and characterized in PCT/EP 95/04155 to Maertens et al. It is stressed again that the whole content, including all the definitions, of the latter document is incorporated by reference in the present application. Thus, the present invention relates to oligomeric particles comprising envelope proteins derived from any HCV strain or genotype known in the art or to particles comprising a mixture of proteins derived from any HCV strain or genotype known in the art. In this regard the present invention also relates to a consensus sequences derived from individual clones as exemplified below and in the examples section (see further).
  • The present invention further relates to an oligomeric particle as described herein obtainable by a method, as well as to said method to produce said oligomeric particle. Said method is characterized by the following steps: [0051]
  • (1) Purifying HCV envelope proteins, possibly including the use of an optionally first detergent. In essence, the purification procedure of step (I) has been described extensively in PCT EP 95/03031 to Maertens et al. Importantly, according to the present invention, the blocking step in the purification procedure as described in PCT EP 95/03031, eg with NEM-biotin, is carried out with an alkylation step as described in the present application, preferentially by using iodoacetamide. Moreover, the purification procedure of step (I) can possibly include the use of a disulphide bond cleavage agent, and possibly include the use of an alkylating agent. Finally, the procedure of step (I) results in purified HCV envelope proteins in a solution. [0052]
  • (II) Replacing the solution of said purified HCV envelope proteins with a detergent or salt, resulting in the formation of oligomeric particles. [0053]
  • (III) Recovering or purifying said oligomeric particles, possibly including further reducing the concentration of the detergent or salt of step (II), which further assists the formation and stabilization of said oligomeric particles, formed after said replacing. [0054]
  • More preferably, the present invention relates to an oligomeric particle as defined herein, as well as the method to produce said particle, wherein said optionally first detergent is Empigen-BB. More preferably, the present invention relates to an oligomeric particle as defined herein, as well as the method to produce said particle, wherein the detergent of step (II) is CHAPS, octylglucaside or Tween, more preferably Tween-20 or Tween-80, or any other detergent. More preferably, the present invention relates to an oligomeric particle as defined herein, as well as the method to produce said particle, wherein said salt is betaine. Even more preferably, the present invention relates to an oligomeric particle as defined above, as well as the method to produce said particle, wherein said Empigen-BB is used at a concentration of 1% to 10% and wherein said CHAPS or Tween is used at a concentration of 0.01% to 10%, or said betaine is used at a concentration of 0.01% to 10%. Even more preferably, the present invention relates to an oligomeric particle as defined above, as well as the method to produce said particle, wherein said Empigen-BB is used at a concentration of 3% and wherein said CHAPS or betaine are used at concentrations of 0.2% or 0.3%, respectively, after which buffer is switched and said CHAPS or betaine are used at concentrations of 0.05% or 0.1-0.5%, respectively. It is to be understood that all percentages used in the method described above are given as weight/volume. It should be clear that the method described above (see also PCT/EP 95/03031 and the examples section of the present application) is an example of how to produce the particles of the present invention. In this regard, the present invention also concerns any other method known in the art which can be used to produce the oligomeric particles of the present invention, such as, for example, omitting the reducing, agent as described in PCT/EP 95/03031 and the examples section (infra), and using instead host cells, which have an optimised redox state in the Endoplasmic Reticulum for reducing cysteine bridges. In addition, it should be clear that a whole range of alkylbetaines can be used, such as, for example, with a C[0055] n tail, in which n=a positive integer ranging from 1 to 20, as well as betaine derivatives, such as, for example, sulfobetaines.
  • Since for the first time successful immunotherapy of chimpanzees with severe chronic active hepatitis C was achieved by vaccination with a purified HCV antigen, the present invention also relates to purified since HCV envelope proteins, in particular E1 or E1s. Moreover, the present invention pertains to a composition comprising said single HCV envelope proteins, and the use thereof as an HCV vaccine, or for the manufacture of an HCV vaccine. [0056]
  • In order to avoid induction of an immune response against irrelevant epitopes, the HCV envelope protein used for vaccination is preferably constructed as a consensus sequence of individual subtypes, strains, or clones. Therefore, the present invention also pertains to the use of an HCV antigen (either in the form of peptide, protein, or a polynucleotide) for vaccination or diagnosis. Furthermore, the present invention also pertains to an oligomeric particle, as defined herein, and the use thereof, in which the HCV envelope protein is encoded by a consensus sequences based on quasispecies variability within an isolate (isolate consensus sequence) or based on the consensus sequence of different isolates within a subtype (subtype consensus sequence), type or species (type or species consensus sequence), or the complete HCV genus (genus consensus sequence). Consequently, the amino acid sequence of this consensus HCV envelope protein is a consensus sequence derived from an isolate-, subtype-, strain-, or genus consensus sequence. For the connotation of the term “consensus” is particularly referred to Maertens and Stuyver (1997), and references used therein. [0057]
  • The oligomeric particle of the present invention displays epitopes extremely efficiently (see infra). Hence, the oligomeric particle is a means to present epitopes in such a way that they can elicit a proficient immune response. In this context, it is comprehended that the HCV envelope proteins as defined herein do not need to contain HCV epitopes exclusively. The HCV envelope proteins, which form the oligomeric particles, may contain epitopes that are derived from HCV solely, and possibly contain epitopes that are derived from other exogenous agents, such as, for example, HBV or HIV. In other words, the oligomeric particle with an HCV envelope protein backbone, can be used as a vehicle to present non-HCV epitopes, possibly in addition to HCV epitopes. Therefore, the present invention also encompasses an oligomeric particle, as defined herein but possibly without HCV epitopes, and its applications and its manufacture, possibly containing non-HCV epitopes. The term “exogenous agent” as used herein, refers to any agent, whether living or not, able to elicit an immune response, and which is not endogenous to the host, and which is not HCV. Specifically, the latter term refers to the group consisting of pathogenic agents, allergens and haptens. Pathogenic agents comprise prions, virus, prokaryotes and eukaryotes. More specifically, virus comprise in particular HBV, HIV, or Herpesvirus, but not HCV. Allergens comprise substances or molecules able to provoke an immune response in an host on their own when a host is exposed to said allergens. Haptens behave similarly to allergens with respect to the ability of provoking an immune response, but in contrast to allergens, haptens need a carrier molecule. [0058]
  • The present invention also relates to a composition comprising an oligomeric particle as defined above. More particularly the present invention relates to a vaccine composition. The term “vaccine composition” relates to an immunogenic composition capable of eliciting protection against HCV, whether partial or complete. It therefore includes HCV peptides, proteins, or polynucleotides. Protection against HCV refers in particular to humans, but refers also to non-human primates, trimera mouse (Zauberman et al., 1999), or other mammals. [0059]
  • The particles of the present invention can be used as such, in a biotinylated form (as explained in WO 93/18054) and/or complexed to Neutralite Avidin (Molecular Probes Inc., Eugene, Oreg., USA). It should also be noted that “a vaccine composition” comprises, in addition to an active substance, a suitable excipient, diluent, carrier and/or adjuvant which, by themselves, do not induce the production of antibodies harmful to the individual receiving the composition nor do they elicit protection. Suitable carriers are typically large slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric aa's, aa copolymers and inactive virus particles. Such carriers are well known to those skilled in the art. Preferred adjuvants to enhance effectiveness of the composition include, but are not limited to: aluminium hydroxide, aluminium in combination with 3-0-deacylated monophosphoryl lipid A as described in WO 93/19780, aluminium phosphate as described in WO 93/24148, N-acetylmuramyl-L-threonyl-D-isoglutamine as described in U.S. Pat. No. 4,606,918, N-acetylnormuramyl-L-alanyl-D-isoglutamine, N-acetylmuramyl-L-alanyl-D-isoglutamyl-L-alanine2-(1′2′dipalmitoyl-sn-glycero-3-hydroxphosphoryloxy) ethylamine and RIBI (ImmunoChem Research Inc., Hamilton, Mont., USA) which contains monophosphoryl lipid A, detoxified endotoxin, trehalose-6,6-dimycolate, and cell wall skeleton (MPL+TDM+CWS) in a 2% squalene/Tween 80 emulsion. Any of the three components MPL, TDM or CWS may also be used alone or combined 2 by 2. Additionally, adjuvants such as Stimulon (Cambridge Bioscience, Worcester, Mass., USA) or SAF-1 (Syntex) may be used, as well as adjuvants such as combinations between QS21 and 3-de-O-acetylated monophosphoryl lipid A (WO94/00153), or MF-59 (Chiron), or poly[di(carboxylatophenoxy) phosphazene] based adjuvants (Virus Research Institute), or blockcopolymer based adjuvants such as Optivax (Vaxcel, Cythx) or inulin-based adjuvants, such as Algammulin and GammaInulin (Anutech), Incomplete Freund's Adjuvant (IFA) or Gerbu preparations (Gerbu Biotechnik). It is to be understood that Complete Freund's Adjuvant (CFA) may be used for non-human applications and research purposes as well. “A vaccine composition” will further contain excipients and diluents, which are inherently non-toxic and non-therapeutic, such as water, saline, glycerol, ethanol, wetting or emulsifying agents, pH buffering substances, preservatives, and the like. Typically, a vaccine composition is prepared as an injectable, either as a liquid solution or suspension. Solid forms, suitable for solution on, or suspension in, liquid vehicles prior to injection may also be prepared. The preparation may also be emulsified or encapsulated in liposomes for enhancing adjuvant effect. The polypeptides may also be incorporated into Immune Stimulating Complexes together with saponins, for example Quil A (ISCOMS). Vaccine compositions comprise an immunologically effective amount of the polypeptides of the present invention, as well as any other of the above-mentioned components. “Immunologically effective amount” means that the administration of that amount to an individual, either in a single dose or as part of a series, is effective for prevention or treatment. This amount varies depending upon the health and physical condition of the individual to be treated, the taxonomic group of the individual to be treated (e.g. human, non-human primate, primate, etc.), the capacity of the individual's immune system to mount an effective immune response, the degree of protection desired, the formulation of the vaccine, the treating doctor's assessment, the strain of the infecting HCV and other relevant factors. It is expected that the amount will fall in a relatively broad range that can be determined through routine trials. Usually, the amount will vann from 0.01 to 1000 μg/dose, more particularly from 0.1 to 100 μg/dose. The vaccine compositions are conventionally administered parenterally, typically by injection, for example, subcutaneously or intramuscularly. Additional formulations suitable for other methods of administration include oral formulations and suppositories. Dosage treatment may be a single dose schedule or a multiple dose schedule. The vaccine may be administered in conjunction with other immunoregulatory agents. Therefore, the instant invention pertains to the use of an oligomeric particle as defined herein for prophylactically inducing immunity against HCV. It should be noted that a vaccine may also be useful for treatment of an individual as pointed-out above, in which case it is called a “therapeutic vaccine”. [0060]
  • The present invention also relates to a composition as defined above which also comprises HCV core, E1, E2, P7, NS2, NS3, NS4A, NS4B, NS5A and/or NS5B protein, or parts thereof. E1, E2, and/or E1E2 particles may, for example, be combined with T cell stimulating antigens, such as, for example, core, P7, NS3, NS4A, NS4B, NS5A and/or NS5B. In particular, the present invention relates to a composition as defined above wherein said NS3 protein, or parts thereof, have an amino acid sequence given by [0061] SEQ ID 1 or SEQ ID 2 (see further in examples section). The purification of these NS3 proteins will preferentially include a reversible modification of the cvsteine residues, and even more preferentially sulfonation of cysteines. Methods to obtain such a reversible modification, including sulfonation have been described for NS3 proteins in Maertens et al. (PCT/EP99/02547). It should be stressed that the whole content, including all the definitions, of the latter document is incorporated by reference in the present application.
  • It is clear from the above that the present invention also relates to the usage of an oligomeric particle as defined above or a composition as defined above for the manufacture of an HCV vaccine composition. In particular, the present invention relates to the usage of an oligomeric particle as defined herein for inducing immunity against HCV in chronic HCV carriers. More in particular, the present invention relates to the usage of an oligomeric particle as defined herein for inducing immunity against HCV in chronic HCV carriers prior to, simultaneously to or after any other therapy, such as, for example, the well-known interferon therapy either or not in combination with the administration of small drugs treating HCV, such as, for example, ribavirin. Such composition may also be employed before or after liver transplantation, or after presumed infection, such as, for example, needle-stick injury. In addition, the present invention relates to a kit containing the oligomeric particles or the single HCV envelope proteins of the present invention to detect HCV antibodies present in a biological sample. The term “biological sample” as used herein, refers to a sample of tissue or fluid isolated from an individual, including but not limited to, for example, serum, plasma, lymph fluid, the external sections of the skin, respiratory intestinal, and genitourinary tracts, oocytes, tears, saliva, milk, blood cells, tumors, organs, gastric secretions, mucus, spinal cord fluid, external secretions such as, for example, excrement, urine, sperm, and the like. Since the oligomeric particles and the single HCV envelope proteins of the present invention are highly immunogenic, and stimulate both the humoral and cellular immune response, the present invention relates also to a kit for detecting HCV related T cell response, comprising the oligomeric particle or the purified single HCV envelope protein of the instant invention. HCV T cell response can for example be measured as described in the examples section, or as described in PCT/EP 94/03555 to Leroux-Roels et al. It should be stressed that the whole content, including all the definitions, of this document is incorporated by reference in the present application. [0062]
  • It should be clear that the present invention also pertains to the use of specific HCV immunoglobulins for treatment and prevention of HCV infection. It is here for the first time demonstrated that sufficient levels of HCV antibodies, especially HCV envelope antibodies, induce amelioration of Hepatitis C disease. It is also demonstrated for the first time that sufficient levels of antibodies can bind circulating virus, and that the presence of Ab-complexed virus coincides with disappearance of HCV antigen from the liver, and with amelioration of liver disease. HCV envelope antibodies may be induced by vaccination or may be passively transferred by injection after the antibodies have been purified from pools of HCV-infected blood or from blood obtained from HCV vaccinees. Therefore, the present invention pertains further to specific antibodies, generated against an oligomeric particle as described above or against a composition as described above, or a single HCV envelope protein. In particular, the present invention relates to a kit comprising said antibodies for detecting HCV antigens. The term “specific antibodies” as used herein, refers to antibodies, which are raised against epitopes which are specific to the oligomeric particle as disclosed in the present invention. In other words, specific antibodies are raised against epitopes which result from the formation of, and are only present on oligomeric particles. Moreover, there are various procedures known to produce HCV peptides. These procedures night result in HCV peptides capable of presenting epitopes. It is conceivable that the HCV peptides, obtained by these various and different procedures, are capable of presenting similar epitopes. Similar epitopes are epitopes resulting from different production or purifying procedures but recognizable by one and the same antibody. However, the oligomeric particles of the instant invention present epitopes extremely efficient. Consequently, the epitopes on the oligomeric particles are highly immunogenic. Therefore, the present invention also pertains to epitopes on oligomeric particles, said epitopes are at least 10 times, preferentially at least 20 times, preferentially at least 50, preferentially at least 100 times, preferentially at least 500 times, and most preferentially at least 1000 times more immunogenic than epitopes on HCV-peptides, which are not produced according to the present invention, ie not produced by detergent-assisted particle formation. It will be appreciated by the skilled that said immunogenecity can, for example, be detected and therefore compared by immunising mammals by means of administering comparable quantities of peptides, produced by either method. Moreover, the term “specific antibody” refers also to antibodies which are raised against a purified single HCV envelope protein. As used herein, the term “antibody” refers to polyclonal or monoclonal antibodies. The term “monoclonal antibody” refers to an antibody composition having a homogeneous antibody population. The term “antibody” is not limiting regarding the species or source of the antibody, nor is it intended to be limited by the manner in which it is made. In addition, the term “antibody” also refers to humanized antibodies in which at least a portion of the framework regions of an immunoglobulin are derived from human immunoglobulin sequences and single chain antibodies, such as, for example, as described in U.S. Pat. No. 4,946,778, to fragments of antibodies such as F[0063] ab, F(ab)2, Fv, and other fragments which retain the antigen binding function and specificity of the parental antibody.
  • Moreover, the present invention also features the use of an oligomeric particle as described above, or a composition as described above to detect antibodies against HCV envelope proteins. As used herein, the term “to detect” refers to any assay known in the art suitable for detection. In particular, the term refers to any immunoassay as described in WO 96/13590. [0064]
  • The terms “peptide”, “polypeptide” and “protein” are used interchangeably in the present invention. “Polypeptide” refers to a polymer of amino acids (amino acid sequence) and does not refer to a specific length of the molecule. Thus, oligopeptides are included within the definition of polypeptide. It is to be understood that peptidomimics are inherent in the terms “polypeptide”, “peptide” and “protein”[0065]
  • Also, the present invention relates to the use of an oligomeric particle as described herein for inducing immunity against HCV, characterized in that said oligomeric particle is used as part of a series of time and compounds. In this regard, it is to be understood that the term “a series of time and compounds” refers to administering with time intervals to an individual the compounds used for eliciting an immune response. The latter compounds may comprise any of the following components: oligomeric particles, HCV DNA vaccine composition, HCV polypeptides. [0066]
  • In this respect, a series comprises administering, either: [0067]
  • (I) an HCV antigen, such as, for example, an oligomeric particle, with time intervals, or [0068]
  • (II) an HCV antigen, such as, for example, an oligomeric particle in combination with a HCV DNA vaccine composition, in which said oligomeric particles and said HCV DNA vaccine composition, can be administered simultaneously, or at different time intervals, including at alternating time intervals, or [0069]
  • (III) either (I) or (II), possibly in combination with other HCV peptides, with time intervals. [0070]
  • In this regard, it should be clear that a HCV DNA vaccine composition comprises nucleic acids encoding HCV envelope peptide, including E1-, E2-, E1/E2-peptides, E1s peptide, [0071] SEQ ID No 13, SEQ ID No 14, NS3 peptide, other HCV peptides, or parts of said peptides. Moreover, it is to be understood that said HCV peptides comprises HCV envelope peptides, including E1-, E2-, E1/E2-peptides, E1s peptide. SEQ ID No 13, SEQ ID No 14, NS3 peptide, other HCV peptides, or parts thereof. The term “other HCV peptides” refers to any HCV peptide or fragment thereof with the proviso that said HCV peptide is not E1, E2, E1s, SEQ ID No 13, SEQ ID No 14, or NS3. In item II of the above scheme, the HCV DNA vaccine composition comprises preferentially nucleic acids encoding HCV envelope peptides. In item II of the above scheme, the HCV DNA vaccine composition consists even more preferentially of nucleic acids encoding HCV envelope peptides, possibly in combination with a HCV-NS3 DNA vaccine composition. In this regard, it should be clear that an HCV DNA vaccine composition comprises a plasmid vector comprising a polynucleotide sequence encoding an HCV peptide as described above, operably linked to transcription regulatory elements. As used herein, a “plasmid vector” refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. Preferred vectors are those capable of autonomous replication and/or expression of nucleic acids to which they have been linked. In general, but not limited to those, plasmid vectors are circular double stranded DNA loops which, in their vector form, are not bound to the chromosome. As used herein, a “polynucleotide sequence” refers to polynucleotides such as deoxyribonucleic acid (DNA), and, where appropriate, ribonucleic acid (RNA). The term should also be understood to include, as equivalents, analogs of either RNA or DNA made from nucleotide analogs, and single (sense or antisense) and double-stranded polynucleotides. As used herein, the term “transcription regulatory elements” refers to a nucleotide sequence which contains essential regulatory elements, such that upon introduction into a living vertebrate cell it is able to direct the cellular machinery to produce translation products encoded by the polynucleotide. The term “operably linked” refers to a juxtaposition wherein the components are configured so as to perform their usual function. Thus, transcription regulatory elements operably linked to a nucleotide sequence are capable of effecting the expression of said nucleotide sequence. Those skilled in the art can appreciate that different transcriptional promoters, terminators, carrier vectors or specific gene sequences may be used succesfully.
  • Finally, the present invention relates to an immunoassay for detecting HCV antibody, which immunoassay comprises: (1) providing the oligomeric particle or the purified single HCV envelope protein as defined herein, or a functional equivalent thereof, (2) incubating a biological sample with said oligomeric particle, or said HCV envelope protein under conditions that allow the formation of antibody-antigen complex, (3) determining whether said antibody-antigen complex comprising said oligomeric particle or said HCV envelope protein is formed. [0072]
  • The present invention will now be illustrated by reference to the following examples which set forth particularly advantageous embodiments. However, it should be noted that these embodiments are merely illustrative and can not be construed as to restrict the invention in any way. [0073]
    • EXAMPLES Example 1
  • Expression, Purification, and Detergent-Assisted Homo-Oligomerization of the HCV E1 Protein [0074]
  • The HCV E1s protein (amino acids 192-326) was expressed and purified from RK13 cells using recombinant vaccinia virus pvHCV-11A according to the protocol described in Maertens et al. (PCT/EP 95/03031). In addition, the purified E1 protein in 3% Empigen-BB which displays an apparent molecular weight corresponding to an E1 homo-dimer (approximately about 60 kDa; FIG. 1), was pooled and the pooled fractions were again applied to a size exclusion chromatography column (according to PCT/EP 95/03031) and run in the presence of 0.2% CHAPS or 3% betaine. Surprisingly, although the E1s protein is devoid of its membrane anchor region, a homogeneous population of specifically associated E1 homo-oligomers with an apparent molecular weight of 260-280 kDa could be obtained with both detergents (FIG. 2). Such a homo-oligomeric structure could contain an approximate number of 9 E1s monomers. It should be clear that the latter is a rough estimate as the shape of the oligomer may drastically influence its apparent molecular weight as measured by size exclusion chromatography. By switching from 0.2% CHAPS to 0.05% CHAPS and repeating the same procedure, the apparent molecular weight further shifted beyond the resolution of the column (void of the column, >600 kDa, FIG. 3), suggesting the formation of particles. Switching from 3% betaine to 0.1% betaine yielded a population of E1s oligomers with a similar behaviour (data not shown). Other detergents could be chosen by means of which similar detergent-assisted oligomerization could be achieved. The oligomerization leading to the particle formation is not unique for CHAPS or betaine, since similar results were obtained by using Tween-20 or Tween-80, or octylglucaside. Moreover, further removal of the detergent may be possible which may allow to generate even larger particles. The presence of detergent may, therefore, not longer be needed to obtain particles. The particles may be obtained by e.g. SCC, without any detergent. Notably, an E1 monomer is approximately 31 kDa, while an E2 monomer is approximately 70 kDa. These values, however, may differ depending on the glycosylation status of the protein. [0075]
    • Example 2
  • Analysis of the Higher Order Oligomeric Structures of E1s by Means of Dynamic Light Scattering. [0076]
  • In order to confirm the unexpected result that particles have been created, E1s preparations in 0.05% CHAPS and 0.1% betaine, prepared according to example 1, or in 0.1% betaine, prepared by dilution of preparations in 0.5% betaine, were subjected to analysis by means of dynamic light scattering (DLS). [0077]
  • The dynamic light scattering technique measures Brownian motion and relates this to the size of particles. The larger the particle, the slower the Brownian motion will be. The velocity of the Brownian motion is defined by a property known as the diffusion coefficient (usually given by the symbol D). The size of the particle is calculated from the diffusion coefficient by using the Stokes-Einstein equation: d(H)=kT/3πηD, in which d(H) is the hydrodynamic diameter, k is the Boltzmann constant, T is the absolute temperature, η is the viscosity. Notably, the measured diameter is a value which refers to how a particle diffuses within a fluid. So, it is referred to as hydrodynamic diameter. The diffusion coefficient is derived from an autocorrelation function (variation of intensity fluctuation of light with time). The instrument uses a computer-controlled correlator to calculate the intensity of the autocorrelation function automatically. [0078]
  • For measuring size distributions, the above autocorrelation function is corrected to obtain linear curves and the instrument is equipped with a computer program for analysis of the size distribution. However, the technique has restrictive assumptions similar to those of the technique called multi angle laser light scattering (MALLS) and neither method can be considered to yield absolute data. The results of size distributions from DLS have to be interpreted as semi-quantitative indicators of polydispersity, rather than as a true representation of the distribution. [0079]
  • Samples containing E1s particles (80-400 μg E1s/ml PBS-0.05% CHAPS, 0.1% or 0.5% betaine) were pipetted in the measuring cell of an LSP 3.53 DLS instrument equipped with a 10 mW HeNe Laser (PolymerLabs). A readout of the analysis is provided in FIGS. [0080] 4 (E1s in 0.05% CHAPS) and 5 (E1s in 0.1% or 0.5% betaine).
  • These analyses indeed confirmed the unexpected result that the obtained E1s structures were spherical, monodisperse particles. The E1s particles in PBS/0.1% betaine showed an average size distribution of 21.3±4 nm, in PBS/0.5% betaine: 27.9±5 nm, whereas a diameter of 12.5 was obtained for E1s in PBS/0.05% CHAPS. [0081]
    • Example 3
  • Size and Shape Analysis by Means of E1 Electron Microscopy. [0082]
  • Ten μl of E1s (226 μg/ml in PBS/0.05% CHAPS; and 143 μg/ml in [0083] PBS 3% betaine) was visualized with a standard negative staining with 1% uranyl acetate on carbon stabilized formvar grids. The sample was applied for 30 seconds and then rinsed with dH2O before staining for 5 seconds and photography (FIG. 6).
  • Statistical analysis yielded the following results: the E1s particle in CHAPS had a mean diameter of 8.7±0.27 nm (range 4.3-29.0; 95% CI 5.4) and that the E1s particle in betaine was less homogeneous with a mean diameter of 9.7±0.55 nm (range 4.3-40.5; 95% CI 11.0). Surprisingly, the 3% betaine preparation, which initially showed a MW of 250-300 kDa as analysed by SEC even shows larger particles than the 0.05% CHAPS preparation, which initially showed a MW of >600 kDa. We therefore hypothesized that intermediate homo-oligomeric forms of E1s obtained by 3% betaine may have formed higher order particles over time. This surprising effect points to other possibilities for obtaining higher-order particles. A size distribution of the particles (FIG. 7) shows that the CHAPS preparation is monodisperse, although a tailing to larger size particles is observed (up to 29 nm for 0.05% CHAPS). Since larger structures are overestimated in DLS analyses, the presence of these larger particles, although less in number, may explain the larger diameter obtained by DLS analysis (example 2). The difference in diameter may also be explained by the fact that DLS measures a particle in motion, while electron microscopy measures static particles. It should be clear that the immunogenicity of these preparations as shown in the examples below is due to the entirety of the preparation, and may be due to the average, smaller, or larger particles, or to the mixture thereof. [0084]
    • Example 4
  • Immunization of a Chimpanzee Chronically Infected with HCV Subtype 1b [0085]
  • A chimpanzee (Phil) already infected for over 13 years (5015 days before immunization) with an HCV subtype 1b strain was vaccinated with E1 (aa 192-326) which was derived from a different strain of genotype 1b, with a 95.1% identity on the amino acid level (see also Table 2), and which was prepared as described in examples 1-3. The chimpanzee received in [0086] total 6 intramuscular immunizations of each 50 μg E1 in PBS/0.05% CHAPS mixed with RIBI R-730 (MPLA+TDM+CWS) according to the manufacturer's protocol (Ribi Inc. Hamilton, Mont.). The 6 immunizations were given in two series of three shots with a three week interval and with a lag period of 6 weeks between the two series. Starting 150 days prior to immunization, during the immunization period and until 1 year post immunization (but see below) the chimpanzee was continuously monitored for various parameters indicative for the activity of the HCV induced disease. These parameters included blood chemistry, ALT, AST, gammaGT, blood chemistry, viral load in the serum, viral load in the liver and liver histology. In addition, the immune answer to the immunization was monitored both on the humoral and cellular level. During this period the animal was also monitored for any adverse effects of the immunization, such as change in behaviour, clinical symptoms, body weight, temperature and local reactions (redness, swelling, indurations). Such effects were not detected.
  • Clearly, ALT (and especially gammaGT, data not shown) levels decreased as soon as the antibody level against E1 reached its maximum (FIG. 8). ALT rebounded rather rapidly as soon as the antibody levels started to decline, but gammaGT remained at a lower level as long as anti-E1 remained detectable. [0087]
  • E2 antigen in the liver decreased to almost undetectable levels during the period in which anti-E1 was detectable and the E2 antigen rebounded shortly after the disappearance of these antibodies. Together with the Core and E2 antigen becoming undetectable in the liver, the inflammation of the liver markedly decreased (see also Table 3). This is a major proof that the vaccine induces a reduction of the liver damage, probably by clearing, at least partially, the viral antigens from its major target organ, the liver. [0088]
  • The viraemia level, as measured by Amplicor HCV Monitor (Roche, Basel, Switzerland), remained approximately unchanged in the serum during the whole study period. [0089]
  • More detailed analyses of the humoral response revealed that the maximum end-point titer reached 14.5×10[0090] 3 (after the sixth immunization) and that this titer dropped to undetectable 1 year post immunization (FIG. 8). FIG. 9 shows that the main epitopes, which can be mimicked by peptides, recognized by the B-cells are located at the N-terminal region of E2 (peptides V1V2 and V2V3, for details on the peptides used see Table 4). Since the reactivity against the recombinant E1 is higher and longer lasting, it can also be deduced from this figure, that the antibodies recognizing these peptides represent only part of the total antibody population against E1. The remaining part is directed against epitopes which cannot be mimicked by peptides, i.e discontinuous epitopes. Such epitopes are only present on the complete E1 molecule or even only on the particle-like structure. Such an immune response against E1 is unique, at least compared to what is normally observed in human chronic HCV carriers (WO 96/13590 to Maertens et al.) and in chimpanzees (van Doorn et al., 1996), who raise anti-E1 antibodies in their natural course of infection. In those patients, anti-E1 is in part also directed to discontinuous epitopes but a large proportion is directed against the C4 epitope (±50% of the patient sera), a minor proportion against V1V2 (ranging from 2-70% depending on the genotype), and reactivity against V2V3 was only exceptionally recorded (Maertens et al., 1997).
  • Analysis of the T-cell reactivity indicated that also this compartment of the immune system is stimulated by the vaccine in a specific way, as the stimulation index of these T-cells rises from 1 to 2.5, and remains somewhat elevated during the follow up period (FIG. 10). It is this T cell reactivity that is only seen in Long term responders to interferon therapy (see: PCT/EP 94/03555 to Leroux-Roels et al.; Leroux-Roels et al., 1996). [0091]
    • Example 5
  • Immunization of a Chronic HCV Carrier with Different Subtype [0092]
  • A chimpanzee (Ton) already infected for over 10 years (3809 days before immunization) with HCV from [0093] genotype 1a was vaccinated with E1 from genotype 1b, with only a 79.3% identity on the amino acid level (see also Table 2), and prepared as described in the previous examples. The chimpanzee received a total of 6 intramuscular immunizations of 50 μg E1 in PBS/0.05% CHAPS each mixed with RIBI R-730 according to the manufacturer's protocol (Ribi Inc. Hamilton, Mont.). The 6 immunizations were given in two series of three shots with a three week interval and with a lag period of 4 weeks between the two series. Starting 250 days prior to immunization, during the immunization period and until 9 months (but see below) post immunization the chimpanzee was continuously monitored for various parameters indicative for the activity of the HCV induced disease. These parameters included blood chemistry, ALT, AST, gammaGT, viral load in the serum, viral load in the liver and liver histology. In addition, the immune answer to the immunization was monitored both on the humoral and cellular level. During this period the animal was also monitored for any adverse effects of the immunization, such as change in behaviour, clinical symptoms, body weight, temperature and local reactions (redness, swelling, indurations). Such effects were not detected. Clearly, ALT levels (and gammaGT levels, data not shown) decreased as soon as the antibody level against E1 reached its maximum (FIG. 11). ALT and gammaGT rebounded as soon as the antibody levels started to decline, but ALT and gammaGT remained at a lower level during the complete follow up period. ALT levels were even significantly reduced after vaccination (62±6 U/l) as compared to the period before vaccination (85±11 U/l). Since less markers of tissue damage were recovered in the serum, these findings were a first indication that the vaccination induced an improvement of the liver disease.
  • E2 antigen levels became undetectable in the period in which anti-E1 remained above a titer of 1.0×10[0094] 3, but became detectable again at the time of lower E1 antibody levels. Together with the disappearance of HCV antigens, the inflammation of the liver markedly decreased from moderate chronic active hepatitis to minimal forms of chronic persistent hepatitis (Table 3). This is another major proof that the vaccine induces a reduction of the liver damage, probably by clearing, at least partially, the virus from its major target organ, the liver.
  • The viraemia level, as measured by Amplicor HCV Monitor (Roche, Basel, Switzerland), in the serum remained at approximately similar levels during the whole study period. More detailed analysis of the humoral response revealed that the maximum end-point titer reached was 30×10[0095] 3 (after the sixth immunization) and that this titer dropped to 0.5×103 nine months after immunization (FIG. 11). FIG. 12 shows that the main epitopes, which can be mimicked by peptides and are recognized by the B-cells, are located at the N-terminal region (peptides V1V2 and V2V3, for details on the peptides used see Table 4). Since the reactivity against the recombinant E1 is higher and longer lasting, it can also be deduced from this figure, that the antibodies recognizing these peptides represent only part of the total antibody population against E1. The remaining part is most likely directed against epitopes which cannot be mimicked by peptides, i.e. discontinuous epitopes. Such epitopes are probably only present on the complete E1 molecule or even only on the particle-like structure. Such an immune response against E1 is unique, at least compared to what is normally observed in human chronic HCV carriers, which have detectable anti-E1. In those patients, anti-E1 is in part also discontinuous, but a large proportion is directed against he C4 epitope (50% of the patient sera), a minor proportion against V1V2 (ranging from 2-70% depending on the genotype) and exceptionally reactivity against V2V3 was recorded (Maertens et al., 1997). As this chimpanzee is infected with an 1a isolate the antibody response was also evaluated for cross-reactivity towards a E1-1a antigen. As can be seen in FIG. 13, such cross-reactive antibodies are indeed generated, although, they form only part of the total antibody population. Remarkable is the correlation between the reappearance of viral antigen in the liver and the disappearance of detectable anti-1a E1 antibodies in the serum.
  • Analysis of the T-cell reactivity indicated that also this compartment of the immune system is stimulated by the vaccine in a specific way, as the stimulation index of these T-cells rises from 0.5 to 5, and remains elevated during the follow up period (FIG. 14). [0096]
    • Example 6
  • Reboosting of HCV Chronic Carriers with E1 [0097]
  • As the E1 antibody titers as observed in examples 4 and 5 were not stable and declined over time, even to undetectable levels for the 1b infected chimp, it was investigated if this antibody response could be increased again by additional boosting. Both chimpanzees were immunized again with three consecutive intramuscular immunization with a three week interval (50 μg E1 mixed with RIBI adjuvant). As can be judged from FIGS. 8 and 11, the anti-E1 response could indeed be boosted, once again the viral antigen in the liver decreased below detection limit. The viral load in the serum remained constant although in Ton (FIG. 11). A viremia level of <10[0098] 5 genome equivalents per ml was measured for the first time during the follow up period.
  • Notable is the finding that, as was already the case for the first series of immunizations, the chimpanzee infected with the subtype 1b HCV strain (Phil) responds with lower anti-E1 titers, than the chimpanzee infected with [0099] subtype 1a HCV strain (maximum titer in the first round 14.5×103 versus 30×103 for Ton and after additional boosting only 1.2×103 for Phil versus 40×103 for Ton). Although for both animals the beneficial effect seems to be similar, it could be concluded from this experiment that immunization of a chronic carrier with an E1 protein derived from another subtype or genotype may be especially beneficial to reach higher titers, maybe circumventing a preexisting and specific immune suppression existing in the host and induced by the infecting subtype or genotype. Alternatively, the lower titers observed in the homologous setting (1b vaccine+1b infection) may indicate binding of the bulk of the antibodies to virus. Therefore, the induced antibodies may possess neutralizing capacity.
    • Example 7a
  • Construction of a NS3 Protein Combining the Major Epitopes Known to Correlate with Control of Infection [0100]
  • Also other epitopes besides the ones in E1 may be linked with clearing of HCV during acute phase or by interferon therapy. Several of these epitopes are localized within NS3 (Leroux-Roels et al., 1996; Rehermann et al., 1996 and 1997; Diepolder et al., 1995 and 1997). Two of the major epitopes are the CTL epitope mapped by Rehermann and coworkers (aa 1073-1081), and the T-cell (CD4) epitope mapped by Diecolder and coworkers (aa 1248-1261). Unfortunately, these epitopes are scattered all over the NS3 protein. In order to have at least those epitopes available, a relatively large protein would be needed (aa 1073-1454). Producing such a large protein usually results in low yields, and may result upon vaccination in a response which is only for a small part targeted to the important epitopes. Therefore, production of a smaller protein would be a more suitable solution to this problem. In order to do so, some of the epitopes need to be repositioned within such a smaller protein. By taking advantage of the knowledge that exists, ie another CTL epitope (aa 1169-1177) which is not linked with HCV clearance (Rehermann et al. 1996, 1997), an NS3 molecule was designed to start at aa 1166 and to end at aa 1468 (Table 5). This construct already includes the epitopes described by Weiner and coworkers, and Diepolder and coworkers. By mutating the region 1167 to 1180 to the sequence of the region 1071 to 1084, the non-relevant CTL epitope was changed to the epitope Rehermann and coworkers found to be linked with viral clearance. The construct was additionally modified to contain a methionine at position 1166 to allow initiation of translation. This methionine will be cleaved off in [0101] E. coli since it is followed by an alanine. In this way, the introduction of new epitopes, which are not present in the natural NS3, is limited to a minimum. Alternatively, if the expression of this protein would be cumbersome, the CTL epitope may be linked to the C-terminus at aa 1468 as depicted in detail in Table 5.
  • The coding sequence of an HCV NS-3 fragment was isolated and expressed as described in Maertens et al. (PCT/EP99/02547; clone 19b; HCV aa 1188-1468 was used as starting material). The CTL epitope as described by Rehermann, and not present in the 19b NS-3 fragment was fused to this fragment. Both N-terminal and C-terminal fusions were constructed, since effects of the fusion on expression levels, susceptibility to proteolytic breakdown and functionality may be affected by the position of the epitope. [0102]
  • Using the pIGRI2NS-3 plasmid, which is an [0103] E. coli expression plasmid expressing the NS-3 19b fragment under control of the leftward promoter of phage lambda, as a template for PCR, NS3 19b coding sequences, fused respectively N- and C-terminally with the Rehermann CTL epitope (named NS-319bTn and NS-3 19bTc, respectively), were first subcloned into the pGEM-T (Promega) cloning vector giving rise to vectors pGEM-TNS-319bTn and pGEM-TNS-319bTc. The PCR-amplified sequences were verified by DNA sequence analysis.
  • In the case of fusing the T-cell epitope sequence to the N-terminal region of NS-3, PCR was carried out with a long sense primer carrying the CTL epitope and a short antisense primer homologous to [0104] sequences 3′ of the NS-3 19b stopcodon. Primer sequences are depicted below.
    Primer 9038 (sense)
    5′-GCCATGGCGACCTGCATCAACGGTGTTTGCTGGACCGTTTACCACGGTCGTGC (SEQ ID NO 5)
    GGCTGTTTGCACCCGTGGGGTTGCGAAGGCGGTGG-3′
  • Primer 1901 (Antisense) [0105]
  • 5′-TTTTATCAGACCGCTTCTGCG-3′ (SEQ ID NO 6) [0106]
  • In the case of the C-terminally fused NS-3, PCR was carried out with a short sense primer homologous to [0107] sequences 5′ of the NS-3 19b startcodon and a long antisense primer carrying the CTL epitope followed by in-frame stopcodons. Primer sequences are depicted below.
  • Primer 1052 (Sense) [0108]
  • 5′-AGCAAACCACCAAGTGGA-3′ (SEQ ID NO 7) [0109]
    Primer 9039 (antisense)
    5′-CTCTAGACTATTAACCGTGGTAAACGGTCCAGCAAACACCGTTGATGCAGGTC (SEQ ID NO 8)
    GCCAGGCTGAAGTCGACTGTCTGG-3′
  • Starting from the coding sequences cloned into the pGEM-T vectors, the NS-3 19bT sequences are inserted into the pIGRI2 [0110] E. coli expression vector. For the N-terminally fused NS-3 19bT, the NS-3 19bT coding sequence was isolated as a 379 bp NcoI/SnaBI fragment and ligated with SnaBI/AllwNI and AlwNI/NcoI fragments from vector pIGRI2NS-3, resulting in the vector pIGRI2NS-3Tn. For the C-terminally fused NS-3 19bT, the NS-3 19bT coding sequence was isolated as a 585 bp SnaBI/SpeI fragment and inserted into the SnaBI/SpeI opened vector pIGRI2NS-3, resulting in the vector pIGRI2NS-3Tc.
  • Both pIGRI2NS-3Tn and pIGRI2NS-3Tc vectors were subsequently transformed to the [0111] E. coli expession strain MC1061(pAcI) and after temperature induction of the lambda PL promotor, expression levels were analysed on SDS-PAGE and Western blot, using a polyclonal rabbit anti NS-3 serum.
    Amino acid sequence of the NS-3 19bTn protein
    (SEQ ID NO:1)
    MATCINGVCWTVYHGRAAVCTRGVAKAVDFVPVESMETTMRSPVFTDNSS
    PPAVPQTFQVAHLHAPTGSGKSTKVPAAYAAQGYKVLVLNPSVAATLGFG
    AYMSKAHGVDPNIRTGVRTITTGAPITYSTYGKFLADGGCSGGAYDIIIC
    DECHSIDSTSILGIGTVLDQAETAGARLVVLATATPPGSVTVPHPNIEEV
    ALSSTGEIPFYGKAIPIEVIKGGRHLIFCHSKKKCDELAAKLSGFGINAV
    AYYRGLDVSVIPTSGDVVVVATDALMTGFTGDFDSVIDCNTCVTQTVDFS
  • [0112]
    Amino acid sequence of the NS-3 19bTc protein
    (SEQ ID NO:1)
    MGVAKAVDFVPVESMETTMRSPVFTDNSSPPAVPQTFQVAHLHAPTGSGK
    STKVPAAYAAQGYKVLVLNPSVAATLGFGAYMSKAHGVDPNIRTGVRTIT
    TGAPITYSTYGKFLADGGCSGGAYDIIICDECHSIDSTSILGIGTVLDQA
    ETAGARLVVLATATPPGSVTVPHPNIEEVALSSTGEIPFYGKAIPIEVIK
    GGRHLIFCHSKKKCDELAAKLSGFGINAVAYYRGLDVSVIPTSGDVVVVA
    TDALMTGFTGDFDSVIDCNTCVTQTVDFSLATCINGVCWTVYHG
  • [0113]
    Nucleotide sequence of the NS-3 19bTn coding region
    ATGGCGACCTGCATCAACGGTGTTTGCTGGACCGTTTACCACGGTCGTGCGGCTGTT (SEQ ID NO 3)
    TGCACCCGTGGGGTTGCGAAGGCGGTGGACTTTGTACCCGTAGAGTCTATGGAAACC
    ACCATGCGGTCCCCGGTCTTTACGGATAACTCATCTCCTCCGGCCGTACCGCAGACA
    TTCCAAGTGGCCCATCTACACGCCCCCACTGGTAGTGGCAAGAGCACTAAGGTGCCG
    GCTGCATATGCAGCCCAAGGGTACAAGGTACTTGTCCTGAACCCATCCGTTGCCGCC
    ACCTTAGGATTCGGGGCGTATATGTCTAAAGCACATGGTGTCGACCCTAACATTAGA
    ACTGGGGTAAGGACCATCACCACGGGCGCCCCCATTACGTACTCCACCTACGGCAA
    GTTTCTTGCCGACGGTGGTTGCTCTGGGGGCGCTTACGACATCATAATATGTGATGA
    GTGCCACTCGATTGACTCAACCTCCATCTTGGGCATCGGCACCGTCCTGGATCAGGC
    GGAGACGGCTGGAGCGCGGCTTGTCGTGCTCGCCACTGCTACACCTCCGGGGTCGGT
    CACCGTGCCACATCCCAACATCGAGGAGGTGGCTCTGTCCAGCACTGGAGAGATCCC
    CTTTTATGGCAAAGCCATCCCCATCGAGGTCATCAAAGGGGGGAGGCACCTCATTTT
    CTGCCATTCCAAGAAGAAATGTGACGAGCTCGCCGCAAAGCTATCGGGCTTCGGAA
    TCAACGCTGTAGCGTATTACCGAGGCCTTGATGTGTCCGTCATACCGACTAGCGGAG
    ACGTCGTTGTTGTGGCAACAGACGCTCTAATGACGGGCTTTACCGGCGACTTTGACT
    CAGTGATCGACTGTAACACATGCGTCACCCAGACAGTCGACTTCAGCTAA
  • [0114]
    Nucleotide sequence of the NS-3 19bTc coding region
    ATGGGGGTTGCGAAGGCGGTGGACTTTGTACCCGTAGAGTCTATGGAAACCACC (SEQ ID NO 4)
    ATGCGGTCCCCGGTCTTTACGGATAACTCATCTCCTCCGGCCGTACCGCAGACAT
    TCCAAGTGGCCCATCTACACGCCCCCACTGGTAGTGGCAAGAGCACTAAGGTGC
    CGGCTGCATATGCAGCCCAAGGGTACAAGGTACTTGTCCTGAACCCATCCGTTGC
    CGCCACCTTGGATTCGGGGCGTATATGTCTAAAGCACATGGTGTCGACCCTAAC
    ATTAGAACTGGGGTAAGGACCATCACCACGGGCGCCCCCATTACGTACTCCACCT
    ACGGCAAGTTTCTTGCCGACGGTGGTTGCTCTGGGGGCGCTFACGACATCATAAT
    ATGTGATGAGTGCCACTCGATTGACTCAACCTCCATCTTGGGCATCGGCACCGTC
    CTGGATCAGGCGGAGACGGCTGGAGCGCGGCTTGTCGTGCTCGCCACTGCTACA
    CCTCCGGGGTCGGTCACCGTGCCACATCCCAACATCGAGGAGGTGGCTCTGTCCA
    GCACTGGAGAGATCCCCTTTTATGGCAAAGCCATCCCCATCGAGGTCATCAAAGG
    GGGGAGGCACCTCATTTTCTGCCATTCCAAGAAGAAATGTGACGAGCTCGCCGC
    AAAGCTATCGGGCTTCGGAATCAACGCTGTAGCGTATTACCGAGGCCTTGATGTG
    TCCGTCATACCGACTAGCGGAGACGTCGTTGTTGTGGCAACAGACGCTCTAATGA
    CGGGCTTTACCGGCGACTTTGACTCAGTGATCGACTGTAACACATGCGTCACCCA
    GACAGTCGACTTCAGCCTGGCGACCTGCATCAACGGTGTTTGCTGGACCGTTTAC
    CACGGTTAA
    • Example 7b
  • Purification of the NS-3 19bTn and NS-3 19bTc Proteins [0115]
  • [0116] E. coli cell pasts from erlenmeyer cultures were broken by a cell disrupter (CSL, model B) at 1.4 kbar in 50 mM TRIS, pH 8. This lysate was cleared by centrifugation (15000 g, 30 min, 4° C.). The supernatant was discarded, since both for the N- and the C-terminal construct NS3 was recovered in the pellet. This pellet turned out to be highly stable for the N-terminal construct allowing thorough washing (first wash with 2% sarcosyl, 0.5 M guanidiniumchloride and 10 mM DTT, second and third wash with 1% Triton X-100, 0.5 M guanidiniumchloride and 10 mM EDTA) before solubilisation. This was not the case for the C-terminal construct. Purification was further pursued on the N-terminal construct. The washed pellet was finally dissolved in 6 M guanidiniumchloride/50 mM Na2HPO4, at pH 7.2 and was sulfonated as described in Maertens et al. (PCT/EP99/02547). The sulfonated pellet was first desalted on a Sephadex G25 column to 6 M Urea/50 mM triethanolamine, pH 7.5, and finally purified by two sequential anion-exchange chromatographies in the same buffer composition. The first anion-exchange was performed on a Hyper DQ (50 μm) column (BioSpra Inc. Marlborough, Mass. USA) and the NS3 was recovered between 0.11 and 0.19 M NaCl. After dilution, these fractions were applied to a second Hyper DQ (20 μm) column (BioSpra Inc. Marlborough, Mass. USA) and the NS3 was recovered in the fractions containing 0.125 M NaCl. These fractions were desalted to 6 M Urea in PBS, pH 7.5. The final purity was estimated >90% based on SDS-PAGE followed by silver staining. The N-terminal sequencing by EDMAN degradation showed that this NS3 has an intact N-terminus, in which the desired epitope is present in the correct sequence. It was also confirmed that the methionine used for the start of translation was cleaved of as predicted.
    • Example 8
  • Construction of an E2 Protein without Hypervariable Region I [0117]
  • An immunodominant homologous response has been noted to the HVR I region of E2. This response will be of little use in a vaccine approach, since a vaccine approach is a heterologous set-up (the vaccine strain is always different from the field strains). Therefore, deletion of this region would be necessary to have an E2 protein inducing antibodies against the more conserved, but less immunogenic regions of E2. By carefully analyzing the E2 leader sequence and the E2 hypervariable region the most ideal construct for expression of an E2 protein without HVR I was designed. This construct allows expression of an E2 peptide starting at position aa 409 instead of [0118] aa 384. As a leader sequence the C-terminal 20 amino acids of E1 were used. However, since the delineation of this HVR is not unambiguous, a second version was made (starting at aa 412), which has also a high probability to be cleaved at the right position.
  • Intermediate Construct pvHCV-99 (See also FIGS. 15 and 16) [0119]
  • In the expression cassette, the coding sequence of E2-715 should be preceded by an E1 leader signal peptide, starting at Met364. Therefore, in plasmid pvHCV-92 (FIG. 15), which contains the coding sequence for E2-715 HCV type 1b with the long version of the E1 signal peptide (starting at Met347), a deletion was made by a double-digestion with EcoRI and NcoI, followed by a 5′-overhang fill-in reaction with T4 DNA polymerase. Ligation of the obtained blunt ends (recircularization of the 6621 bp-fragment), resulted in plasmid pvHCV-99, which codes for the same protein (E2-715) with a shorter E1 leader signal peptide (starting at Met364). pvHCV-99 was deposited in the strain list as ICCG 3635. It should be clear that HCV or heterologous signal sequences of variable length may be used. [0120]
  • The plasmids pvHCV-100 and -101 should contain a deletion in the E2 sequence, i.e. a deletion of the hypervariable region I (HVR-I). In plasmid pvHCV-100, amino acids 384(His)-408(Ala) were deleted, while in plasmid pvHCV-101 aminoacids 384(His)-411(Ile) were deleted. [0121]
  • Construction pvHCV-100 [0122]
  • For the construction of pvHCV-100, two oligonucleotides were designed: [0123]
  • HCV-pr 409 [8749]: [0124]
  • 5′-CTT TGC CGG CGT CGA CGG GCA GAA AAT CCA GCT CGT AA-3′ (SEQ ID NO 9) [0125]
  • HCV-pr 408 [8750]: [0126]
  • 5′-TTA CGA GCT GGA TTT TCT GCC CGT CGA CGC CGG CAA AG-3′ (SEQ ID NO 10) [0127]
  • PCR amplification ([0128] denaturation 5 min 95° C., 30 cycles of amplification consisting of annealing at 55° C., polymerization at 72° C., and denaturation at 95° C. for 1 min each, elongation for 10 min at 72° C.) of the pvHCV-99 template with Gpt-pr [3757] and HCV-pr 408 [8750] resulted in a 221 bp fragment, while amplification with HCV-pr 409 [8749] and TKr-pr [3756] resulted in a 1006 bp fragment. Both PCR fragments overlap one another by 19 nucleotides. These two fragments were assembled and amplified by PCR with the Gpt-pr [3757] and TKr-pr [3756] primers. The resulting 1200 bp fragment was digested with EcoRI and HinDIII and ligated into the EcoRI/HinDIII digested pgsATA18 [ICCG 1998] vector (5558 bp).This construct, pvHCV-100, was analysed by restriction and sequence analysis, and deposited in the strainlist as ICCG 3636.
  • Construction pvHCV-101 [0129]
  • For the construction of pvHCV-101, two oligonucleotides were designed: [0130]
  • HCV-pr 411 [8747]: [0131]
  • 5′-CTT TGC CGG CGT CGA CGG GCA GCT CGT AAA CAC CAA CG-3′ (SEQ ID NO 11) [0132]
  • HCV-pr 410 [8748]: [0133]
  • 5′-CGT TGG TGT TTA CGA GCT GCC CGT CGA CGC CGG CAA AG-3′ (SEQ ID NO 12) [0134]
  • PCR amplification of the pvHCV-99 template with Gpt-pr [3757] and HCV-pr 410 [8748] resulted in a 221 bp fragment, while amplification with HCV-pr 411 [8747] and TKr-pr [3756] resulted in a 997 bp fragment. Both PCR fragments overlap one another by 19 nucleotides. These two fragments were assembled and amplified bv PCR with the Gpt-pr [3757] and TKr-pr [3756]. The resulting 1200 bp fragment was digested with EcoRI and HinDIII and ligated into the EcoRI/HinDIII digested pgsATA18 [ICCG 1998] vector (5558 bp). This construct, pvHCV-101, was analysed by restriction and sequence analysis, and deposited in the strainlist as ICCG 3637. [0135]
  • All plasmids were checked by sequence analysis and deposited in the Innogenetics strainlist. For each plasmid two mini-DNA preparations (PLASmix) were made under sterile conditions and pooled. DNA concentration was determined and QA was performed by restriction analysis. Purified DNA was used to generate recombinant vaccinia virus as described in Maertens et al. (PCT/EP95/03031). The recombinant viruses vvHCV-100 and vvHCV-101 were, however, generated on WHO certified Vero cells. After two rounds of plaque purification the expression product was analysed by means of Western-blot analysis as described in Maertens et al. (PCT/EP95/03031). Proteins were visualised by a specific anti-E2 monoclonal antibody (IGH 212, which can be obtained from the inventors at Innogenetics N.V., Zwijnaarde, Belgium) of an estimated molecular weight of 69 and 37 kDa for vvHCV-100 and of 68 and 35 kDa for vvHCV-101. These molecular weights indicate the presence of both a glycosylated and non-glycosylated E2-protein, which was confirmed by treatment of the samples prior to Western-blot analysis with PNGaseF. This treatment results in the detection of only one single protein of 37 kDa and 35 kDa for vvHCV-100 and vvHCV-101, respectively. [0136]
    Amino acid sequence of the mature E2, derived from pvHCV-100
    QKIQLVNTNGSWHINRTALNCNDSLQTGFFAALEYKHKFNSSGCPERLASCRSIDKFAQG (SEQ ID NO 13)
    WGPLTYTEPNSSDQRPYCWHYAPRPCGIVPASQVCGPVYCFTPSPVVVGTTDRFGVPTY
    NWGANDSDVLILNNTRPPRGNWFGCTWMNGTGFTKTCGGPPCNIGGAGNNTLTCPTDC
    FRKHPEATYARCGSGPWLTPRCMVHYPYRLWHYPCTVNFTIFKVRMYVGGVEHRFEAA
    CNWTRGERCDLEDRDRSELSPLLLSTTEWQILPCSFTTLPALSTGLIHLHQNIVDVQYLYG
    VGSAVVSLVIK
  • [0137]
    Amino acid sequence of the mature E2 derived from pvHCV-101
    QLVNTNGSWHINRTALNCNDSLQTGFFALLFYKHKFNSSGCPERLASCRSIDKFAQGWG (SEQ ID NO 14)
    PLTYTEPNSSDQRPYCWHYAPRPCGIVPASQVCGPVYCFTSPVVVGTTDRFGVPTYNW
    GANDSDVLILNNTRPPRGNWFGCTWMNGTGETKTCGGPPCNIGGAGNNTLTCPTDCFR
    KHPEATYARCGSGPWLTPRCMVHYPYRLWHYPCTVNFTIFKVRMYVGGVEHRFEAAC
    NWTRGERCDLEDRDRSELSPLLLSTTEWQILPCSFTTLPALSTGLIHLHQNIVDVQYLYGV
    GSAVVSLVIK
    • Example 9
  • An E1 Particle with further Improved Immunogenicity [0138]
  • As set out in example 1, the E1s protein was purified according to the protocol described in PCT/EP 95/03031 to Maertens et al. This protocol includes covalent modification of cysteines (free cysteines and cysteines involved in intermolecular bridging, the latter after reduction of these cysteine bridges using DTT) using maleimide derivates (N-ethyl maleimide and biotin-maleimide, both obtained from Sigma). As an alternative method for maleimide blocking, active halogens were also evaluated. These compounds, ie the active halogens, block free cysteines by means of alkylation. By way of example, an active halogen (iodoacetamde, Merck) was evaluated. The same protocol was used to purify E1 as described in Maertens et al. (PCT/EP 95/03031), but instead of maleimide compounds, iodoacetemide was used. The E1s protein obtained by this procedure behaved throughout the complete purification procedure similarly as the maleimide-blocked proteins. Upon final lowering of the detergent concentration to 0.05% CHAPS or switching to 0.5% betaine as described in example 1, similar particles were obtained as determined by DLS. The surprising effect was found, however, upon immunization of mice with this acetamide-modified E1s. [0139]
  • In total three series of 6 mice each were immunized with E1s using three injections with a three week interval, each injection consisting of 5 μg E1s at 100 μg/ml PBS and mixed with an equal volume of RIBI adjuvant (R-700). A first series received E1-maleimide formulated in 0.05% CHAPS, a second series received E1-acetamide also formulated in 0.05% CHAPS, while a third series received E1-acetamide formulated with 0.12% betaine. Finally, all mice were bled 10 days after the third immunization. End point titers (defined as the dilution of the serum still resulting in a [0140] OD 2 times higher then background values) for each animal individuallv were determined against E1-maleimide and E1-acetamide. FIG. 17 shows these end-point titers, presented as mean with standard deviations. Mice that received E1-maleimide mounted only an antibody response which is able to recognize maleimide-containing epitopes (no reactivity at all on E1-acetamide), mice that received E1-acetamide clearly mount an antibody response against true E1 epitopes, since the antibodies are reactive against both E1-acetamide and E1-maleimide. This was clearly demonstrated in an additional experiment, in which antibodies for specific regions of E1 were determined using peptides which were neither modified with acetamide nor with maleimide. The results, as shown in FIG. 18, demonstrate that the mice immunized with E1-acetamide (CHAPS and betaine formulated) do mount an antibody response which is able to recognize the peptides V1V2, V2V3, V3V4, V5C4, C4V6. As V6 was not part of E1s, we can conclude that antibodies were mounted against C4, V3 (V3V4 is positive while V4V5 is not) and V1V2. Mice immunized with E1s-maleimide mount only a very low response against the V1V2 and V2V3 peptides. This stresses once more the fact that the reasonably high titer measured for these mouse antibodies against the maleimide-E1s is mainly directed against maleimide-dependent epitopes. In addition, we were able to prove that the E1s-acetamide induced response is partially of the Th1 type, since a substantial amount of the induced antibodies is of the IgG2(a+b) subtype. The amount of IgG2 is even higher for the betaine formulation compared to the CHAPS formulation (FIG. 19). From these results it is concluded that HCV envelope proteins, in which at least one cysteine (but potentially more than one cysteine) is alkylated, are extremely immunogenic proteins.
  • Consequently, the acetamide-modified E1 formulated in betaine was also used to reboost the chimpanzees Phil and Ton. Both chimpanzees were immunized again with two consecutive intramuscular immunisations with a three week time interval (50 μg E1 mixed with RIBI adjuvant as for the examples 4 and 5). As can be judged from FIGS. 20 and 21, the anti-E1 response could indeed be boosted again, and this to higher levels than obtained in the previous immunisations after two injections. This titration was performed against a standard, which is a mixture of three human high titre anti-E1 sera (obtained from chronic HCV carriers). The anti-E1 titer of these sera was defined as some unit/ml. In chimpanzee Phil (FIG. 20), titers twice as high as in human carriers were induced only after two immunizations. In chimpanzee Ton (FIG. 21), titers up to 140-fold higher were induced. This stresses once more the high immunogenecity of these E1-particles. [0141]
    • Example 10
  • Alkylated E1 has Superior Qualities for Diagnostic Use [0142]
  • The E1s-acetamide as described in example 9 was further evaluated as antigen for the detection of anti-E1 antibodies in serum samples from human chronic HCV carriers. By way of example these antigens were bound to LIA-membranes, and strips were processed essentially as described in Zrein et al. (1998). Serum samples from 72 blood donors were evaluated first, in order to determine the optimal concentration of the E1 antigen which can be used in the assay in order to exclude “false” positives. For E1s-maleimide, this concentration proved to be 8 μg/ml, while for E1s-acetamide a concentration up to 50 μg/ml did not result in false positive results (no samples showing a relative color staining above 0.5). Using 8 and 50 μg/ml, respectively, for E1s-maleimide and E1s-[0143] acetamide 24 sera of HCV chronic carriers were screened for antibodies against E1s. As shown in Table 6, the E1s-acetamide clearly results in more samples scoring positive (67% versus 38% for E1s-maleimide). No sample was found which only scored positive on E1s-maleimide. For samples scoring positive both on E1s-maleimide and on E1s-acetamide, the reactivity on the latter is higher. From this example it can be concluded that alkylated envelope proteins of HCV are better antigens to detect human antibodies than maleimide-modified envelope proteins.
    • Example 11
  • Production of Mixed Particles Containing E1 and E2 [0144]
  • E1s and E2s (vvHCV-44) were produced and purified as described in Maertens et al. PCT/EP95/030301 except for the fact the maleimide-modificiation was replaced by alkylation using iodoacetamide. E1s and E2s in 3% empigen alone or as an equimolar mixture were injected on a Superdex-200 PC 3.2/30 column equilibrated in PBS/0.2% CHAPS. This column is designed to use with the SMART™ HPLC equipment from Pharmacia LKB (Sweden). The fractions were screened by means of three different sandwich ELISAs. For these ELISAs, E1-(IGH 207) and E2-(IGH 223) specific monoclonals were coated at 2 μg/ml. Fractions of the gel filtration were incubated in a {fraction (1/2500)} dilution. Two other E1 (IGH 200) and E2 (IGH 212) monoclonals, conjugated with biotin were used for detection of the bound antigen. The streptavidin-HRP/TMB system was used to develop the bound biotin into a yellow color which was measured at 450 nm. [0145]
  • This ELISA system was used in a homologous (anti-E1 coating/anti-E1 detection or anti-E2 coating/anti-E2 detection) and a heterologous set-up (anti-E1 coating/anti-E2 detection). The latter theoretically only detects particles in which both E1 and E2 are incorporated. The reactive fractions were pooled, concentrated on a 10 kDa filter, and again chromatographed on Superdex-200 in PBS/0.05% CHAPS. All these fractions were tested for reactivity by using the different ELISA set-ups. As can be judged from FIG. 22, the addition of E2 to E1 does not result in a major shift in the retention time, compared to E1 alone, indicating that particles are indeed still present. These particles contain both E1 and E2, since only in this set-up the heterologous ELISA scores positive. [0146]
    • Example 12
  • Production of Mixed Particles Containing E1 from 2 Different Genotypes [0147]
  • E1s of genotype 1b and of genotype 4 (vvHCV-72) were produced and purified as described in Maertens et al., PCT/EP95/030301 except for the fact the maleimide-modificiation was replaced by alkylation using iodoacetamide for the genotype 1b. E1s-1b and E1s-4 in 3% empigen alone or as an equimolar mixture were injected on a Superdex-200 PC 3.2/30 column equilibrated in PBS/0.2% CHAPS. This column is designed to use with the SMART™ HPLC equipment from Pharmacia LKB (Sweden). The major protein containing fractions were pooled, concentrated on a 10 kDa filter, and again chromatographed on Superdex-200 in PBS/0.05% CHAPS. All these fractions were tested for reactivity by using an ELISA set-up which should only detect particles containing E1 from both genotypes. For this ELISA streptavidin was coated at 2 μg/ml. Fractions of the gel filtration were incubated in a {fraction (1/2500)} dilution. An E1 monoclonal antibody (IGH 200) which only recognizes E1 from [0148] genotype 1 and 10 was used for detection of the bound antigen. The goat-anti-mouse-HRP/TMB system was used for development of the assay into a yellow color which was measured at 450 nm. As can be judged from FIG. 23, the addition of E1-4 to E1-1b does not result in a major shift in the retention time of the proteins, indicating that particles are indeed still present. These particles contain both E1 proteins, ie E1s of genotype 1b and genotype 4, since only in this set-up the ELISA scores positive.
    • LIST OF REFERENCES
  • Deleersnyder V., Pillez A., Wychowski C., Blight K., Xu J., Hahn Y. S., Rice C. M., Dubuisson J. Formation of native hepatitis C virus glycoprotein complexes. J. Virol. 1997: 71: 697-704. [0149]
  • Diepolder H M, Zachoval R, Hoffmann R M, Wierenga E A, Santantonio T, Jung M C, Eichenlaub D, Pape G R. Possible mechanism involving T-lymphocyte response to [0150] non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 1995: 346: 1006-1007.
  • Diepolder H M, Gerlach J T, Zachoval R, Hoffmann R M, Jung M C, Wierenga E A, Scholz S, Santantonio T, Houghton M, Southwood S, Sette A, Pape G R. Immunodominant CD4+ T-cell epitope within [0151] nonstructural protein 3 in acute hepatitis C virus infection. J. Virol., 1997: 71: 6011-6019.
  • Fancy, D. A., Melcher, K., Johnston, S. T. and Kodadek, T. New chemistry for the study of multiprotein complexes: the six-histidine tag as a receptor for a protein crosslinking reagent. Chem Biol (1996) 3: 551-559. [0152]
  • G. T. Hermanson in Bioconjugate Techniques (1996) Part I section 1.43 and section 2.2.1, Academic Press San Diego Calif., USA. [0153]
  • Houghton M. Immunity to HCV: The case for vaccine development. 4th International meeting on hepatitis C Virus and related viruses. Sattelite Symposium: New appraoch to prevention and therapy of HCV infection. Mar. 7, 1997, Kyoto, Japan. [0154]
  • Leroux-Roels G, Esquivel C A, DeLeys R, Stuyver L, Elewaut A, Philippe J, Desombere I, Paradijs J, Maertens G Lymphoproliferative responses to hepatitis C virus core, E1, E2, and NS3 in patients with chronic hepatitis C infection treated with interferon alfa. Hepatology 1996: 23: 8-16. [0155]
  • Maertens G. and Stuyver L. Genotypes and genetic variation of hepatitis C virus. In: The molecular medicine of viral hepatitis. Ed: Harrison T. J. and Zuckerman A. J. 1997 [0156]
  • Major M. E. and Feinstone S. M. The molecular virology of hepatitis C. Hepatology 1997: 25:1527-1538. [0157]
  • Maertens G., Depla E., Ducatteeuw A., Vandeponseele P., Bosman F., Venneman A., de Martynoff G., Stuyver L., Dekeyser F., Vandeperre B., Zrein M. And Buyse M.-A. Hepatology 1997: 26: 186A. [0158]
  • Rehermann B, Chang K M, McHutchinson J, Kokka R, Houghton M, Rice C M, Chisari F V. Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients. J Virol 1996 70: 7092-7102. [0159]
  • Rehermann B, Takaki A, Liebetrau A, Luda S, Seifert U, Salha K, Manns M, Wiese M. Characterization of the cytotoxic and helper T cell response in [0160] patients 18 years after a single source outbreak of HCV infection. Hepatology, 1997:26: 406A
  • Sambrook, J., Fritsch, E. F. and Maniatis, T. (1989) Molecular Cloning, a laboratory manual, second edition. Cold Spring Harbor University Press, Cold Sprint Harbor, N.Y. USA [0161]
  • van Doorn L J, Kleter B; Pike I, Quint W. Analysis of hepatitis C virus isolates by serotyping and genotyping. J Clin Microbiol 1996; 34: 1784-1787. [0162]
  • Villa E., Buttafoco P., Grottola A., Scarcelli A.,, Giannini F., Manerti F. Neutrtalizing antibodies against HCV: liver transplant as an experimental model. J. Hepatol. 1998: 28: [0163]
  • Weiner A J, Erickson A L, Kansopon J, Crawford K, Muchmore E, Houghton M, Walker C M Association of cytotoxic T lymphocyte (CTL) escape mutations with persistent hepatitis C virus (HCV) infection. Princess Takamatsu Symp, 1995: 25: 227-235. [0164]
  • Yi M., Nakamoto Y., Kaneko S., Yamashita T., Murakami S. Delineation of regions important for heteromeric association of Hepatitis C virus E1 and E2. Virol. 1997a: 231: 119-129. [0165]
  • Zauberman, A., Nussbaum, O., Ilan, E., Eren, R., Ben-Moshe, O., Arazi, Y., Berre, S., Lubin, I., Shouval, D., Galun, E., Reisner, Y. and Dagan, S. The trimera mouse system: a mouse model for hepatitis C infection and evaluation of therapeutic agents. Jun. 6-9, 1999; Oral 4.3. In: 6th International Symposium on Hepatitis C & Related Viruses. Bethesda USA [0166]
  • Zrein, M., Louwagie, J., Boeykens, H., Govers, L., Hendrickx, G., Bosman, F., Sablon, E., Demarquilly, C., Boniface, M. and Saman, E. (1998) Assessment of a new immunoassay for serological confirmation and discrimination of human T-cell lymphotropic virus infections. Clin. Diagn. Lab. Imm. 5: 45-49. [0167]
    TABLE 1
    The E1s consensus sequence of HCV-B
    AA Position* 200 233 235 251 253 271 293 298 304 313 314 322
    Region V1 V3 V3 V4 V4 HR HR V5 C4 C4 C4 C4
    HCV-J I S F S I L F Y — V S —
    HCV-B con M N S A V F I H C I T M
    HCCl9A — — — — — L — — — — — —
    HCCl9B — D — — — — — — Y — — —
    HCCl9C — — — — — — — — — — — T
    HCCl10A — — — — — — — — — — — —
    HCCl10B — D — — I — — — — — — —
    HCCl11A — — — — — — — — — — — —
    HCCl11B — — — — — — — — — — — —
    HCCl14 — — — — — — — — — — — —
    HCCl17 — — — — I — — — — — — —
  • [0168]
    TABLE 2
    The Els vaccine sequence aligned with the HCV sequence of the virus present
    in the chronic carriers
    192                                                              259
    Ton (1a) YQVRNSTGLYHVTNDCPNSSIVYEAADAILHTPGCVPCVREGNASRCWVAMTPTVATRDGKLPTTQLR
     *   ** *       *          * *           * *      *   * * ****   **
    E1 vaccin YEVRNVSGMYHVTNDCSNSSIVYEAADMIMHTPGCVPCVRENNSSRCWVALTPTLAARNASVPTTTIR
            *         *                      *                 *
    Phil (1b) YEVRNVSGVYHVTNDCSNASIVYEAADMIMHTPGCVPCVREGNSSRCWVALTPTLAARNVSVPTTTIR
    260                                                             326
    Ton (1a) RHIDLLVGSATLCSALYVGDLCGSVFLVGQLFTFSPRRHWTTQECNCSMYPGHITGHRMAWDMMMNW
      *     * **   *                 *     * * *    *
    E1 vaccin RHVDLLVGAAAFCSAMYVGDLCCSVFLVSQLFTISPRRHETVQDCNCSIYPGHITGHRMAWDMMMNW
         *                           *                   **
    Phil (1b) RHVDLIVGAAAFCSAMYVGDLCGSVFLVSQLFTFSPRRHETVQDCNCSIYPGHVSGHRMAWDMMMNW
  • [0169]
    TABLE 3
    Changes induced by therapeutic vaccination (6 × 50 μg E1s)
    Ton (subtype 1a) Phil (subtype 1b)
    Before After Before After
    Serum
    E1Ab liter
    0 30000 0 14500
    HCV RNA titer (105) 2-3 no change 2-4 no change
    ALT(IU) 85 ± 11 62 ± 6 44 ± 4 37 ± 6
    Liver
    Antigen staining strongly positive negative strongly positive negative
    Histology CAH CPH CAH CPH
    Portal inflammation light none severe moderate
    Lobular hepatitis moderate minimal severe moderate
    Interface hepatitis + − + −
    Histological activity 4 1-2 6-8 2-3
  • [0170]
    TABLE 4
    E1 peptides Genotype name # aa
    YEVRNVSGIYHVTNDCSNSSIVYEAADMHTPGC 1b V1V2 888 192-226
    IVYEAADMIMIITPGCVPCVRENNSSRCVW 1b V2V3 1036 212-244
    VRENNSSRCWVALTPTLAARNASVPTTTIRRIIVD 1b V3V4 1022 230-263
    HVDLLVGAAAFCSAMYVGDLCGSVFLVSQL 2b IIR 1150 261-290
    SQLFTISPRRHETVQDCNCSIYPGHITGHRMAWDMMMNWS 1b V5C4 1176 288-327
    SIYPGHITGHRMAWDMMMNWSPTTALVVSQLLRI 1b C4V6 1039 307-340
  • [0171]
    TABLE 5
                           aa 1188
                           *
    MAT CINGVCWTV YHGRAAVCTRGVAK . . . proposed sequence
    GGPLLCPAGHAVGIFRAAVCTRGVAK . . . natural sequence
  • double underlined: minimal CTL epitope [0172]
  • single underlined: additional surrounding natural amino acids [0173]
  • At the C-terminus the epitope and its surroundings may be linked directly. [0174]
    VDFSLAT CINGVCWTV YHG Proposed sequence
    VDFSLDPTFTIETITLPQD Natural sequence
       *
       aa 1468
  • [0175]
    TABLE 6
    antigen E1s-maleimide E1s-acetamide
    μg/ml 8 50
    17758 2 4
    17761 0 0.5
    17763 0 0.5
    17766 0 1
    17767 0 1
    17771 0.5 2
    17773 0 0
    17775 0 0.5
    17776 0 0.5
    17777 0.5 2
    17779 0 0
    17784 3 4
    17785 0.5 2
    17786 0 2
    17789 2 4
    17790 2 4
    17794 2 4
    17795 0 1
    17796 0 0
    17798 0 0.5
    17820 2 4
    17825 2 3
    17827 2 4
    17842 1 2
    # pos 9 16
    % pos 38 67
  • [0176]
  • 1 30 1 300 PRT Hepatitis C virus 1 Met Ala Thr Cys Ile Asn Gly Val Cys Trp Thr Val Tyr His Gly Arg 1 5 10 15 Ala Ala Val Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe Val Pro 20 25 30 Val Glu Ser Met Glu Thr Thr Met Arg Ser Pro Val Phe Thr Asp Asn 35 40 45 Ser Ser Pro Pro Ala Val Pro Gln Thr Phe Gln Val Ala His Leu His 50 55 60 Ala Pro Thr Gly Ser Gly Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala 65 70 75 80 Ala Gln Gly Tyr Lys Val Leu Val Leu Asn Pro Ser Val Ala Ala Thr 85 90 95 Leu Gly Phe Gly Ala Tyr Met Ser Lys Ala His Gly Val Asp Pro Asn 100 105 110 Ile Arg Thr Gly Val Arg Thr Ile Thr Thr Gly Ala Pro Ile Thr Tyr 115 120 125 Ser Thr Tyr Gly Lys Phe Leu Ala Asp Gly Gly Cys Ser Gly Gly Ala 130 135 140 Tyr Asp Ile Ile Ile Cys Asp Glu Cys His Ser Ile Asp Ser Thr Ser 145 150 155 160 Ile Leu Gly Ile Gly Thr Val Leu Asp Gln Ala Glu Thr Ala Gly Ala 165 170 175 Arg Leu Val Val Leu Ala Thr Ala Thr Pro Pro Gly Ser Val Thr Val 180 185 190 Pro His Pro Asn Ile Glu Glu Val Ala Leu Ser Ser Thr Gly Glu Ile 195 200 205 Pro Phe Tyr Gly Lys Ala Ile Pro Ile Glu Val Ile Lys Gly Gly Arg 210 215 220 His Leu Ile Phe Cys His Ser Lys Lys Lys Cys Asp Glu Leu Ala Ala 225 230 235 240 Lys Leu Ser Gly Phe Gly Ile Asn Ala Val Ala Tyr Tyr Arg Gly Leu 245 250 255 Asp Val Ser Val Ile Pro Thr Ser Gly Asp Val Val Val Val Ala Thr 260 265 270 Asp Ala Leu Met Thr Gly Phe Thr Gly Asp Phe Asp Ser Val Ile Asp 275 280 285 Cys Asn Thr Cys Val Thr Gln Thr Val Asp Phe Ser 290 295 300 2 294 PRT Hepatitis C virus 2 Met Gly Val Ala Lys Ala Val Asp Phe Val Pro Val Glu Ser Met Glu 1 5 10 15 Thr Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Ala 20 25 30 Val Pro Gln Thr Phe Gln Val Ala His Leu His Ala Pro Thr Gly Ser 35 40 45 Gly Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln Gly Tyr Lys 50 55 60 Val Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala 65 70 75 80 Tyr Met Ser Lys Ala His Gly Val Asp Pro Asn Ile Arg Thr Gly Val 85 90 95 Arg Thr Ile Thr Thr Gly Ala Pro Ile Thr Tyr Ser Thr Tyr Gly Lys 100 105 110 Phe Leu Ala Asp Gly Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile Ile 115 120 125 Cys Asp Glu Cys His Ser Ile Asp Ser Thr Ser Ile Leu Gly Ile Gly 130 135 140 Thr Val Leu Asp Gln Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu 145 150 155 160 Ala Thr Ala Thr Pro Pro Gly Ser Val Thr Val Pro His Pro Asn Ile 165 170 175 Glu Glu Val Ala Leu Ser Ser Thr Gly Glu Ile Pro Phe Tyr Gly Lys 180 185 190 Ala Ile Pro Ile Glu Val Ile Lys Gly Gly Arg His Leu Ile Phe Cys 195 200 205 His Ser Lys Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu Ser Gly Phe 210 215 220 Gly Ile Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile 225 230 235 240 Pro Thr Ser Gly Asp Val Val Val Val Ala Thr Asp Ala Leu Met Thr 245 250 255 Gly Phe Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn Thr Cys Val 260 265 270 Thr Gln Thr Val Asp Phe Ser Leu Ala Thr Cys Ile Asn Gly Val Cys 275 280 285 Trp Thr Val Tyr His Gly 290 3 903 DNA Hepatitis C virus 3 atggcgacct gcatcaacgg tgtttgctgg accgtttacc acggtcgtgc ggctgtttgc 60 acccgtgggg ttgcgaaggc ggtggacttt gtacccgtag agtctatgga aaccaccatg 120 cggtccccgg tctttacgga taactcatct cctccggccg taccgcagac attccaagtg 180 gcccatctac acgcccccac tggtagtggc aagagcacta aggtgccggc tgcatatgca 240 gcccaagggt acaaggtact tgtcctgaac ccatccgttg ccgccacctt aggattcggg 300 gcgtatatgt ctaaagcaca tggtgtcgac cctaacatta gaactggggt aaggaccatc 360 accacgggcg cccccattac gtactccacc tacggcaagt ttcttgccga cggtggttgc 420 tctgggggcg cttacgacat cataatatgt gatgagtgcc actcgattga ctcaacctcc 480 atcttgggca tcggcaccgt cctggatcag gcggagacgg ctggagcgcg gcttgtcgtg 540 ctcgccactg ctacacctcc ggggtcggtc accgtgccac atcccaacat cgaggaggtg 600 gctctgtcca gcactggaga gatccccttt tatggcaaag ccatccccat cgaggtcatc 660 aaagggggga ggcacctcat tttctgccat tccaagaaga aatgtgacga gctcgccgca 720 aagctatcgg gcttcggaat caacgctgta gcgtattacc gaggccttga tgtgtccgtc 780 ataccgacta gcggagacgt cgttgttgtg gcaacagacg ctctaatgac gggctttacc 840 ggcgactttg actcagtgat cgactgtaac acatgcgtca cccagacagt cgacttcagc 900 taa 903 4 885 DNA Hepatitis C virus 4 atgggggttg cgaaggcggt ggactttgta cccgtagagt ctatggaaac caccatgcgg 60 tccccggtct ttacggataa ctcatctcct ccggccgtac cgcagacatt ccaagtggcc 120 catctacacg cccccactgg tagtggcaag agcactaagg tgccggctgc atatgcagcc 180 caagggtaca aggtacttgt cctgaaccca tccgttgccg ccaccttagg attcggggcg 240 tatatgtcta aagcacatgg tgtcgaccct aacattagaa ctggggtaag gaccatcacc 300 acgggcgccc ccattacgta ctccacctac ggcaagtttc ttgccgacgg tggttgctct 360 gggggcgctt acgacatcat aatatgtgat gagtgccact cgattgactc aacctccatc 420 ttgggcatcg gcaccgtcct ggatcaggcg gagacggctg gagcgcggct tgtcgtgctc 480 gccactgcta cacctccggg gtcggtcacc gtgccacatc ccaacatcga ggaggtggct 540 ctgtccagca ctggagagat ccccttttat ggcaaagcca tccccatcga ggtcatcaaa 600 ggggggaggc acctcatttt ctgccattcc aagaagaaat gtgacgagct cgccgcaaag 660 ctatcgggct tcggaatcaa cgctgtagcg tattaccgag gccttgatgt gtccgtcata 720 ccgactagcg gagacgtcgt tgttgtggca acagacgctc taatgacggg ctttaccggc 780 gactttgact cagtgatcga ctgtaacaca tgcgtcaccc agacagtcga cttcagcctg 840 gcgacctgca tcaacggtgt ttgctggacc gtttaccacg gttaa 885 5 88 DNA Hepatitis C virus 5 gccatggcga cctgcatcaa cggtgtttgc tggaccgttt accacggtcg tgcggctgtt 60 tgcacccgtg gggttgcgaa ggcggtgg 88 6 21 DNA Hepatitis C virus 6 ttttatcaga ccgcttctgc g 21 7 18 DNA Hepatitis C virus 7 agcaaaccac caagtgga 18 8 77 DNA Hepatitis C virus 8 ctctagacta ttaaccgtgg taaacggtcc agcaaacacc gttgatgcag gtcgccaggc 60 tgaagtcgac tgtctgg 77 9 38 DNA Hepatitis C virus 9 ctttgccggc gtcgacgggc agaaaatcca gctcgtaa 38 10 38 DNA Hepatitis C virus 10 ttacgagctg gattttctgc ccgtcgacgc cggcaaag 38 11 38 DNA Hepatitis C virus 11 ctttgccggc gtcgacgggc agctcgtaaa caccaacg 38 12 38 DNA Hepatitis C virus 12 cgttggtgtt tacgagctgc ccgtcgacgc cggcaaag 38 13 307 PRT Hepatitis C virus 13 Gln Lys Ile Gln Leu Val Asn Thr Asn Gly Ser Trp His Ile Asn Arg 1 5 10 15 Thr Ala Leu Asn Cys Asn Asp Ser Leu Gln Thr Gly Phe Phe Ala Ala 20 25 30 Leu Phe Tyr Lys His Lys Phe Asn Ser Ser Gly Cys Pro Glu Arg Leu 35 40 45 Ala Ser Cys Arg Ser Ile Asp Lys Phe Ala Gln Gly Trp Gly Pro Leu 50 55 60 Thr Tyr Thr Glu Pro Asn Ser Ser Asp Gln Arg Pro Tyr Cys Trp His 65 70 75 80 Tyr Ala Pro Arg Pro Cys Gly Ile Val Pro Ala Ser Gln Val Cys Gly 85 90 95 Pro Val Tyr Cys Phe Thr Pro Ser Pro Val Val Val Gly Thr Thr Asp 100 105 110 Arg Phe Gly Val Pro Thr Tyr Asn Trp Gly Ala Asn Asp Ser Asp Val 115 120 125 Leu Ile Leu Asn Asn Thr Arg Pro Pro Arg Gly Asn Trp Phe Gly Cys 130 135 140 Thr Trp Met Asn Gly Thr Gly Phe Thr Lys Thr Cys Gly Gly Pro Pro 145 150 155 160 Cys Asn Ile Gly Gly Ala Gly Asn Asn Thr Leu Thr Cys Pro Thr Asp 165 170 175 Cys Phe Arg Lys His Pro Glu Ala Thr Tyr Ala Arg Cys Gly Ser Gly 180 185 190 Pro Trp Leu Thr Pro Arg Cys Met Val His Tyr Pro Tyr Arg Leu Trp 195 200 205 His Tyr Pro Cys Thr Val Asn Phe Thr Ile Phe Lys Val Arg Met Tyr 210 215 220 Val Gly Gly Val Glu His Arg Phe Glu Ala Ala Cys Asn Trp Thr Arg 225 230 235 240 Gly Glu Arg Cys Asp Leu Glu Asp Arg Asp Arg Ser Glu Leu Ser Pro 245 250 255 Leu Leu Leu Ser Thr Thr Glu Trp Gln Ile Leu Pro Cys Ser Phe Thr 260 265 270 Thr Leu Pro Ala Leu Ser Thr Gly Leu Ile His Leu His Gln Asn Ile 275 280 285 Val Asp Val Gln Tyr Leu Tyr Gly Val Gly Ser Ala Val Val Ser Leu 290 295 300 Val Ile Lys 305 14 304 PRT Hepatitis C virus 14 Gln Leu Val Asn Thr Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu 1 5 10 15 Asn Cys Asn Asp Ser Leu Gln Thr Gly Phe Phe Ala Ala Leu Phe Tyr 20 25 30 Lys His Lys Phe Asn Ser Ser Gly Cys Pro Glu Arg Leu Ala Ser Cys 35 40 45 Arg Ser Ile Asp Lys Phe Ala Gln Gly Trp Gly Pro Leu Thr Tyr Thr 50 55 60 Glu Pro Asn Ser Ser Asp Gln Arg Pro Tyr Cys Trp His Tyr Ala Pro 65 70 75 80 Arg Pro Cys Gly Ile Val Pro Ala Ser Gln Val Cys Gly Pro Val Tyr 85 90 95 Cys Phe Thr Pro Ser Pro Val Val Val Gly Thr Thr Asp Arg Phe Gly 100 105 110 Val Pro Thr Tyr Asn Trp Gly Ala Asn Asp Ser Asp Val Leu Ile Leu 115 120 125 Asn Asn Thr Arg Pro Pro Arg Gly Asn Trp Phe Gly Cys Thr Trp Met 130 135 140 Asn Gly Thr Gly Phe Thr Lys Thr Cys Gly Gly Pro Pro Cys Asn Ile 145 150 155 160 Gly Gly Ala Gly Asn Asn Thr Leu Thr Cys Pro Thr Asp Cys Phe Arg 165 170 175 Lys His Pro Glu Ala Thr Tyr Ala Arg Cys Gly Ser Gly Pro Trp Leu 180 185 190 Thr Pro Arg Cys Met Val His Tyr Pro Tyr Arg Leu Trp His Tyr Pro 195 200 205 Cys Thr Val Asn Phe Thr Ile Phe Lys Val Arg Met Tyr Val Gly Gly 210 215 220 Val Glu His Arg Phe Glu Ala Ala Cys Asn Trp Thr Arg Gly Glu Arg 225 230 235 240 Cys Asp Leu Glu Asp Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu Leu 245 250 255 Ser Thr Thr Glu Trp Gln Ile Leu Pro Cys Ser Phe Thr Thr Leu Pro 260 265 270 Ala Leu Ser Thr Gly Leu Ile His Leu His Gln Asn Ile Val Asp Val 275 280 285 Gln Tyr Leu Tyr Gly Val Gly Ser Ala Val Val Ser Leu Val Ile Lys 290 295 300 15 135 PRT Hepatitis C virus 15 Tyr Gln Val Arg Asn Ser Thr Gly Leu Tyr His Val Thr Asn Asp Cys 1 5 10 15 Pro Asn Ser Ser Ile Val Tyr Glu Ala Ala Asp Ala Ile Leu His Thr 20 25 30 Pro Gly Cys Val Pro Cys Val Arg Glu Gly Asn Ala Ser Arg Cys Trp 35 40 45 Val Ala Met Thr Pro Thr Val Ala Thr Arg Asp Gly Lys Leu Pro Thr 50 55 60 Thr Gln Leu Arg Arg His Ile Asp Leu Leu Val Gly Ser Ala Thr Leu 65 70 75 80 Cys Ser Ala Leu Tyr Val Gly Asp Leu Cys Gly Ser Val Phe Leu Val 85 90 95 Gly Gln Leu Phe Thr Phe Ser Pro Arg Arg His Trp Thr Thr Gln Glu 100 105 110 Cys Asn Cys Ser Met Tyr Pro Gly His Ile Thr Gly His Arg Met Ala 115 120 125 Trp Asp Met Met Met Asn Trp 130 135 16 135 PRT Hepatitis C virus 16 Tyr Glu Val Arg Asn Val Ser Gly Met Tyr His Val Thr Asn Asp Cys 1 5 10 15 Ser Asn Ser Ser Ile Val Tyr Glu Ala Ala Asp Met Ile Met His Thr 20 25 30 Pro Gly Cys Val Pro Cys Val Arg Glu Asn Asn Ser Ser Arg Cys Trp 35 40 45 Val Ala Leu Thr Pro Thr Leu Ala Ala Arg Asn Ala Ser Val Pro Thr 50 55 60 Thr Thr Ile Arg Arg His Val Asp Leu Leu Val Gly Ala Ala Ala Phe 65 70 75 80 Cys Ser Ala Met Tyr Val Gly Asp Leu Cys Gly Ser Val Phe Leu Val 85 90 95 Ser Gln Leu Phe Thr Ile Ser Pro Arg Arg His Glu Thr Val Gln Asp 100 105 110 Cys Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His Arg Met Ala 115 120 125 Trp Asp Met Met Met Asn Trp 130 135 17 135 PRT Hepatitis C virus 17 Tyr Glu Val Arg Asn Val Ser Gly Val Tyr His Val Thr Asn Asp Cys 1 5 10 15 Ser Asn Ala Ser Ile Val Tyr Glu Ala Ala Asp Met Ile Met His Thr 20 25 30 Pro Gly Cys Val Pro Cys Val Arg Glu Gly Asn Ser Ser Arg Cys Trp 35 40 45 Val Ala Leu Thr Pro Thr Leu Ala Ala Arg Asn Val Ser Val Pro Thr 50 55 60 Thr Thr Ile Arg Arg His Val Asp Leu Ile Val Gly Ala Ala Ala Phe 65 70 75 80 Cys Ser Ala Met Tyr Val Gly Asp Leu Cys Gly Ser Val Phe Leu Val 85 90 95 Ser Gln Leu Phe Thr Phe Ser Pro Arg Arg His Glu Thr Val Gln Asp 100 105 110 Cys Asn Cys Ser Ile Tyr Pro Gly His Val Ser Gly His Arg Met Ala 115 120 125 Trp Asp Met Met Met Asn Trp 130 135 18 35 PRT Hepatitis C virus 18 Tyr Glu Val Arg Asn Val Ser Gly Ile Tyr His Val Thr Asn Asp Cys 1 5 10 15 Ser Asn Ser Ser Ile Val Tyr Glu Ala Ala Asp Met Ile Met His Thr 20 25 30 Pro Gly Cys 35 19 29 PRT Hepatitis C virus 19 Ile Val Tyr Glu Ala Ala Asp Met Ile Met His Thr Pro Gly Cys Val 1 5 10 15 Pro Cys Val Arg Glu Asn Asn Ser Ser Arg Cys Trp Val 20 25 20 34 PRT Hepatitis C virus 20 Val Arg Glu Asn Asn Ser Ser Arg Cys Trp Val Ala Leu Thr Pro Thr 1 5 10 15 Leu Ala Ala Arg Asn Ala Ser Val Pro Thr Thr Thr Ile Arg Arg His 20 25 30 Val Asp 21 30 PRT Hepatitis C virus 21 His Val Asp Leu Leu Val Gly Ala Ala Ala Phe Cys Ser Ala Met Tyr 1 5 10 15 Val Gly Asp Leu Cys Gly Ser Val Phe Leu Val Ser Gln Leu 20 25 30 22 40 PRT Hepatitis C virus 22 Ser Gln Leu Phe Thr Ile Ser Pro Arg Arg His Glu Thr Val Gln Asp 1 5 10 15 Cys Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His Arg Met Ala 20 25 30 Trp Asp Met Met Met Asn Trp Ser 35 40 23 34 PRT Hepatitis C virus 23 Ser Ile Tyr Pro Gly His Ile Thr Gly His Arg Met Ala Trp Asp Met 1 5 10 15 Met Met Asn Trp Ser Pro Thr Thr Ala Leu Val Val Ser Gln Leu Leu 20 25 30 Arg Ile 24 26 PRT Hepatitis C virus 24 Met Ala Thr Cys Ile Asn Gly Val Cys Trp Thr Val Tyr His Gly Arg 1 5 10 15 Ala Ala Val Cys Thr Arg Gly Val Ala Lys 20 25 25 26 PRT Hepatitis C virus 25 Gly Gly Pro Leu Leu Cys Pro Ala Gly His Ala Val Gly Ile Phe Arg 1 5 10 15 Ala Ala Val Cys Thr Arg Gly Val Ala Lys 20 25 26 19 PRT Hepatitis C virus 26 Val Asp Phe Ser Leu Ala Thr Cys Ile Asn Gly Val Cys Trp Thr Val 1 5 10 15 Tyr His Gly 27 19 PRT Hepatitis C virus 27 Val Asp Phe Ser Leu Asp Pro Thr Phe Thr Ile Glu Thr Ile Thr Leu 1 5 10 15 Pro Gln Asp 28 6710 DNA Hepatitis C virus 28 agcttttgcg atcaataaat ggatcacaac cagtatctct taacgatgtt cttcgcagat 60 gatgattcat tttttaagta tttggctagt caagatgatg aatcttcatt atctgatata 120 ttgcaaatca ctcaatatct agactttctg ttattattat tgatccaatc aaaaaataaa 180 ttagaagccg tgggtcattg ttatgaatct ctttcagagg aatacagaca attgacaaaa 240 ttcacagact ttcaagattt taaaaaactg tttaacaagg tccctattgt tacagatgga 300 agggtcaaac ttaataaagg atatttgttc gactttgtga ttagtttgat gcgattcaaa 360 aaagaatcct ctctagctac caccgcaata gatcctgtta gatacataga tcctcgtcgc 420 aatatcgcat tttctaacgt gatggatata ttaaagtcga ataaagtgaa caataattaa 480 ttctttattg tcatcatgaa cggcggacat attcagttga taatcggccc catgttttca 540 ggtaaaagta cagaattaat tagacgagtt agacgttatc aaatagctca atataaatgc 600 gtgactataa aatattctaa cgataataga tacggaacgg gactatggac gcatgataag 660 aataattttg aagcattgga agcaactaaa ctatgtgatg tcttggaatc aattacagat 720 ttctccgtga taggatactc ataaatccag ttgccgccac ggtagccaat caccgtatcg 780 tataaatcat cgtcggtacg ttcggcatcg ctcatcacaa tacgtgcctg gacgtcgagg 840 atttcgcgtg ggtcaatgcc gcgccagatc cacatcagac ggttaatcat gcgataccag 900 tgagggatgg ttttaccatc aagggccgac tgcacaggcg gttgtgcgcc gtgattaaag 960 cggcggacta gcgtcgaggt ttcaggatgt ttaaagcggg gtttgaacag ggtttcgctc 1020 aggtttgcct gtgtcatgga tgcagcctcc agaatactta ctggaaacta ttgtaacccg 1080 cctgaagtta aaaagaacaa cgcccggcag tgccaggcgt tgaaaagatt agcgaccgga 1140 gattggcggg acgaatacga cgcccatatc ccacggctgt tcaatccagg tatcttgcgg 1200 gatatcaaca acatagtcat caaccagcgg acgaccagcc ggttttgcga agatggtgac 1260 aaagtgcgct tttggataca tttcacgaat cgcaaccgca gtaccaccgg tatccaccag 1320 gtcatcaata acgatgaagc cttcgccatc gccttctgcg cgtttcagca ctttaagctc 1380 gcgctggttg tcgtgatcgt agctggaaat acaaacggta tcgacatgac gaatacccag 1440 ttcacgcgcc agtaacgcac ccggtaccag accgccacgg cttacggcaa taatgccttt 1500 ccattgttca gaaggcatca gtcggcttgc gagtttacgt gcatggatct gcaacatgtc 1560 ccaggtgacg atgtattttt cgctcatgtg aagtgtccca gcctgtttat ctacggctta 1620 aaaagtgttc gaggggaaaa taggttgcgc gagattatag ggccttactt tgtaatataa 1680 tgatatatat tttcacttta tctcatttga gaataaaaat gtttttgttt aaccactgca 1740 tgatgtcaat tccgatccta gaagcgatgc tacgctagtc acaatcacca ctttcatatt 1800 tagaatatat gtatgtaaaa atatagtaga atttcatttt gtttttttct atcgattaaa 1860 tagaattcga gctcggtacc cggggatccc acaagctgtc gtggacatgg tggcgggggc 1920 ccattgggga gtcctggcgg gtctcgccta ctattccatg gtggggaact gggctaaggt 1980 tttgattgtg atgctactct ttgccggcgt cgacgggcat acccgcgtgt caggaggggc 2040 agcagcctcc gataccaggg gccttgtgtc cctctttagc cccgggtcgg ctcagaaaat 2100 ccagctcgta aacaccaacg gcagttggca catcaacagg actgccctga actgcaacga 2160 ctccctccaa acagggttct ttgccgcact attctacaaa cacaaattca actcgtctgg 2220 atgcccagag cgcttggcca gctgtcgctc catcgacaag ttcgctcagg ggtggggtcc 2280 cctcacttac actgagccta acagctcgga ccagaggccc tactgctggc actacgcgcc 2340 tcgaccgtgt ggtattgtac ccgcgtctca ggtgtgcggt ccagtgtatt gcttcacccc 2400 gagccctgtt gtggtgggga cgaccgatcg gtttggtgtc cccacgtata actggggggc 2460 gaacgactcg gatgtgctga ttctcaacaa cacgcggccg ccgcgaggca actggttcgg 2520 ctgtacatgg atgaatggca ctgggttcac caagacgtgt gggggccccc cgtgcaacat 2580 cgggggggcc ggcaacaaca ccttgacctg ccccactgac tgttttcgga agcaccccga 2640 ggccacctac gccagatgcg gttctgggcc ctggctgaca cctaggtgta tggttcatta 2700 cccatatagg ctctggcact acccctgcac tgtcaacttc accatcttca aggttaggat 2760 gtacgtgggg ggcgtggagc acaggttcga agccgcatgc aattggactc gaggagagcg 2820 ttgtgacttg gaggacaggg atagatcaga gcttagcccg ctgctgctgt ctacaacaga 2880 gtggcagata ctgccctgtt ccttcaccac cctgccggcc ctatccaccg gcctgatcca 2940 cctccatcag aacatcgtgg acgtgcaata cctgtacggt gtagggtcgg cggttgtctc 3000 ccttgtcatc aaataagctt aattaattag cttgggatcg gctgtgagcg tatggcaaac 3060 gaaggaaaaa tagttatagt agccgcactc gatgggacat ttcaacgtaa accgtttaat 3120 aatattttga atcttattcc attatctgaa atggtggtaa aactaactgc tgtgtgtatg 3180 aaatgcttta aggaggcttc cttttctaaa cgattgggtg aggaaaccga gatagaaata 3240 ataggaggta atgatatgta tcaatcggtg tgtagaaagt gttacatcga ctcataatat 3300 tatatttttt atctaaaaaa ctaaaaataa acattgatta aattttaata taatacttaa 3360 aaatggatgt tgtgtcgtta gataaaccgt ttatgtattt tgaggaaatt gataatgagt 3420 tagattacga accagaaagt gcaaatgagg tcgcaaaaaa actgccgtat caaggacagt 3480 taaaactatt actaggagaa ttattttttc ttagtaagtt acagcgacac ggtatattag 3540 atggtgccac cgtagtgtat ataggatctg ctcccggatc gatcctgcat taatgaatcg 3600 gccaacgcgc ggggagaggc ggtttgcgta ttgggcttcc tcgctgcgct cggtcgttcg 3660 gctgcggcga gcggtatcag ctcactcaaa ggcggtaata cggttatcca cagaatcagg 3720 ggataacgca ggaaagaaca tgtgagcaaa aggccagcaa aaggccagga accgtaaaaa 3780 ggccgcgttg ctggcgtttt tccataggct ccgcccccct gacgagcatc acaaaaatcg 3840 acgctcaagt cagaggtggc gaaacccgac aggactataa agataccagg cgtttccccc 3900 tggaagctcc ctcgtgcgct ctcctgttcc gaccctgccg cttaccggat acctgtccgc 3960 ctttctccct tcgggaagcg tggcgctttc tcatagctca cgctgtaggt atctcagttc 4020 ggtgtaggtc gttcgctcca agctgggctg tgtgcacgaa ccccccgttc agcccgaccg 4080 ctgcgcctta tccggtaact atcgtcttga gtccaacccg gtaagacacg acttatcgcc 4140 actggcagca gccactggta acaggattag cagagcgagg tatgtaggcg gtgctacaga 4200 gttcttgaag tggtggccta actacggcta cactagaaga acagtatttg gtatctgcgc 4260 tctgctgaag ccagttacct tcggaaaaag agttggtagc tcttgatccg gcaaacaaac 4320 caccgctggt agcggtggtt tttttgtttg caagcagcag attacgcgca gaaaaaaagg 4380 atctcaagaa gatcctttga tcttttctac ggggtctgac gctcagtgga acgaaaactc 4440 acgttaaggg attttggtca tgagattatc aaaaaggatc ttcacctaga tccttttaaa 4500 ttaaaaatga agttttaaat caatctaaag tatatatgag taaacttggt ctgacagtta 4560 ccaatgctta atcagtgagg cacctatctc agcgatctgt ctatttcgtt catccatagt 4620 tgcctgactc cccgtcgtgt agataactac gatacgggag ggcttaccat ctggccccag 4680 tgctgcaatg ataccgcgag acccacgctc accggctcca gatttatcag caataaacca 4740 gccagccgga agggccgagc gcagaagtgg tcctgcaact ttatccgcct ccatccagtc 4800 tattaattgt tgccgggaag ctagagtaag tagttcgcca gttaatagtt tgcgcaacgt 4860 tgttgccatt gctacaggca tcgtggtgtc acgctcgtcg tttggtatgg cttcattcag 4920 ctccggttcc caacgatcaa ggcgagttac atgatccccc atgttgtgca aaaaagcggt 4980 tagctccttc ggtcctccga tcgttgtcag aagtaagttg gccgcagtgt tatcactcat 5040 ggttatggca gcactgcata attctcttac tgtcatgcca tccgtaagat gcttttctgt 5100 gactggtgag tactcaacca agtcattctg agaatagtgt atgcggcgac cgagttgctc 5160 ttgcccggcg tcaatacggg ataataccgc gccacatagc agaactttaa aagtgctcat 5220 cattggaaaa cgttcttcgg ggcgaaaact ctcaaggatc ttaccgctgt tgagatccag 5280 ttcgatgtaa cccactcgtg cacccaactg atcttcagca tcttttactt tcaccagcgt 5340 ttctgggtga gcaaaaacag gaaggcaaaa tgccgcaaaa aagggaataa gggcgacacg 5400 gaaatgttga atactcatac tcctcctttt tcaatattat tgaagcattt atcagggtta 5460 ttgtctcatg agcggataca tatttgaatg tatttagaaa aataaacaaa taggggttcc 5520 gcgcacattt ccccgaaaag tgccacctga cgtctaagaa accattatta tcatgacatt 5580 aacctataaa aataggcgta tcacgaggcc ctttcgtctc gcgcgtttcg gtgatgacgg 5640 tgaaaacctc tgacacatgc agctcccgga gacggtcaca gcttgtctgt aagcggatgc 5700 cgggagcaga caagcccgtc agggcgcgtc agcgggtgtt ggcgggtgtc ggggctggct 5760 taactatgcg gcatcagagc agattgtact gagagtgcac catatgcggt gtgaaatacc 5820 gcacagatgc gtaaggagaa aataccgcat caggcgattc cgttgcaatg gctggcggta 5880 atattgttct ggatattacc agcaaggccg atagtttgag ttcttctact caggcaagtg 5940 atgttattac taatcaaaga agtattgcga caacggttaa tttgcgtgat ggacagactc 6000 ttttactcgg tggcctcact gattataaaa acacttctca ggattctggc gtaccgttcc 6060 tgtctaaaat ccctttaatc ggcctcctgt ttagctcccg ctctgattct aacgaggaaa 6120 gcacgttata cgtgctcgtc aaagcaacca tagtacgcgc cctgtagcgg cgcattaagc 6180 gcggcgggtg tggtggttac gcgcagcgtg accgctacac ttgccagcgc cctagcgccc 6240 gctcctttcg ctttcttccc ttcctttctc gccacgttcg ccggctttcc ccgtcaagct 6300 ctaaatcggg ggctcccttt agggttccga tttagtgctt tacggcacct cgaccccaaa 6360 aaacttgatt agggtgatgg ttcacgtagt gggccatcgc cctgatagac ggtttttcgc 6420 cctttgacgt tggagtccac gttctttaat agtggactct tgttccaaac tggaacaaca 6480 ctcaacccta tctcggtcta ttcttttgat ttataaggga ttttgccgat ttcggcctat 6540 tggttaaaaa atgagctgat ttaacaaaaa tttaacgcga attttaacaa aatattaacg 6600 cttacaattt aaatatttgc ttatacaatc ttcctgtttt tggggctttt ctgattatca 6660 accggggtac atatgattga catgctagtt ttacgattac cgttcatcgg 6710 29 1110 DNA Hepatitis C virus CDS (1)..(1110) 29 atg gtg gcg ggg gcc cat tgg gga gtc ctg gcg ggt ctc gcc tac tat 48 Met Val Ala Gly Ala His Trp Gly Val Leu Ala Gly Leu Ala Tyr Tyr 1 5 10 15 tcc atg gtg ggg aac tgg gct aag gtt ttg att gtg atg cta ctc ttt 96 Ser Met Val Gly Asn Trp Ala Lys Val Leu Ile Val Met Leu Leu Phe 20 25 30 gcc ggc gtc gac ggg cat acc cgc gtg tca gga ggg gca gca gcc tcc 144 Ala Gly Val Asp Gly His Thr Arg Val Ser Gly Gly Ala Ala Ala Ser 35 40 45 gat acc agg ggc ctt gtg tcc ctc ttt agc ccc ggg tcg gct cag aaa 192 Asp Thr Arg Gly Leu Val Ser Leu Phe Ser Pro Gly Ser Ala Gln Lys 50 55 60 atc cag ctc gta aac acc aac ggc agt tgg cac atc aac agg act gcc 240 Ile Gln Leu Val Asn Thr Asn Gly Ser Trp His Ile Asn Arg Thr Ala 65 70 75 80 ctg aac tgc aac gac tcc ctc caa aca ggg ttc ttt gcc gca cta ttc 288 Leu Asn Cys Asn Asp Ser Leu Gln Thr Gly Phe Phe Ala Ala Leu Phe 85 90 95 tac aaa cac aaa ttc aac tcg tct gga tgc cca gag cgc ttg gcc agc 336 Tyr Lys His Lys Phe Asn Ser Ser Gly Cys Pro Glu Arg Leu Ala Ser 100 105 110 tgt cgc tcc atc gac aag ttc gct cag ggg tgg ggt ccc ctc act tac 384 Cys Arg Ser Ile Asp Lys Phe Ala Gln Gly Trp Gly Pro Leu Thr Tyr 115 120 125 act gag cct aac agc tcg gac cag agg ccc tac tgc tgg cac tac gcg 432 Thr Glu Pro Asn Ser Ser Asp Gln Arg Pro Tyr Cys Trp His Tyr Ala 130 135 140 cct cga ccg tgt ggt att gta ccc gcg tct cag gtg tgc ggt cca gtg 480 Pro Arg Pro Cys Gly Ile Val Pro Ala Ser Gln Val Cys Gly Pro Val 145 150 155 160 tat tgc ttc acc ccg agc cct gtt gtg gtg ggg acg acc gat cgg ttt 528 Tyr Cys Phe Thr Pro Ser Pro Val Val Val Gly Thr Thr Asp Arg Phe 165 170 175 ggt gtc ccc acg tat aac tgg ggg gcg aac gac tcg gat gtg ctg att 576 Gly Val Pro Thr Tyr Asn Trp Gly Ala Asn Asp Ser Asp Val Leu Ile 180 185 190 ctc aac aac acg cgg ccg ccg cga ggc aac tgg ttc ggc tgt aca tgg 624 Leu Asn Asn Thr Arg Pro Pro Arg Gly Asn Trp Phe Gly Cys Thr Trp 195 200 205 atg aat ggc act ggg ttc acc aag acg tgt ggg ggc ccc ccg tgc aac 672 Met Asn Gly Thr Gly Phe Thr Lys Thr Cys Gly Gly Pro Pro Cys Asn 210 215 220 atc ggg ggg gcc ggc aac aac acc ttg acc tgc ccc act gac tgt ttt 720 Ile Gly Gly Ala Gly Asn Asn Thr Leu Thr Cys Pro Thr Asp Cys Phe 225 230 235 240 cgg aag cac ccc gag gcc acc tac gcc aga tgc ggt tct ggg ccc tgg 768 Arg Lys His Pro Glu Ala Thr Tyr Ala Arg Cys Gly Ser Gly Pro Trp 245 250 255 ctg aca cct agg tgt atg gtt cat tac cca tat agg ctc tgg cac tac 816 Leu Thr Pro Arg Cys Met Val His Tyr Pro Tyr Arg Leu Trp His Tyr 260 265 270 ccc tgc act gtc aac ttc acc atc ttc aag gtt agg atg tac gtg ggg 864 Pro Cys Thr Val Asn Phe Thr Ile Phe Lys Val Arg Met Tyr Val Gly 275 280 285 ggc gtg gag cac agg ttc gaa gcc gca tgc aat tgg act cga gga gag 912 Gly Val Glu His Arg Phe Glu Ala Ala Cys Asn Trp Thr Arg Gly Glu 290 295 300 cgt tgt gac ttg gag gac agg gat aga tca gag ctt agc ccg ctg ctg 960 Arg Cys Asp Leu Glu Asp Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu 305 310 315 320 ctg tct aca aca gag tgg cag ata ctg ccc tgt tcc ttc acc acc ctg 1008 Leu Ser Thr Thr Glu Trp Gln Ile Leu Pro Cys Ser Phe Thr Thr Leu 325 330 335 ccg gcc cta tcc acc ggc ctg atc cac ctc cat cag aac atc gtg gac 1056 Pro Ala Leu Ser Thr Gly Leu Ile His Leu His Gln Asn Ile Val Asp 340 345 350 gtg caa tac ctg tac ggt gta ggg tcg gcg gtt gtc tcc ctt gtc atc 1104 Val Gln Tyr Leu Tyr Gly Val Gly Ser Ala Val Val Ser Leu Val Ile 355 360 365 aaa taa 1110 Lys 370 30 369 PRT Hepatitis C virus 30 Met Val Ala Gly Ala His Trp Gly Val Leu Ala Gly Leu Ala Tyr Tyr 1 5 10 15 Ser Met Val Gly Asn Trp Ala Lys Val Leu Ile Val Met Leu Leu Phe 20 25 30 Ala Gly Val Asp Gly His Thr Arg Val Ser Gly Gly Ala Ala Ala Ser 35 40 45 Asp Thr Arg Gly Leu Val Ser Leu Phe Ser Pro Gly Ser Ala Gln Lys 50 55 60 Ile Gln Leu Val Asn Thr Asn Gly Ser Trp His Ile Asn Arg Thr Ala 65 70 75 80 Leu Asn Cys Asn Asp Ser Leu Gln Thr Gly Phe Phe Ala Ala Leu Phe 85 90 95 Tyr Lys His Lys Phe Asn Ser Ser Gly Cys Pro Glu Arg Leu Ala Ser 100 105 110 Cys Arg Ser Ile Asp Lys Phe Ala Gln Gly Trp Gly Pro Leu Thr Tyr 115 120 125 Thr Glu Pro Asn Ser Ser Asp Gln Arg Pro Tyr Cys Trp His Tyr Ala 130 135 140 Pro Arg Pro Cys Gly Ile Val Pro Ala Ser Gln Val Cys Gly Pro Val 145 150 155 160 Tyr Cys Phe Thr Pro Ser Pro Val Val Val Gly Thr Thr Asp Arg Phe 165 170 175 Gly Val Pro Thr Tyr Asn Trp Gly Ala Asn Asp Ser Asp Val Leu Ile 180 185 190 Leu Asn Asn Thr Arg Pro Pro Arg Gly Asn Trp Phe Gly Cys Thr Trp 195 200 205 Met Asn Gly Thr Gly Phe Thr Lys Thr Cys Gly Gly Pro Pro Cys Asn 210 215 220 Ile Gly Gly Ala Gly Asn Asn Thr Leu Thr Cys Pro Thr Asp Cys Phe 225 230 235 240 Arg Lys His Pro Glu Ala Thr Tyr Ala Arg Cys Gly Ser Gly Pro Trp 245 250 255 Leu Thr Pro Arg Cys Met Val His Tyr Pro Tyr Arg Leu Trp His Tyr 260 265 270 Pro Cys Thr Val Asn Phe Thr Ile Phe Lys Val Arg Met Tyr Val Gly 275 280 285 Gly Val Glu His Arg Phe Glu Ala Ala Cys Asn Trp Thr Arg Gly Glu 290 295 300 Arg Cys Asp Leu Glu Asp Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu 305 310 315 320 Leu Ser Thr Thr Glu Trp Gln Ile Leu Pro Cys Ser Phe Thr Thr Leu 325 330 335 Pro Ala Leu Ser Thr Gly Leu Ile His Leu His Gln Asn Ile Val Asp 340 345 350 Val Gln Tyr Leu Tyr Gly Val Gly Ser Ala Val Val Ser Leu Val Ile 355 360 365 Lys

Claims (49)

1. An oligomeric particle consisting essentially of HCV envelope proteins and having a diameter of 1 to 100 nanometer.
2. Oligomeric particle according to claim 1 having a diameter of 2 to 40 nanometer.
3. Oligomeric particle according to any of claims 1 or 2, in which the amino acid sequence of the HCV envelope protein is a consensus sequence derived from an isolate-, subtype-, strain-, or genus-consensus sequence.
4. Oligomeric particle according to any of claims 1 to 3, possibly containing non-HCV epitopes.
5. Oligomeric particle according to any of claims 1 to 4, wherein at least one cysteine residue of said envelope protein is alkylated.
6. Oligomeric particle according to claim 5, wherein said cysteine residue is alkylated by means of active halogens, ethylenimine or N-(iodoethyl)trifluoroacetamide.
7. Oligomeric particle according to any of claims 1 to 4, wherein at least one cysteine residue of said envelope protein is mutated to a natural amino acid, preferentially selected from the group consisting of methionine, glutamic acid, glutamine and lysine.
8. Oligomeric particle according to any of claims 1 to 7, wherein said envelope proteins are HCV E1 proteins or parts thereof.
9. Oligomeric particle according to any of claims 1 to 7, wherein said envelope proteins are HCV E1s proteins or parts thereof.
10. Oligomeric particle according to any of claims 1 to 7, wherein said envelope proteins are HCV E2 proteins or parts thereof.
11. Oligomeric particle according to any of claims 1 to 7, wherein said envelope proteins are SEQ ID No 13 and/or SEQ ID No 14, or parts thereof.
12. Oligomeric particle according to any of claims 1 to 11, wherein said envelope proteins are encoded by an isolate nucleotide consensus sequence, subtype nucleotide consensus sequence, species nucleotide consensus sequence, or genus nucleotide consensus sequence, or parts thereof.
13. Oligomeric particle according to any of claims 1 to 7, wherein said envelope proteins are a mixture of HCV E1, HCV E1s, HCV E2 proteins and/or SEQ ID No 13 and/or SEQ ID No 14, or parts thereof.
14. Oligomeric particle according to any of claims 1 to 13, wherein said envelope proteins, or parts thereof, are derived from different HCV strains or genotypes.
15. Oligomeric particle according to any of claims 1 to 14, wherein said envelope proteins, or parts thereof, are a mixture consisting of HCV envelope proteins from one strain or genotype of HCV and at least one other strain or genotype of HCV.
16. Oligomeric particle according to any of claims 1 to 15, obtainable by a method characterized by the following steps:
I purifying HCV envelope proteins in solution,
possibly including the use of an optionally first detergent,
possibly including the use of a disulphide bond cleavage agent,
possibly including the use of an alkylating agent,
II replacing said solution of said purified HCV envelope proteins with a detergent or salt, resulting in oligomeric particles,
III purifying the oligomeric particles formed after said replacing,
possibly including further reducing the concentration of the detergent or salt of step II.
17. Oligomeric particle according to claim 16, wherein said optionally first detergent is Empigen-BB, wherein the detergent of step II is CHAPS, octylglucaside, Tween, or any other detergent, and wherein said salt is betaine.
18. Oligomeric particle according to any of claims 16 or 17, wherein said Empigen-BB is used at a concentration of 1% to 10% and wherein said CHAPS or Tween is used at a concentration of 0.01% to 10%, or said betaine is used at a concentration of 0.01% to 10%.
19. Method according to any of claims 16 to 18 to produce oligomeric particles according to any of claims 1 to 14.
20. Method to produce an oligomeric particle according to any of claims 1 to 14, characterized by the following steps:
I purifying HCV envelope proteins in solution,
possibly including the use of an optionally first deterrent,
possibly including the use of a disulphide bond cleavage agent,
possibly including the use of an alkylating agent,
II replacing said solution of said purified HCV envelope proteins with a detergent or salt, resulting in oligomeric particles.
III purifying the oligomeric particles formed after said replacing,
possibly including further reducing the concentration of the detergent or salt of step II.
21. Method to produce an oligomeric particle according to claim 20, wherein said optionally first detergent is Empigen-BB, wherein the detergent of step II is CHAPS, octylglucaside, Tween, or any other detergent, and wherein said salt is betaine.
22. Method to produce an oligomeric particle according to any of claims 20 or 21, wherein said Empigen-BB is used at a concentration of 1% to 10% and wherein said CHAPS or Tween is used at concentrations of 0.01% to 10%, or said betaine is used at a concentration of 0.01%o to 10%.
23. Composition comprising an oligomeric particle according to any of claims 1 to 22.
24. Composition according to claim 23, which also comprises HCV core, P7, E1, E2, NS2, NS3, NS4A, NS4B, NS5A and/or NS5B protein, or parts thereof.
25. Composition according to claim 24 wherein said NS3 protein, or parts thereof, have an amino acid sequence given by SEQ ID No 1 or SEQ ID No 2.
26. Use of the oligomeric particle according to any of claims 1 to 25 for the manufacture of an HCV vaccine composition.
27. Use of the oligomeric particle according to any of claims 1 to 25 for inducing immunity against HCV in chronic HCV carriers.
28. Use of the oligomeric particle according to claim 27 for inducing immunity against HCV in chronic HCV carriers prior to, simultaneously to or after any other therapy.
29. Use of the oligomeric particle according to claim 27 for inducing immunity against HCV in HCV-infected individuals prior to or after liver transplantation, or after presumed infection.
30. Use of the oligomeric particle according to any of claims 1 to 28 for prophylactically inducing immunity against HCV.
31. Use of the oligomeric particle according to any of claims 1 to 28 for inducing immunity against HCV, characterized in that said oligomeric particle or said composition is used as a part of a series of time and compounds.
32. The oligomeric particle or the composition according to any of claims 1 to 25 for use as an HCV vaccine.
33. The oligomeric particle or the composition according to any of claims 1 to 25 for inducing immunity against HCV in chronic HCV carriers.
34. The oligomeric particle or the composition according to claim 33 for inducing immunity against HCV in chronic HCV carriers prior to, simultaneously to or after any other therapy.
35. The oligomeric particle or the composition according to any of claims 1 to 25 for inducing immunity against HCV in HCV-infected individuals prior to or after liver transplantation, or after presumed infection.
36. The oligomeric particle or the composition according to any of claims 1 to 25 for prophylactically inducing immunity against HCV.
37. The oligomeric particle or the composition according to any of claims 1 to 25 for inducing immunity against HCV, characterized in that said oligomeric particle is part of a series in time and compounds.
38. A purified single HCV envelope protein.
39. The purified single HCV envelope protein according to claim 38, wherein said envelope protein is E1 or E1s.
40. Composition containing the purified single HCV envelope protein according to any of claims 38 or 39.
41. The composition according to claim 40 for use as an HCV vaccine.
42. Use of the composition according to claim 40 as an HCV vaccine.
43. Use of the composition according to claim 40 for the manufacture of an HCV vaccine.
44. Specific antibodies generated against the oligomeric particle according to any of claims 1 to 25, or against the purified single HCV envelope protein according to any of claims 38 to 40.
45. Use of the specific antibody according to claim 44, to treat or prevent HCV infection.
46. Kit for detecting HCV antigens, comprising the specific antibody according to claim 44.
47. Kit for detecting HCV antibodies present in a biological sample, comprising the oligomeric particle according to any of claims 1 to 25, or the purified single HCV envelope protein according to any of claims 38 to 40, in a suitable container.
48. Kit for detecting HCV related T cell response, comprising the oligomeric particle according to any of claims 1 to 25, or the purified single HCV envelope protein according to any of claims 38 to 40.
49. Immunoassay for detecting HCV antibody, which immunoassay comprises:
(1) providing the oligomeric particle according to any of claims 1 to 25, or the purified single HCV envelope protein according to any of claims 38 to 40, or parts thereof,
(2) incubating a biological sample with said oligomeric particle, or said HCV envelope protein under conditions that allow formation of antibody-antigen complex,
(3) determining whether said antibody-antigen complex comprising said oligomeric particle or said HCV envelope protein is formed.
US10/414,219 1998-06-24 2003-04-16 Particles of HCV envelope proteins: use for vaccination Abandoned US20030202987A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/414,219 US20030202987A1 (en) 1998-06-24 2003-04-16 Particles of HCV envelope proteins: use for vaccination
US11/381,408 US20070048281A1 (en) 1998-06-24 2006-05-03 Hcv combination therapy
US11/445,274 US20060275323A1 (en) 1998-06-24 2006-06-02 Particles of HCV envelope proteins: use for vaccination

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP98870142 1998-06-24
EP98870142.1 1998-06-24
EP99870033.0 1999-02-22
EP99870033 1999-02-22
US09/355,040 US6635257B1 (en) 1998-06-24 1999-06-23 Particles of HCV envelope proteins: use for vaccination
US10/414,219 US20030202987A1 (en) 1998-06-24 2003-04-16 Particles of HCV envelope proteins: use for vaccination

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US09/355,040 Division US6635257B1 (en) 1998-06-24 1999-06-23 Particles of HCV envelope proteins: use for vaccination
PCT/EP1999/004342 Division WO1999067285A1 (en) 1998-06-24 1999-06-23 Particles of hcv envelope proteins: use for vaccination

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/381,408 Continuation-In-Part US20070048281A1 (en) 1998-06-24 2006-05-03 Hcv combination therapy
US11/445,274 Division US20060275323A1 (en) 1998-06-24 2006-06-02 Particles of HCV envelope proteins: use for vaccination

Publications (1)

Publication Number Publication Date
US20030202987A1 true US20030202987A1 (en) 2003-10-30

Family

ID=26152268

Family Applications (3)

Application Number Title Priority Date Filing Date
US09/355,040 Expired - Fee Related US6635257B1 (en) 1998-06-24 1999-06-23 Particles of HCV envelope proteins: use for vaccination
US10/414,219 Abandoned US20030202987A1 (en) 1998-06-24 2003-04-16 Particles of HCV envelope proteins: use for vaccination
US11/445,274 Abandoned US20060275323A1 (en) 1998-06-24 2006-06-02 Particles of HCV envelope proteins: use for vaccination

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/355,040 Expired - Fee Related US6635257B1 (en) 1998-06-24 1999-06-23 Particles of HCV envelope proteins: use for vaccination

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/445,274 Abandoned US20060275323A1 (en) 1998-06-24 2006-06-02 Particles of HCV envelope proteins: use for vaccination

Country Status (20)

Country Link
US (3) US6635257B1 (en)
EP (2) EP1555270A1 (en)
JP (1) JP2002518037A (en)
KR (1) KR100559096B1 (en)
CN (1) CN1313864A (en)
AT (1) ATE286067T1 (en)
AU (1) AU765940B2 (en)
BR (1) BR9911397A (en)
CA (1) CA2330526A1 (en)
DE (1) DE69922958T3 (en)
DK (1) DK1090033T4 (en)
ES (1) ES2237115T5 (en)
HU (1) HU227275B1 (en)
IL (2) IL140217A0 (en)
NZ (2) NZ528952A (en)
PL (1) PL201679B1 (en)
PT (1) PT1090033E (en)
RU (1) RU2247729C2 (en)
TR (1) TR200003843T2 (en)
WO (1) WO1999067285A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070072176A1 (en) * 2002-05-17 2007-03-29 Genevieve Inchauspe Novel peptide compositions and their use in particular in the preparation of pharmaceutical compositions active against the hepatitis C virus

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040185061A1 (en) * 1994-07-29 2004-09-23 Innogenetics N.V. Redox reversible HCV proteins with native-like conformation
US7108855B2 (en) 1998-06-24 2006-09-19 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
EP1555270A1 (en) * 1998-06-24 2005-07-20 Innogenetics N.V. HCV NS3 proteins and nucleic acids
EP1221968B1 (en) * 1999-10-13 2010-01-13 Novartis Vaccines and Diagnostics, Inc. Method of obtaining cellular immune responses from proteins
HU228264B1 (en) * 2000-06-08 2013-02-28 Intercell Ag Immunostimulatory oligodeoxynucleotides
IL153923A0 (en) * 2000-09-08 2003-07-31 Gryphon Therapeutics Inc Synthetic erythropoiesis stimulating proteins
AU2001292667A1 (en) * 2000-09-13 2002-03-26 Hawaii Biotechnology Group, Inc. Immunogenic composition of hepatitis c and methods of use thereof
US7101561B2 (en) * 2000-12-01 2006-09-05 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
RU2274643C2 (en) 2001-04-24 2006-04-20 Иннодженетикс Н.В. Isolated envelope hcv protein, method for its preparing and drug, vaccine, pharmaceutical composition (variants) comprising thereof
GB0114629D0 (en) * 2001-06-15 2001-08-08 Pfizer Ltd Method
US20040126395A1 (en) * 2001-12-18 2004-07-01 Geert Maertens Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
KR20040076869A (en) * 2001-12-18 2004-09-03 인노제네틱스 엔. 브이. Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
JP2004085528A (en) * 2002-07-05 2004-03-18 Kansai Tlo Kk Method and apparatus for detecting protein association by change in diffusion constant
EP1852441B1 (en) * 2002-09-24 2012-03-28 The Burnham Institute Agents that modulate EPH receptor activity
JP2006507256A (en) * 2002-09-24 2006-03-02 ザ バーナム インスティチュート Novel drug that modulates Eph receptor activity
EP1481985A1 (en) * 2003-05-28 2004-12-01 Innogenetics N.V. Modified hepatitis C virus (HCV) NS3 for medical treatment
EP1561470A1 (en) * 2003-06-20 2005-08-10 Innogenetics N.V. HCV vaccines comprising the envelope-1 (E1) protein or the corresponding DNA and at least one antiviral agent
AU2004280630A1 (en) * 2003-10-10 2005-04-21 Powderject Vaccines, Inc. Method
WO2006070028A1 (en) * 2004-12-23 2006-07-06 Berthet Francois Xavier Pathogenic infection detection compositions and methods
GB0500020D0 (en) 2005-01-04 2005-02-09 Novartis Ag Organic compounds
EP1574517A1 (en) * 2004-03-09 2005-09-14 Innogenetics N.V. HCV E1 comprising specific disulfide bridges
WO2006033012A2 (en) * 2004-09-24 2006-03-30 Pfizer Limited Method of screening for modulators of hepatitis c virus infection
DE102004057111A1 (en) 2004-11-26 2006-06-01 Niles-Simmons Industrieanlagen Gmbh Method for intermediate machining of waves
DE602006017964D1 (en) 2005-01-27 2010-12-16 Burnham Inst La Jolla EPHB RECEPTOR BINDING PEPTIDES
WO2007041432A2 (en) * 2005-09-30 2007-04-12 Novartis Vaccines And Diagnostics, Inc. Cross-neutralization of hcv with recombinant proteins
WO2007111965A2 (en) * 2006-03-22 2007-10-04 Genimmune N.V. Hepatitis c virus neutralizing antibodies
RU2329303C2 (en) * 2006-08-02 2008-07-20 Государственное учреждение Научно-исследовательский институт вирусологии им. Д.И. Ивановского Российской академии медицинских наук Monoclonal antibody immunoreactive with nucleocapsid (core) protein of c-4g5 hepatitis virus, method of diagnostics of hepatitis c viral (hcv) infection, and combination of monoclonal antibodies for its implementation
CA2722423A1 (en) * 2008-04-22 2009-10-29 Rutgers, The State University Hcv e2 construct compositions and methods
US9758794B2 (en) 2008-04-22 2017-09-12 Rutgers, The State University Of New Jersey HCV E2 construct compositions and methods
US20110217330A1 (en) * 2008-11-05 2011-09-08 Bruno Rene Andre Novel method
BR112013032675A2 (en) * 2011-06-19 2017-08-08 Vaxine Pty Ltd adjuvant vaccine composition comprising inulin particles
JP6567824B2 (en) * 2011-10-12 2019-08-28 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Human papillomavirus vaccine and method of use thereof
RU2510998C2 (en) * 2012-08-01 2014-04-10 Николай Николаевич Грановский VACCINE OF VIRUS-LIKE PARTICLES CONTAINING ALL HEPATITIS C VIRUS STRUCTURAL ANTIGENS, AND METHOD FOR PREPARING IT IN Hansenula polymorpha YEAST
AU2014248535B2 (en) 2013-03-12 2017-03-30 Inovio Pharmaceuticals, Inc. Improved vaccines for human papilloma virus and methods for using the same
EP3515483A4 (en) 2016-09-21 2020-12-16 The Governors of the University of Alberta IMMUNOGENIC COMPOSITIONS OF HEPATITIS C VIRUS AND METHOD OF USING THEREOF
JP6795468B2 (en) * 2017-07-14 2020-12-02 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Human papillomavirus vaccine and how to use it
JP7075130B2 (en) * 2019-10-25 2022-05-25 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Human papillomavirus vaccine and how to use it

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4395395A (en) * 1979-05-21 1983-07-26 The United States Of America As Represented By The Department Of Health And Human Services Detection of non-A, non-B hepatitis associated antigen
US5942234A (en) * 1990-11-08 1999-08-24 Chiron Corporation Hepatitis C virus asialoglycoproteins
US6150134A (en) * 1994-07-29 2000-11-21 Innogenetics, N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
US6635257B1 (en) * 1998-06-24 2003-10-21 Innogentics N.V. Particles of HCV envelope proteins: use for vaccination

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2175657C2 (en) * 1990-11-08 2001-11-10 Чирон Корпорейшн Hepatitis c virus (hcv) asialoglycoprotein, immunogenic composition, method of induction of immune response, method of immune assay
ES2239819T3 (en) * 1993-11-04 2005-10-01 Innogenetics N.V. IMMUNODOMINANT EPITOPES OF HUMAN T-CELLS OF HEPATITIS VIRUS C.
DE69526973T3 (en) * 1994-10-21 2010-01-07 Innogenetics N.V. SEQUENCES OF HEPATITIS C-VIRUS GENOTYPE 7, AND THEIR USE AS PREVENTIVE, THERAPEUTIC AND DIAGNOSTIC AGENTS
DE69739268D1 (en) * 1996-11-08 2009-04-02 Us Gov Health & Human Serv PREPARATION AND CLEANING OF HEPATITIS C VIRUS-RELATED PARTICLES
AU751362B2 (en) * 1998-04-17 2002-08-15 Innogenetics N.V. Improved immunodiagnostic assays using reducing agents

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4395395A (en) * 1979-05-21 1983-07-26 The United States Of America As Represented By The Department Of Health And Human Services Detection of non-A, non-B hepatitis associated antigen
US5942234A (en) * 1990-11-08 1999-08-24 Chiron Corporation Hepatitis C virus asialoglycoproteins
US6150134A (en) * 1994-07-29 2000-11-21 Innogenetics, N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
US6635257B1 (en) * 1998-06-24 2003-10-21 Innogentics N.V. Particles of HCV envelope proteins: use for vaccination

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070072176A1 (en) * 2002-05-17 2007-03-29 Genevieve Inchauspe Novel peptide compositions and their use in particular in the preparation of pharmaceutical compositions active against the hepatitis C virus
US20090075879A1 (en) * 2002-05-17 2009-03-19 Transgene Sa Novel Peptide Compositions and the Use Thereof, in Particular, in the Preparation of Active Pharmaceutical Compositions Against the Hepatitis C Virus
US20090087449A1 (en) * 2002-05-17 2009-04-02 Transgene Sa Novel Peptide Compositions and the Use Thereof, in Particular, in the Preparation of Active Pharmaceutical Compositions Against the Hepatitis C Virus
US8067228B2 (en) 2002-05-17 2011-11-29 Transgene Sa Nucleic acid compositions and their use against the hepatitic C virus
US8080525B2 (en) 2002-05-17 2011-12-20 Transgene Sa Peptide compositions and their use against the hepatitis C virus
US8293528B2 (en) 2002-05-17 2012-10-23 Transgene Sa Peptide compositions and their use in particular in the preparation of pharmaceutical compositions active against the hepatitis C virus

Also Published As

Publication number Publication date
EP1555270A1 (en) 2005-07-20
HUP0102478A2 (en) 2001-10-28
IL140217A0 (en) 2002-02-10
HU227275B1 (en) 2011-01-28
PL201679B1 (en) 2009-04-30
EP1090033B2 (en) 2007-12-19
BR9911397A (en) 2002-01-15
KR100559096B1 (en) 2006-03-15
TR200003843T2 (en) 2001-06-21
DE69922958D1 (en) 2005-02-03
EP1090033B1 (en) 2004-12-29
CN1313864A (en) 2001-09-19
US20060275323A1 (en) 2006-12-07
US6635257B1 (en) 2003-10-21
HUP0102478A3 (en) 2004-10-28
AU765940B2 (en) 2003-10-02
CA2330526A1 (en) 1999-12-29
DE69922958T3 (en) 2008-06-26
NZ508797A (en) 2004-02-27
HK1037639A1 (en) 2002-02-15
EP1090033A1 (en) 2001-04-11
JP2002518037A (en) 2002-06-25
ES2237115T3 (en) 2005-07-16
AU4615299A (en) 2000-01-10
NZ528952A (en) 2004-09-24
PT1090033E (en) 2005-05-31
ATE286067T1 (en) 2005-01-15
KR20010053181A (en) 2001-06-25
WO1999067285A1 (en) 1999-12-29
DK1090033T3 (en) 2005-04-25
DK1090033T4 (en) 2008-03-31
DE69922958T2 (en) 2006-03-30
IL140217A (en) 2009-09-22
PL345018A1 (en) 2001-11-19
RU2247729C2 (en) 2005-03-10
ES2237115T5 (en) 2008-05-16

Similar Documents

Publication Publication Date Title
US6635257B1 (en) Particles of HCV envelope proteins: use for vaccination
KR102077131B1 (en) Recombinant measles virus expressing chikungunya virus polypeptides and their applications
CN109486803B (en) Engineered phenylalanine ammonia lyase polypeptides
CA2444006A1 (en) Expression of core-glycosylated hcv envelope proteins in yeast
JP2002167336A (en) Polypeptide composition of immune response hepatitis c virus
JPH09509568A (en) Sperm antigen corresponding to the self-antigen epitope of sperm zona pellucida binding protein
KR20130126755A (en) Torque teno virus(ttv) isolates and compositions
US6740323B1 (en) HBV/HCV virus-like particle
WO1995020664A9 (en) Mammalian expression systems for hepatitis c virus envelope genes
CN112048484A (en) A genotype VII Newcastle disease recombinant virus expressing the VP2 protein of a virulent bursal strain and its vaccine
EP0741787A1 (en) Mammalian expression systems for hepatitis c virus envelope genes
CA2392527A1 (en) Hbv/hcv virus-like particle
KR102335519B1 (en) Vaccine composition for preventing or reducing clinical symptom of severe acute respiratory syndrome coronavirus 2
CN106701806B (en) Assess serial transcription factor Reporter System and its application of Chinese medicine and/or natural drug efficiency
CN109929847B (en) PEX26 gene, protein and application thereof
CN112553255A (en) Recombinant virus for expressing infectious bursal disease virus VP2 antigen and preparation and application thereof
CN108588100B (en) Inhibin B double-gene fragment combined expression vector and application thereof
CN112322626B (en) A CpG-ODN with specific immunostimulatory effect on PRRSV and its application
TWI272104B (en) Immunization against flavivirus
KR102713784B1 (en) A TLR2 overexpressed animal model for atherosclerosis and a method of producing thereof
KR20230075800A (en) Rheumatoid arthritis disease simulation model and screening platform with coronavirus infection
HK1037639B (en) Particles of hcv envelope proteins: use for vaccination
MXPA00012473A (en) Particles of hcv envelope proteins:use for vaccination

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION